Modified multi-segmented antisense oligonucleotides for use

HK40137445APending Publication Date: 2026-09-11AUSPER BIOPHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125826
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-12
Filing Date
2026-07-07
Publication Date
2026-09-11

Smart Images

  • Figure 00000239_0000
    Figure 00000239_0000
  • Figure 00000239_0001
    Figure 00000239_0001
  • Figure 00000239_0002
    Figure 00000239_0002
Patent Text Reader

Abstract

Modified multi-segment antisense oligonucleotides and methods for reducing expression of target mRNA, DNA, and proteins are provided. Such methods, oligonucleotides, and compositions may be used to treat, prevent, or ameliorate a disease or disorder.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480010584.2 (22) Application Date 2024.01.10 (66) Domestic Priority Data PCT / CN2023 / 000034 2023.01.10 CN PCT / CN2023 / 106924 2023.07.12 CN (85) PCT International Application Entering National Phase Date 2025.08.01 (86) PCT International Application Application Data PCT / CN2024 / 071514 2024.01.10 (87) PCT International Application Publication Data WO2024 / 149282 EN 2024.07.18 (71) Applicant Hangzhou Haobo Pharmaceutical Co., Ltd. Address 310052 Room 2501, Building 5, No. 688 Bin'an Road, Binjiang District, Hangzhou City, Zhejiang Province (72) Inventors: Cheng Guofeng, Yang Chengyong (74) Patent Agency: Beijing Kunrui Law Firm 11494 Patent Attorney: Feng Xinqin (51) Int.Cl. C12N 15 / 113 (2006.01) C07H 21 / 00 (2006.01) A61K 31 / 7088 (2006.01) A61K 31 / 7115 (2006.01) (54) Invention Title: Modified Multisegment Antisense Oligonucleotides for Use (57) Abstract: Modified multisegment antisense oligonucleotides and methods for reducing the expression of target mRNA, DNA and proteins are provided. Such methods, oligonucleotides and compositions may be used to treat, prevent or improve diseases or disorders. Claims 9 pages, Description 170 pages, Drawings 162 pages, CN 121358861 A 2026.01.16 CN 1 21 35 88 61 A 1. A modified multi-segment antisense oligonucleotide complementary to a nucleotide sequence in a gene transcript, wherein the modified multi-segment antisense oligonucleotide comprises from 5′ to 3′: 5′W1-G1-S1-G2-W2 3′ (Formula I) wherein: W1 is a 5′ wing segment; W2 is a 3′ wing segment; G1 is a first nick segment; S1 is a first separator segment; and G2 is a second nick segment, wherein each segment is linked by a nucleoside internucleotide bond, and wherein at least one nucleoside of each of W1, W2, and S1 is a modified nucleoside. 2. The modified multisegment antisense oligonucleotide according to claim 1, wherein the modified multisegment antisense oligonucleotide comprises from 5′ to 3′: 5′W1-G1-S1-G2-S2-G3-W2 3′ (Formula II) wherein: S2 is a second separator segment; and G3 is a third nick segment, wherein at least one nucleoside of S2 is a modified nucleoside.3. The modified multisegment antisense oligonucleotide according to claim 1 or claim 2, wherein W1 comprises 2 to 25 linked nucleosides. 4. The modified multisegment antisense oligonucleotide according to claim 3, wherein the first 5′ nucleoside of W1 is a modified nucleoside and / or wherein the last 3′ nucleoside of W1 is a modified nucleoside. 5. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 4, wherein W2 comprises 2 to 35 linked nucleosides. 6. The modified multisegment antisense oligonucleotide according to claim 5, wherein the first 5′ nucleoside of W2 is a modified nucleoside and / or wherein the last 3′ nucleoside of W2 is a modified nucleoside. 7. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 6, wherein G1 comprises 1 to 10 linked deoxynucleosides. 8. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 7, wherein G2 comprises 1 to 10 linked deoxynucleosides. 9. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 8, wherein S1 comprises 1 to 3 linked nucleosides. 10. The modified multisegment antisense oligonucleotide according to any one of claims 2 to 9, wherein G3 comprises 1 to 10 linked deoxynucleosides. 11. The modified multisegment antisense oligonucleotide according to any one of claims 2 to 10, wherein S2 comprises 1 to 3 linked nucleosides. 12. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 11, wherein the modified multisegment antisense oligonucleotide has a length of 11 to 50 nucleotides. 13. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 11, wherein the modified multisegment antisense oligonucleotide has a length of 11 to 30 nucleotides. Claims 1 / 9 Page 2 CN 121358861 A 14. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 11, wherein the modified multisegment antisense oligonucleotide has a length of at least 20 nucleotides. 15. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 11, wherein the modified multisegment antisense oligonucleotide has a length of 20 nucleotides. 16. The modified multisegment antisense oligonucleotide according to claim 15, wherein W1 comprises 2 to 8 linked nucleosides. 17. The modified multisegment antisense oligonucleotide according to claim 15, wherein W1 comprises 2 to 6 linked nucleosides. 18. The modified multisegment antisense oligonucleotide according to claim 15, wherein W1 comprises 4, 5, or 6 linked nucleosides. 19. The modified multisegment antisense oligonucleotide according to claim 15, wherein W1 comprises 5 linked nucleosides.20. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 19, wherein G1 comprises 2 to 7 linked deoxynucleosides. 21. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 19, wherein G1 comprises 4 linked deoxynucleosides. 22. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 19, wherein G1 comprises 5 linked deoxynucleosides. 23. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 19, wherein G1 comprises 6 linked deoxynucleosides. 24. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 23, wherein G2 comprises 1 to 7 linked deoxynucleosides. 25. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 23, wherein G2 comprises 2 to 7 linked deoxynucleosides. 26. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 23, wherein G2 comprises 1 to 2 linked deoxynucleosides. 27. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 23, wherein G2 comprises 4 linked deoxynucleosides. 28. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 23, wherein G2 comprises 5 linked deoxynucleosides. 29. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 23, wherein G2 comprises 6 linked deoxynucleosides. 30. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 23, wherein G2 comprises 7 linked deoxynucleosides. 31. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 30, wherein G3 comprises 2 to 7 linked deoxynucleosides. 32. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 30, wherein G3 comprises 4 linked deoxynucleosides. 33. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 30, wherein G3 comprises 5 linked deoxynucleosides. 34. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 30, wherein G3 comprises 6 linked deoxynucleosides. 35. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 30, wherein G3 comprises 7 linked deoxynucleosides. 36. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 35, wherein S1 comprises at least one linked nucleoside. 37. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 35, wherein S1 comprises one linked nucleoside.38. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 35, wherein S1 comprises two linked nucleosides. 39. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 38, wherein S2 comprises at least one linked nucleoside. 40. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 38, wherein S2 comprises one linked nucleoside. 41. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 38, wherein S2 comprises two linked nucleosides. 42. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 41, wherein W2 comprises two to eight linked nucleosides. 43. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 41, wherein W2 comprises two to six linked nucleosides. 44. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 41, wherein W2 comprises three linked nucleosides. 45. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 41, wherein W2 comprises 4 linked nucleosides. 46. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 41, wherein W2 comprises 5 linked nucleosides. 47. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 41, wherein W2 comprises 6 linked nucleosides. 48. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 47, wherein S1 is located at position 10 of the modified multisegment antisense oligonucleotide. 49. The modified multisegment antisense oligonucleotide according to any one of claims 15 to 47, wherein S1 is located at position 11 of the modified multisegment antisense oligonucleotide. 50. The modified multisegment antisense oligonucleotide according to claim 48, wherein: W1 comprises 4 linked nucleosides, G1 comprises 5 linked deoxynucleosides, S1 comprises 1 linked nucleoside, G2 comprises 5 linked deoxynucleosides, and W2 comprises 5 linked nucleosides. Claims 3 / 9, page 4, CN 121358861, A 51. The modified multi-segment antisense oligonucleotide according to claim 48, wherein W1 comprises 5 linked nucleosides, G1 comprises 4 linked deoxynucleosides, S1 comprises 1 linked nucleoside, G2 comprises 5 linked deoxynucleosides, and W2 comprises 5 linked nucleosides. 52. The modified multi-segment antisense oligonucleotide according to claim 1, wherein: W1 comprises 2 to 8 linked nucleosides, G1 comprises 2 to 7 linked deoxynucleosides, S1 comprises 1 to 2 linked nucleosides, G2 comprises 2 to 7 linked deoxynucleosides, and53. The modified multi-segment antisense oligonucleotide of claim 52, wherein: W1 contains 2 to 6 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 linked nucleoside, G2 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 6 linked nucleosides. 54. The modified multi-segment antisense oligonucleotide of claim 2, wherein: W1 contains 2 to 8 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 linked nucleoside, G2 contains 1 to 2 linked deoxynucleosides, S2 contains 1 linked nucleoside, G3 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 8 linked nucleosides. 55. The modified multi-segment antisense oligonucleotide of claim 54, wherein: W1 comprises 2 to 6 linked nucleosides, G1 comprises 2 to 7 linked deoxynucleosides, S1 comprises 1 linked nucleoside, G2 comprises 1 to 2 linked deoxynucleosides, S2 comprises 1 linked nucleoside, G3 comprises 2 to 7 linked deoxynucleosides, and W2 comprises 2 to 6 linked nucleosides. 56. The modified multi-segment antisense oligonucleotide of any one of claims 52 to 53, wherein the length of the G1-S1-G2 segment is between 8 and 12 nucleotides. 57. The modified multi-segment antisense oligonucleotide of any one of claims 54 to 54, wherein the length of G1-S1-G2-S2-G3 is between 8 and 12 nucleotides. 58. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 57, wherein G1, G2 and / or G3 comprises a nucleoside modified with 2′-deoxynucleotide. 59. The modified multisegment antisense oligonucleotide according to claim 58, wherein G1, G2 and / or G3 comprises a nucleoside modified with 2′-deoxy-5-methylcytidine. 60. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 59, wherein S1 and / or S2 comprises a nucleoside modified with 2′-O-methoxyethyl sugar. 61. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 59, wherein S1 and / or S2 comprises a nucleoside modified with 5-methylcytidine. 62. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 59, wherein S1 and / or S2 comprises a nucleoside modified with 2′-O-methyl sugar. 63. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 59, wherein S1 and / or S2 comprise a nucleoside modified with a 2′-O-ethyl sugar.64. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 63, wherein S1 and / or S2 comprises a nucleoside modified with a 2′-OH sugar. 65. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 64, wherein S1 and / or S2 comprises a nucleoside modified with a 2′-fluorosugar. 66. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 65, wherein S1 and / or S2 comprises a nucleoside modified with a 2′-fluoro-arabinonucleotide (2′-fluoro-ANA) sugar. 67. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 66, wherein S1 and / or S2 comprises glycol-containing nucleic acid (GNA). 68. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 67, wherein S1 and / or S2 comprises locked nucleic acid (LNA). 69. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 68, wherein W1 comprises a nucleoside modified with a 2′-deoxysugar. 70. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 69, wherein W1 comprises a nucleoside modified with 2'-O-methoxyethyl sugar. 71. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 70, wherein W1 comprises a nucleoside modified with 2'-O-methyl sugar. 72. The modified multisegment antisense oligonucleotide according to claim 71, wherein W1 comprises 2'-O-methyl-5-methylcytidine. 73. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 71, wherein W1 comprises a nucleoside modified with 2′-fluorosugar. 74. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 73, wherein W1 comprises a nucleoside modified with 2′-fluoro-arabinonucleotide (2′-fluoro-ANA). 75. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 74, wherein W1 comprises glycol nucleic acid (GNA). 76. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 75, wherein W1 comprises locked nucleic acid (LNA). 77. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 76, wherein W1 comprises a nucleoside modified with a 2′-O-ethyl sugar. Claims 5 / 9, page 6, CN 121358861 A 78. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 77, wherein W2 comprises a nucleoside modified with a 2′-deoxy sugar. 79. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 78, wherein W2 comprises a nucleoside modified with a 2′-O-methoxyethyl sugar.80. The modified multisegment antisense oligonucleotide of claim 79, wherein W2 comprises 2'-O-methoxyethyl 5-methylcytidine. 81. The modified multisegment antisense oligonucleotide of any one of claims 1 to 78, wherein W2 comprises a nucleoside modified with a 2'-fluorosugar. 82. The modified multisegment antisense oligonucleotide of claim 81, wherein W2 comprises a nucleoside modified with 2'-fluoro-arabinonucleotide (2'-fluoro-ANA). 83. The modified multisegment antisense oligonucleotide of any one of claims 1 to 82, wherein W2 comprises glycol-modified nucleic acid (GNA). 84. The modified multisegment antisense oligonucleotide of any one of claims 1 to 83, wherein W2 comprises locked nucleic acid (LNA). 85. The modified multisegment antisense oligonucleotide of any one of claims 1 to 84, wherein W2 comprises a nucleoside modified with a 2'-O-ethylsugar. 86. The modified multisegment antisense oligonucleotide of any one of claims 1 to 85, wherein at least one internucleotide bond is a phosphodiester bond. 87. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 86, wherein at least one internucleotide bond is a modified internucleotide bond. 88. The modified multisegment antisense oligonucleotide according to claim 87, wherein the modified internucleotide bond is a phosphate thioester internucleotide bond. 89. The modified multisegment antisense oligonucleotide according to claim 87, wherein the modified internucleotide bond comprises a phosphate diamide morpholino modification. 90. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 89, wherein: a. the ratio of EC50 of cells treated with the modified multisegment antisense oligonucleotide to EC50 of cells treated with a modified antisense oligonucleotide having the same template nucleotide sequence but without a separator segment is from about 0.05 to about 250; b. the MTT CC25 value of cells treated with the modified multisegment antisense oligonucleotide is from about 10 nM to about 250 nM; c. the CCK8 CC30 value of cells treated with the modified multisegment antisense oligonucleotide is from about 10 nM to about 250 nM; d. the ratio of CC30 fold to EC50 of cells treated with the modified multisegment antisense oligonucleotide to that of cells having the same template nucleotide sequence but without a separator segment is from about 0.01 to about 50; e. Compared with modified antisense oligonucleotides having the same template nucleobase sequence but without the separator segment, it exhibits a melting temperature reduction of at least 1.1-fold; and / or f. Compared with modified antisense oligonucleotides having the same template nucleobase sequence but without the separator segment, it exhibits an increase in endonuclease recruitment of at least 1.1-fold.91. The modified multi-segment antisense oligonucleotide according to any one of claims 1 to 90, wherein the modified multi-segment antisense oligonucleotide is complementary to a nucleotide sequence in a viral gene transcript, optionally wherein the viral gene is selected from the group consisting of HPV, HBV, EBV, HSV, HIV, and RSV genes. 92. The modified multi-segment antisense oligonucleotide according to any one of claims 1 to 90, wherein the modified multi-segment antisense oligonucleotide is complementary to a human gene transcript. 93. The modified multisegment antisense oligonucleotide of claim 92, wherein the modified multisegment antisense oligonucleotide is complementary to human gene transcripts selected from the group consisting of: DM1 protein kinase (DMPK), α-1 antitrypsin (AAT), thyroxine transporter (TTR), proprotein convertase subtilisin / kexin type 9 (PCSK9), apolipoprotein B (ApoB), apolipoprotein C-III (ApoCIII), TNF-α, SERPINA8 (AGT), complement factor B (CFB), diacylglycerol O-acyltransferase 2 (DGAT2), protein 3 containing the Patatin-like phospholipase domain (PNPLA3), 5′-aminolevulinic acid synthase 1 (ALAS1), and hydroxy acid oxidase 1 gene transcripts. 94. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 90, wherein the modified multisegment antisense oligonucleotide is complementary to a gene transcript selected from the group consisting of: DM1 protein kinase (DMPK), α-1 antitrypsin (AAT), thyroxine transporter (TTR), proprotein convertase subtilisin / kexin type 9 (PCSK9), apolipoprotein B (ApoB), apolipoprotein C-III (ApoCIII), TNF-α, SERPINA8 (AGT), complement factor B (CFB), diacylglycerol O-acyltransferase 2 (DGAT2), Patatin-like phospholipase domain-containing protein 3 (PNPLA3), 5′-aminolevulinic acid synthase 1 (ALAS1) or hydroxy acid oxidase 1, Mat1α, (proto)renin receptor / (P)RR, COVID-19 5'UTR, Acc1, Acc2, ACE2, androgen receptor, ApoB, ASGR1, ASO, ATXN2, B1AR, B2AR, C9ORF72, caspase 2, CD19, CD4, chikungunya virus, CLPro, complement component 5, COVID19, COX2, CTGF, DGAT2, DMD, DMPK, DNM2DUX4, E2 gene, EGFR, envelope, EphA2, epithelial sodium channel α subunit, exon 100 dystrophin, exon 101 dystrophin, exon 102 dystrophin, exon 103 dystrophin, exon 104 dystrophin, exon 105 dystrophin, exon 106 dystrophin, exon 107 dystrophin, exon 108 dystrophin, exon 109 dystrophin, exon 110 dystrophin, exon 111 dystrophin, exon 112 dystrophin, exon 113 dystrophin, exon 114 dystrophin, exon 115 dystrophin Good protein, exon 116 dystrophin, exon 117 dystrophin, exon 118 dystrophin, exon 119 dystrophin, exon 120 dystrophin, exon 121 dystrophin, exon 122 dystrophin, exon 123 dystrophin, exon 124 dystrophin, exon 125 dystrophin, exon 126 dystrophin, exon 127 dystrophin, exon 128 dystrophin, exon 129 dystrophin, exon 130 dystrophin, exon 131 dystrophin, exon 132 dystrophin, exon 133 dystrophin, exon 134 dystrophin, exon 135 dystrophin, exon 136 Muscular dystrophy protein, exon 137 muscular dystrophy protein, exon 138 muscular dystrophy protein, exon 139 muscular dystrophy protein, exon 140 muscular dystrophy protein, exon 141 muscular dystrophy protein, exon 142 muscular dystrophy protein, exon 143 muscular dystrophy protein, exon 144 muscular dystrophy protein, exon 145 muscular dystrophy protein, exon 146 muscular dystrophy protein, exon 147 muscular dystrophy protein, exon 148 muscular dystrophy protein, exon 149 muscular dystrophy protein, exon 150 muscular dystrophy protein Myotrophic protein, exon 151 muscular dystrophy protein, exon 152 muscular dystrophy protein, exon 44 muscular dystrophy protein, exon 53 muscular dystrophy protein, exon 54 muscular dystrophy protein, exon 55 muscular dystrophy protein, exon 56 muscular dystrophy protein, exon 57 muscular dystrophy protein, exon 58 muscular dystrophy protein, exon 59 muscular dystrophy protein, exon 60 muscular dystrophy protein, exon 61 muscular dystrophy protein, exon 62 muscular dystrophy protein, exon 63 muscular dystrophy protein, exon 64 muscular dystrophy proteinMyotrophic dystrophy protein, exon 65 myotrophic dystrophy protein, exon 66 myotrophic dystrophy protein, exon 67 myotrophic dystrophy protein, exon 68 myotrophic dystrophy protein, exon 69 myotrophic dystrophy protein, exon 70 myotrophic dystrophy protein, exon 71 myotrophic dystrophy protein, exon 72 myotrophic dystrophy protein, exon 73 myotrophic dystrophy protein, exon 74 myotrophic dystrophy protein. Claims 7 / 9 pages 8 CN 121358861 A Muscular dystrophy protein, exon 75 muscular dystrophy protein, exon 76 muscular dystrophy protein, exon 77 muscular dystrophy protein, exon 78 muscular dystrophy protein, exon 79 muscular dystrophy protein, exon 80 muscular dystrophy protein, exon 81 muscular dystrophy protein, exon 82 muscular dystrophy protein, exon 83 muscular dystrophy protein, exon 84 muscular dystrophy protein, exon 85 muscular dystrophy protein, exon 86 muscular dystrophy protein, exon 87 muscular dystrophy protein, exon 88 muscular dystrophy protein, exon 89 muscular dystrophy protein, exon 90 muscular dystrophy protein, exon 91 muscular dystrophy protein, exon 92 muscular dystrophy protein, exon 93 muscular dystrophy protein, exon 94 muscular dystrophy protein, exon 95 muscular dystrophy protein, exon 96 muscular dystrophy protein, exon 97 muscular dystrophy protein White, exon 98 dystrophin, exon 99 dystrophin, Fabp3, coagulation factor VII, coagulation factor XI, FAK, FGFR4, FOXP3, FUS, FXII, GFAP, GFP, glycogen synthase, H1N1, HBV, heat shock protein 47, heat shock protein 48, heat shock protein 49, heat shock protein 50, heat shock protein 51, heat shock protein 52, heat shock protein 53 Heat shock protein 54, heat shock protein 55, heat shock protein 56, heat shock protein 57, heat shock protein 58, heat shock protein 59, helicase, HIV, HOXB13, HPRT, HPV, Hsd11β1, HTT, hydroxy acid oxidase 1, hydroxysteroid 17β-dehydrogenase 13, hypoxia-inducible factor 2α, spindle kinase and vascular endothelial growth factor, KRAS, leader sequence, leucine-rich repeat kinase 2 (LRRK2), MERS-CoV, MGMT, miR-16, miR-21, MMP-2, MMP-9, MTL-CEBPA, MuRF1, Mycobacterium tuberculosis, COVID-19N, Rabies N123, Rabies N749, Rabies N903, Rabies N1082, Rabies N53, Rabies N8, Chikungunya virus ns1 gene, Chikungunya virus ns2 gene, Chikungunya virus ns3 gene, Chikungunya virus ns4 gene, ORF1b, ORF1a, HIVP24, rabies P330, P53, rabies P721, rabies P91, PCSK9, PDGF, PDL1, COVID-19 PLP, PNPLA3, Polo-like kinase 1, protein kinase N3, RAF1, RAF-1, RDRP, RSV, SMN2, SNCA, Covid-19 spike protein, STAT3, TAU, TGFB1, TGFB1 and Cox2, TMPRSS2, TMPRSS6, TNFα, thyroxine transporter, VEGF, VEGFR2, VER2, xanthine dehydrogenase and YAP1. 95. The modified multisegment antisense oligonucleotide according to any one of claims 1 to 90, wherein the modified multisegment antisense oligonucleotide is complementary to a gene transcript selected from the group consisting of: oncogene transcripts, inflammatory gene transcripts, metabolic disease gene transcripts, cardiovascular gene transcripts, liver disease gene transcripts, infectious disease gene transcripts, nervous system disease gene transcripts, neuromuscular disease gene transcripts, eye disease gene transcripts, kidney disease gene transcripts, respiratory system disease gene transcripts, blood disease gene transcripts, wound healing gene transcripts, transplant gene transcripts, autoimmune disease gene transcripts, and neuropsychiatric gene transcripts. 96. A modified multisegment antisense oligonucleotide, wherein the modified multisegment antisense oligonucleotide comprises the structure of a modified multisegment antisense oligonucleotide of any one of SEQ ID NO: 11-1453 or 5000-30983. 97. A modified multisegment antisense oligonucleotide, said modified multisegment antisense oligonucleotide comprising the structure of a modified multisegment antisense oligonucleotide of any one of SEQ ID NO: 11-1453 or 5000-30983, or an oligonucleotide having at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% sequence identity therewith. 98. A modified multisegment antisense oligonucleotide, said modified multisegment antisense oligonucleotide comprising the structure of a modified multisegment antisense oligonucleotide of any one of SEQ ID NO: 11-1453 or 5000-30983, or comprising at least one, two, three, four, or five additional modifications thereof to the oligonucleotide. 99. A pharmaceutical composition comprising the modified multisegment antisense oligonucleotide or a salt thereof according to any one of claims 1 to 98, and at least one pharmaceutically acceptable carrier or diluent. 100. A method of treating a disease, disorder, or symptom, the method comprising administering to a subject a modified multisegment antisense oligonucleotide according to any one of claims 1 to 98 or a pharmaceutical composition according to claim 99. 101. The method of claim 100, wherein the administration to the subject is parenteral. (Claims 8 / 9 pages)9 CN 121358861 A 102. The method of claim 100, wherein the administration to the subject is subcutaneous. 103. The method of claim 100, wherein the administration to the subject is percutaneous. 104. The method of claim 100, wherein the administration to the subject is intraocular. 105. The method of claim 100, wherein the administration to the subject is intramuscular. 106. The method of claim 100, wherein the administration to the subject is intravenous. 107. The method of any one of claims 100 to 106, wherein the subject is a human. 108. The method of any one of claims 100 to 106, wherein the subject is a non-human primate. Claims 9 / 9 Page 10 CN 121358861 A Modified multi-segment antisense oligonucleotide for use

[0001] Related Patent Applications

[0002] This application claims priority and benefit to PCT application No. PCT / CN2023 / 000034, filed January 10, 2023, and PCT application No. PCT / CN2023 / 106924, filed July 12, 2023, the contents of each of which are incorporated herein by reference in their entirety. Background Art

[0003] Antisense technology has emerged as an effective means of reducing the expression of specific gene products and may therefore prove to have unique uses in many therapies. Antisense therapy differs from nucleoside therapy in that it can directly target transcripts of targets and antigens of interest and therapeutic value. Antisense technology has emerged as an effective means of reducing the expression of certain gene products and may therefore prove to have unique uses in many therapeutic, diagnostic, and research applications for regulating diseases of interest.

[0004] Many antisense oligonucleotides (ASOs) currently used and tested in clinical practice have minimal efficacy in reducing target levels and / or cause safety concerns. Therefore, there is a need in the art for improved target antisense oligonucleotides. This document provides compositions and methods for addressing the above-mentioned problems. Summary of the Invention

[0005] This disclosure provides a modified multi-segment antisense oligonucleotide structure complementary to a nucleotide sequence in a gene transcript. The modified multi-segment antisense oligonucleotide of this disclosure comprises, in sequence from 5′ to 3′, at least a 5′ wing segment; a first nick segment (G1); a first separator segment (S1); a second nick segment (G2); and a 3′ wing segment (W2), wherein each segment is linked by a nucleotide inter-bond; and wherein at least one nucleotide of each of W1, W2, and S1 is modified. In some embodiments, the modified multi-segment antisense oligonucleotide may have additional separator segments flanked by additional nick segments.

[0006] These modified multisegment antisense oligonucleotides contain separate gap regions that bind to strategically targeted binding enhancers. The targets of these modified multisegment antisense oligonucleotides can be any target, such as mammalian or viral targets. In some respects, the modified multisegment antisense oligonucleotides target HBV, DM1 protein kinase (DMPK), α-1 antitrypsin (AAT), thyroxine transporter (TTR), proprotein convertase subtilisin / kexin type 9 (PCSK9), apolipoprotein B (ApoB), apolipoprotein C-III (ApoCIII), TNF-α, SERPINA8 (AGT), complement factor B (CFB), diacylglycerol O-acyltransferase 2 (DGAT2), Patatin-like phospholipase domain-containing protein 3 (PNPLA3), 5′-aminolevulinic acid synthase 1 (ALAS1), or hydroxy acid oxidase 1. In some implementations, the modified multi-segment antisense oligonucleotide targets Mat1α, (proto)renin receptor / (P)RR, COVID-195'UTR, Accl, Acc2, ACE2, androgen receptor, ApoB, ASGR1, ASO, ATXN2, B1AR, B2AR, C9ORF72, Caspase 2, CD19, CD4, Chikungunya virus, CLPro, Complement component 5, COVID19, COX2, CTGF, DGAT2, DMD, DMPK, DNM2, DUX4, E2 gene, EGFR, Envelope, EphA2, Epithelial sodium channel α subunit, Exon 100 dystrophin, Exon 101 dystrophin, Exon 102 dystrophin, Exon 103 dystrophin, Exon 104 dystrophin, Exon 105 dystrophin, Exon 106 dystrophin, Exon 107 dystrophin, Exon 108 dystrophin Exon 109 dystrophin, Exon 110 dystrophin, Exon 111 dystrophin, Exon 112 dystrophin, Exon 113 dystrophin, Exon 114 dystrophin, Exon 115 dystrophin, Exon 116 dystrophin, Exon 117 dystrophin, Exon 118 dystrophin, Exon 119 dystrophin, Exon 120 dystrophin, Exon 121 dystrophin, Exon 122 dystrophin, Exon 123 dystrophin, Exon 124 dystrophin, Exon 125 dystrophin, Exon 126 dystrophin, Exon 127 dystrophin, Exon 128 dystrophin, Exon 12 ...Myotrophic lateral sclerosis protein (PLS) of exons 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, and 143. Exon 144 dystrophin, Exon 145 dystrophin, Exon 146 dystrophin, Exon 147 dystrophin, Exon 148 dystrophin, Exon 149 dystrophin, Exon 150 dystrophin, Exon 151 dystrophin, Exon 152 dystrophin, Exon 44 dystrophin, Exon 53 dystrophin, Exon 54 dystrophin, Exon 55 dystrophin, Exon 56 dystrophin, Exon 57 dystrophin, Exon 58 dystrophin, Exon 59 dystrophin, Exon 60 dystrophin, Exon 61 dystrophin Good protein, exon 62 dystrophy protein, exon 63 dystrophy protein, exon 64 dystrophy protein, exon 65 dystrophy protein, exon 66 dystrophy protein, exon 67 dystrophy protein, exon 68 dystrophy protein, exon 69 dystrophy protein, exon 70 dystrophy protein, exon 71 dystrophy protein, exon 72 dystrophy protein, exon 73 dystrophy protein, exon Myotrophic dystrophy protein in exon 74, exon 75, exon 76, exon 77, exon 78, exon 79, exon 80, exon 81, exon 82, exon 83, exon 84, exon 85, exon 86 Myotrophic lateral sclerosis protein, exon 87 muscular dystrophy protein, exon 88 muscular dystrophy protein, exon 89 muscular dystrophy protein, exon 90 muscular dystrophy protein, exon 91 muscular dystrophy protein, exon 92 muscular dystrophy protein, exon 93 muscular dystrophy protein, exon 94 muscular dystrophy protein, exon 95 muscular dystrophy protein, exon 96 muscular dystrophy protein, exon 97 muscular dystrophy protein, exon 98 muscular dystrophy protein, exonMuscle dystrophy protein 99, Fabb3, coagulation factor VII, coagulation factor XI, FAK, FGFR4, FOXP3, FUS, FXII, GFAP, GFP, glycogen synthase, H1N1, HBV, heat shock protein 47, heat shock protein 48, heat shock protein 49, heat shock protein 50, heat shock protein 51, heat shock protein 52, heat shock protein 53, heat shock protein 54, heat shock protein 55, heat shock protein 56, heat shock protein 57, heat shock protein 58, heat shock protein 59, helicase, HIV, HOXB13, HPRT, HPV, Hsd11β 1. HTT, hydroxy acid oxidase 1, hydroxysteroid 17β-dehydrogenase 13, hypoxia-inducible factor 2α, spindle kinin and vascular endothelial growth factor, KRAS, leader sequence, leucine-rich repeat kinase 2 (LRRK2), MERS-CoV, MGMT, miR-16, miR-21, MMP-2, MMP-9, MTL-CEBPA, MuRF1, Mycobacterium tuberculosis, COVID-19N, rabies N123, rabies N749, rabies N 903, Rabies N1082, Rabies N53, Rabies N8, Chikungunya virus ns1 gene, Chikungunya virus ns2 gene, Chikungunya virus ns3 gene, Chikungunya virus ns4 gene, ORF1b, ORF1a, HIVP24, Rabies P330, P53, Rabies P721, Rabies P91, PCSK9, PDGF, PDL1, COVID-19 PLP, PNPLA3, Polo-like kinase 1, Protein kinase N3, RAF1, RAF-1, RDRP, RSV, SMN2, SNCA, Covid-19 spike protein, STAT3, TAU, TGFB1, TGFB1 and Cox2, TMPRSS2, TMPRSS6, TNFα, Thyroxine transporter, VEGF, VEGFR2, VER2, Xanthine dehydrogenase or YAP1. They can be used to treat both acute and chronic diseases, including but not limited to the oligonucleotides described in the specification 2 / 170 page 12 CN 121358861 A, whose targets are carcinogenic targets, inflammatory targets, metabolic disease targets, cardiovascular targets, liver disease targets, infectious disease targets, nervous system disease targets, neuromuscular disease targets, eye disease targets, kidney disease targets, respiratory system disease targets, blood disease targets, wound healing targets, transplant targets, autoimmune disease targets, neuropsychiatric targets, etc.

[0007] This disclosure is based at least in part on the following finding: In the modified multi-segment antisense oligonucleotides of this disclosure, the discontinuous gap segment flanked between the 5′ wing segment and the 3′ wing segment provides superior performance compared to conventional gap polymers (from wing to wing).Improved activity of the modified multisegment antisense oligonucleotide (the antisense oligonucleotide composed of the central DNA segment of the segment). Surprisingly, one or more spacer segments placed directly between two gap segments, thus making the gap segments discontinuous, provide improved activity of the modified multisegment antisense oligonucleotide. The inventors unexpectedly discovered that placing spacer segments at specific locations on the multisegment antisense oligonucleotide of this disclosure provides improved activity. Unbound by theory or mechanism, one or more spacer segments side-attached between gap segments provide advantageous secondary structures for improved physicochemical properties (e.g., solubility) and alternative interactions with nucleases (e.g., endonucleases, such as RNase H) when forming a double strand with the target nucleic acid, thereby increasing the ability of the modified multisegment antisense oligonucleotide of this disclosure to target and / or degrade target mRNA.

[0008] Furthermore, specific types of nucleoside modifications in the spacer segments provide unexpected activity improvements. Unbound by theory or mechanism, the inventors have observed that certain modifications of nucleosides in the separator segments (including 2′-O-methoxyethyl and 2′-O-methyl modifications) increase the ability of the modified multisegmental antisense oligonucleotides of this disclosure to target and / or degrade target mRNA.

[0009] Unbound by theory or mechanism, certain combinations of nucleoside modifications and the localization of the separator segments within the modified multisegmental antisense oligonucleotides improve interactions with RNase H endonucleases without impairing hybridization with the target sequence.

[0010] Substituting nucleosides with sugar-modified nucleosides (e.g., 2′-O-MOE) in conventional notched polymers (i.e., those not multisegmented) results in enhanced binding affinity to the target sequence. This type of enhancement has been explored in conventional notched polymer designs to form more stable duplexes with the target sequence, thereby improving notched polymer activity. The stability of the duplexes can be determined by quantitative melting temperature (Tm). Higher melting temperatures generally indicate enhanced binding to the target sequence and are expected to lead to increased recruitment and functional activity of nucleases (e.g., silencing of target expression).

[0011] Contrary to current teachings in the art and unlike conventional not-segmented nicked polymers, the inventors have unexpectedly discovered that the introduction of certain nucleotides (e.g., 2′-O-MOE) as separators at certain positions in the continuous sequence of deoxynucleotides unexpectedly lowers, rather than increases, Tm. More surprisingly, modified multisegmented antisense oligonucleotides with this Tm reduction are associated with improved bioactivity and potency compared to corresponding conventional nicked polymer designs. Without being bound by theory or mechanism, certain combinations of nucleotide modifications and the localization of separator segments within the full-length multisegmented antisense oligonucleotide can lead to changes in secondary structure that, in turn, favor enhanced interaction with nucleases (e.g., endonucleases such as RNase H) and improved functional activity.

[0012] This disclosure is based, at least in part, on the discovery that certain nucleoside modifications at certain positions in the 5′ wing and / or 3′ wing reduce in vivo toxicity. The inventors unexpectedly discovered that certain modified nucleosides at certain positions in the 3′ wing (e.g., LNA) reduce in vivo toxicity. Without being bound by theory or mechanism, certain combinations of nucleoside modifications with localization within the 5′ wing and / or 3′ wing contribute to the complementarity of the modified multisegmental antisense oligonucleotide while reducing interactions with off-target sequences. The modified multisegmental antisense oligonucleotides described herein possess one or more of the following: increased in vivo activity, reduced off-target binding, reduced toxicity, and a wider safety margin, which are advantageous for therapeutic use.

[0013] This document provides methods for regulating the expression of target mRNAs and proteins, modified multisegmental antisense oligonucleotides, and compositions.

[0014] Methods for preventing, treating, and improving diseases, disorders, and symptoms, modified multisegment antisense oligonucleotides, and compositions thereof are also provided. (3 / 170 pages, 13 CN 121358861 A) Brief Description of the Drawings

[0015] Figures 1A-1E show a series of graphs depicting the inhibition of PCSK9 mRNA levels in Hepa1-6 cells after treatment with the modified multisegment antisense oligonucleotides of this disclosure.

[0016] Figures 2A-2F show a series of graphs depicting the inhibition of PCSK9 mRNA levels in Hepa1-6 cells after treatment with the modified multisegment antisense oligonucleotides of this disclosure.

[0017] Figures 3A-3E show a series of graphs depicting the inhibition of DMPK mRNA levels in Sol8 cells after treatment with the modified multisegment antisense oligonucleotides of this disclosure.

[0018] Figures 4A-4F show a series of graphs depicting the inhibition of DMPK mRNA levels in Sol8 cells after treatment with the modified multisegment antisense oligonucleotides of this disclosure.

[0019] Figures 5A-5D show a series of graphs depicting the inhibition of TTR mRNA levels in AML-12 cells after treatment with the modified multisegment antisense oligonucleotides of this disclosure.

[0020] Figures 6A-6D show a series of graphs depicting the inhibition of TTR mRNA levels in AML-12 cells after treatment with the modified multisegment antisense oligonucleotides of this disclosure.

[0021] Figures 7A-7D show a series of graphs depicting the inhibition of AAT mRNA levels in AML-12 cells after treatment with the modified multisegment antisense oligonucleotides of this disclosure.

[0022] Figure 8 shows a graph depicting the effect of the modified multisegment antisense oligonucleotides of this disclosure on plasma PCSK9 protein levels.

[0023] Figure 9 shows a graph depicting the percentage inhibition of plasma PCSK9 protein levels after treatment with the modified multisegment antisense oligonucleotides of this disclosure.

[0024] Figure 10 shows a graph depicting the effect of the modified multisegment antisense oligonucleotides of this disclosure on plasma TTR protein levels.

[0025] Figure 11 shows a graph depicting the percentage inhibition of plasma TTR protein levels after treatment with the modified multisegment antisense oligonucleotides of this disclosure.

[0026] Figures 12A-12B show graphs depicting the effect of the modified multisegment antisense oligonucleotides of this disclosure on hepatitis B virus (HBV) surface antigen (HBsAg) levels in genotype C HBV transgenic mice.

[0027] Figure 13 shows a graph depicting the effect of the modified multisegment antisense oligonucleotides of this disclosure on HBsAg levels in pcDNA3.1-preS2-GTD HDI-HBV mice.

[0028] Figure 14 shows a graph depicting the effect of the modified multi-segment antisense oligonucleotide of this disclosure on HBsAg levels in pcDNA3.1-preS2-GTD HDI-HBV mice.

[0029] Figure 15 shows a graph depicting the effect of the modified multi-segment antisense oligonucleotide of this disclosure on HBsAg levels in pcDNA3.1-preS2-GTD HDI-HBV mice.

[0030] Figures 16A-16B show graphs depicting the effect of the modified multi-segment antisense oligonucleotide of this disclosure on HBsAg levels in pcDNA3.1-preS2-GTD HDI-HBV mice.

[0031] Figure 17 shows a graph depicting the effect of the modified multi-segment antisense oligonucleotide of this disclosure on HBsAg levels in pcDNA3.1-preS2-GTD HDI-HBV mice.

[0032] Figure 18 shows a graph depicting the effect of the modified multi-segment antisense oligonucleotide of this disclosure on HBsAg levels in pAAV-1.2HBV-GTA HDI-HBV mice. Specification 4 / 170 pages 14 CN 121358861 A

[0033] Figure 19 shows a graph depicting the effect of the modified multi-segment antisense oligonucleotide of this disclosure on HBsAg levels in pcDNA3.1-preS2-GTD HDI-HBV mice.

[0034] Figure 20 shows a 20% pre-UREA-TBE PAGE gel of RNase H cleavage products. Channel 1: AUS1233, Channel 2: AUS1493, Channel 3: AUS1493, Channel 4: AUS1013, Channel 5: AUS1014, Channel 6: AUS1015, Channel 7: AUS1212, Channel 8: AUS1654, Channel 9: AUS1655, Channel 10: Molecular weight marker

[0035] Figure 21 shows a table of exemplary modified multi-segment antisense oligonucleotides of the present disclosure, the entire contents of which are incorporated herein by reference. Modifications at each position of the modified multi-segment antisense oligonucleotide sequence are read using the legend in Table 2.2. Examples of modified multi-segment antisense oligonucleotides of the present disclosure are AUS1010 to AUS1714 (SEQ ID NO: 11 to SEQ ID NO: 666).

[0036] Figure 22 shows a table of exemplary modified multi-segment antisense oligonucleotides of the present disclosure. In Figure 22, lowercase letters represent 2′-deoxynucleosides, and uppercase letters represent nucleosides having any of the modifications shown in the section titled Exemplary Modifications, such as 2′-O-methoxyethyl nucleosides, 2′-O-methoxyethyl cytidine, 2′-O-methyl nucleosides, 2′-O-methyl nucleosides, 2′-OH nucleosides, GNA, LNA, LNA having a cytosine base, 2′-fluoro2′-deoxynucleosides, 2′-fluoro2′-deoxycytidine, 2′-F-arabinose (2′-F-ANA), or 2′-F-arabinose (2′-F-ANA), or combinations thereof. In Figure 22, lowercase "c" represents 2′-deoxycytidine or 2′-deoxy5-methylcytidine, and uppercase "C" represents cytidine or 5-methylcytidine with or without the aforementioned sugar modifications. SEQ ID NO: 5,000 to SEQ ID NO: 30,983 are exemplary modified multi-segment antisense oligonucleotides. Detailed Description

[0037] It should be understood that both the foregoing general description and the following detailed description are exemplary and illustrative only, and are not, limitations of the claimed invention. In this document, the singular is used to include the plural unless otherwise stated. As used herein, unless otherwise stated, the use of "or" means "and / or". Furthermore, the use of the terms "including" and other forms such as "includes" and "included" is not limiting. In addition, unless otherwise stated, the terms "element" or "component" cover both elements and components that include one unit and elements and components that include more than one subunit.

[0038] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. All references or portions thereof cited in this application, including but not limited to patents, patent applications, articles, books and papers, in whole or in part, to the references discussed herein, are expressly incorporated herein by reference.

[0039] Definitions

[0040] Unless explicitly defined herein, all nomenclature used in molecular biology, analytical chemistry, synthetic organic chemistry, and medicinal chemistry as described herein, and procedures and techniques used in analytical chemistry, synthetic organic chemistry, and medicinal chemistry as described herein, shall be used in conjunction with the nomenclature used in these fields.The techniques are those well-known and commonly used in the art. Standard techniques are available for chemical synthesis and chemical analysis. Where permitted, all patents, applications, published applications and other publications, GENBANK accession numbers and relevant sequence information available from databases such as the National Center for Biotechnology Information (NCBI) and other data mentioned throughout this disclosure are incorporated herein by reference in whole or in part for the literature discussed herein.

[0041] Unless otherwise stated, the following terms have the following meanings:

[0042] "2'-O-methoxyethyl" (also known as 2'-MOE and 2'-O(CH2)2-OCH3) refers to the O-methoxy-ethyl modification at the 2' position of the furanose ring. A 2'-O-methoxyethyl modified sugar is a modified sugar.

[0043] "2'-MOE nucleoside" (also known as 2'-O-methoxyethyl nucleoside) means a nucleoside containing a 2'-MOE modified sugar moiety.

[0044] "2′-substituted nucleoside" means a nucleoside containing a substituent other than H or OH at the 2′ position of the furanyl ring. In some embodiments, the 2′-substituted nucleoside includes nucleosides with bicyclic sugar modification.

[0045] "3′ target site" refers to a target nucleic acid region complementary to the 3′ end of a specific antisense oligonucleotide.

[0046] "5′ target site" refers to a target nucleic acid region complementary to the 5′ end of a specific antisense oligonucleotide.

[0047] "5-methylcytosine" means cytosine modified with a methyl group attached to the 5-position. 5-methylcytosine is a modified nucleobase.

[0048] "About" means within ±7% of the value. For example, if it is stated that "the oligonucleotide affects at least about 70% inhibition of the target", it implies that the target level is inhibited in the range of 63% to 77%.

[0049] "Acceptable safety profile" means a pattern of side effects within clinically acceptable limits.

[0050] "Active pharmaceutical agent" means one or more substances in a pharmaceutical composition that provide therapeutic benefit when administered to an individual.

[0051] "Active target region" means a target region targeted by one or more active antisense oligonucleotides. "Active antisense oligonucleotide" means an antisense oligonucleotide that reduces the level of a target nucleic acid or protein.

[0052] "Simultaneous administration" means the combined administration of two agents in any manner, wherein the pharmacological effects of the two agents are simultaneously manifested in the patient. Simultaneous administration does not require the two agents to be administered as a single pharmaceutical composition, in the same dosage form, or via the same route of administration. The effects of the two agents do not need to be simultaneously manifested. The effects only need to overlap over a certain period of time and do not need to extend together.

[0053] "Animals" means human or non-human animals, including but not limited to mice, rats, rabbits, dogs, cats, pigs, primates, etc.Animals and non-human primates, including but not limited to monkeys and chimpanzees.

[0054] "Antibody" refers to a molecule characterized by reacting specifically with an antigen in some way, wherein the antibody and the antigen are each defined according to the other. An antibody may refer to the complete antibody molecule or any fragment or region thereof, such as the heavy chain, light chain, Fab region, and Fc region.

[0055] "Antisense activity" means any detectable or measurable activity attributable to the hybridization of an antisense oligonucleotide with its target nucleic acid. In some embodiments, antisense activity is a reduction in the amount or expression of the target nucleic acid or the protein encoded by such target nucleic acid.

[0056] "Antisense oligonucleotide" or "ASO" means an oligonucleotide capable of hybridizing with a target nucleic acid by hydrogen bonding. Examples of antisense oligonucleotides include single-stranded oligonucleotides having a nucleobase sequence that allows hybridization with a corresponding region or segment of the target nucleic acid.

[0057] "Antisense inhibition" means a reduction in the level of the target nucleic acid in the presence of an antisense oligonucleotide complementary to the target nucleic acid, compared to the level of the target nucleic acid in the absence of an antisense oligonucleotide.

[0058] "Antisense mechanism" refers to all those mechanisms involving hybridization of oligonucleotides with target nucleic acids, where the result or effect of hybridization is target degradation or target occupancy, accompanied by stagnation of cellular mechanisms involving, for example, transcription or splicing.

[0059] "Area under curve" (AUC) is the integral of the drug concentration in plasma over time. AUC can be determined for the total time for which data is available, for example until the drug is no longer detectable (AUC0-t), the area under the curve extrapolated from time 0 to infinity, or for a specific cutoff time window, for example 24 hours after administration (AUC0-24).

[0060] "Base complementarity" refers to the ability of the nucleobases of an antisense oligonucleotide to perform precise base pairing (i.e., hybridization) with the corresponding nucleobases in the target nucleic acid, and is mediated by Watson-Crick, Hoogsteen, or reverse Hoogsteen hydrogen binding between the corresponding nucleobases. Instructions 6 / 170 pages 16 CN 121358861 A

[0061] "Bicyclic sugar" means a furanose ring modified by bridging two non-twinned carbon atoms. Bicyclic sugar is a modified sugar.

[0062] "Body weight" means the total weight of an animal, including all tissues, including adipose tissue.

[0063] "Cap structure" or "terminal cap portion" means a chemical modification incorporated at either end of an antisense compound.

[0064] "cEt'′" or "restricted ethyl" means a bicyclic sugar moiety containing a bridge connecting a 4′-carbon and a 2′-carbon, wherein the bridge has the following formula: 4'-CH(CH3)-O-2'.

[0065] "Restricted ethyl nucleoside" (also called cEt nucleoside) means a nucleoside containing a bicyclic sugar moiety containing a 4'-CH(CH3)-O-2' bridge.

[0066] "Chemically distinct region" refers to a region of an antisense compound that is chemically distinct from another region of the same antisense compound in some respects. For example, a region having a 2'-O-methoxyethyl nucleotide is chemically distinct from a region having a nucleotide without 2'-O-methoxyethyl modification.

[0067] "Co-administration" means administering two or more pharmaceutical agents to an individual. The two or more pharmaceutical agents may be in a single pharmaceutical composition or in separate pharmaceutical compositions. Each of the two or more pharmaceutical agents may be administered via the same or different routes of administration. Co-administration includes parallel administration or sequential administration.

[0068] "Complementarity" means the ability of nucleobases of the first and second nucleic acids to pair.

[0069] "Diluent" means a component in the composition that lacks pharmacological activity but is pharmaceutically necessary or desired. For example, in an injectable drug, the diluent may be a liquid, such as a saline solution.

[0070] "Dosage unit" means the form in which the pharmaceutical agent is provided, such as a pill, tablet, or other dosage unit known in the art.

[0071] "Dosage" refers to a specified amount of a drug agent delivered in a single administration or over a specified time period. In some embodiments, the dosage may be administered in two or more boluses, tablets, or injections. For example, in some embodiments, when subcutaneous administration is required, the desired dosage requires a volume that is not easily contained in a single injection. In such embodiments, the desired dosage may be achieved using two or more injections. In some embodiments, the dosage may be administered in two or more injections to minimize injection site reactions in an individual. In other embodiments, the drug agent is administered by infusion over an extended time period or continuously. Dosage may be expressed as the amount of drug agent per hour, per day, per week, or per month.

[0072] "Dosage regimen" is a combination of dosages designed to achieve one or more desired effects.

[0073] "Duration" means the time period during which an activity or event continues. In some embodiments, the duration of treatment is the time period during which a dose of the drug agent is administered.

[0074] In the context of modulating activity or treating or preventing a condition, "effective amount" means, in a single dose or as part of a series, the amount of active ingredient that effectively modulates, treats, prevents, or improves the condition in a subject requiring such modulation, treatment, or prevention. Effective amount will vary depending on the health and physical condition of the subject being treated, the subject's taxonomy, the formulation of the composition, assessment of the medical condition, and other relevant factors.

[0075] "Efficacy" means the ability to produce a desired effect.

[0076] "Expression" includes all functions that translate the coding information of a gene into structures present and manipulated in the cell. Such structures include, but are not limited to, the products of transcription and translation.

[0077] The term "fragment" applied to polynucleotides should be understood to mean a nucleotide sequence that is reduced in length relative to a reference nucleic acid or nucleotide sequence and contains adjacent nucleotides that are identical or nearly identical (e.g., 60%, 70%, 80%, 90%, 92%, 95%, 98%, or 99% identical) to, substantially composed of, and / or composed of, that nucleotide sequence. Such nucleic acid fragments according to the invention may, where appropriate, be incorporated into larger polynucleotides in which the nucleic acid fragment is a component, as described on page 7 / 170 of the specification, CN 121358861 A. In some embodiments, such fragments may contain oligonucleotides of at least about 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150, 200, or more consecutive nucleotides of the nucleic acid or nucleotide sequence according to the invention, substantially composed of, and / or composed of, these oligonucleotides.

[0078] "Completely complementary" or "100% complementary" means that each nucleobase of the first nucleic acid has a complementary nucleobase in the second nucleic acid. In some embodiments, the first nucleic acid is an antisense oligonucleotide, and the target nucleic acid is the second nucleic acid.

[0079] "Completely modified motif" refers to an antisense oligonucleotide containing a neighboring sequence of nucleosides, wherein substantially each nucleoside is a sugar-modified nucleoside with uniform modification.

[0080] "Gap polymer" means an antisense oligonucleotide in which an inner region of a continuous sequence of deoxynucleosides linked to support recruitment by a nuclease (e.g., RNase H) is located between an outer region containing one or more nucleosides, wherein the nucleosides containing the inner regions may be chemically different from the one or more nucleosides containing the outer regions. The inner region may be referred to as a "gap", and each of the 5′ and 3′ outer regions may be referred to as a "wing".

[0081] A “gap” is an internal segment of a modified multisegment antisense oligonucleotide or gap polymer containing one or more linked deoxyribonucleotides and located directly or indirectly between the 5′ wing (W1) and the 3′ wing (W2). A gap may be interchangeably referred to as a “gap”, a “gap region”, or a “gap segment”.

[0082] “Hybridization” means annealing of a complementary nucleic acid molecule. In some embodiments, the complementary nucleic acid molecule includes, but is not limited to, antisense oligonucleotides and nucleic acid targets.

[0083] “Closely adjacent” means that there are no intermediate elements between adjacent elements.

[0084] “Individual” means a human or non-human animal selected for treatment or therapy.

[0085] “Individual compliance” means that an individual adheres to the recommended or prescribed therapy.

[0086] Terms such as “induction,” “inhibition,” “enhancement,” “elevation,” “increase,” “decrease,” or similar terms generally indicate a quantitative difference between two states. Such terms can refer to a statistically significant difference between two states. These terms are applied, for example, to expression levels and activity levels. As used herein, the terms “inhibition” or “decrease,” or grammatical variations thereof, refer to a reduction or decrease in a specified level or activity of at least about 5%, about 10%, about 15%, about 25%, about 35%, about 40%, about 50%, about 60%, about 75%, about 80%, about 90%, about 95%, or more. In some embodiments, inhibition or reduction results in very little or no detectable activity (at most, insignificant amounts, such as less than about 10% or even 5%).

[0087] “Inhibition of expression or activity” refers to a reduction or blockage of expression or activity and does not necessarily indicate the complete elimination of expression or activity.

[0088] “Injection site reaction” refers to inflammation or abnormal redness of the skin at an individual injection site.

[0089] "Intraperitoneal administration" means administration by infusion or injection into the peritoneum.

[0090] "Intravenous administration" means administration into a vein.

[0091] "Extended" antisense oligonucleotide is an antisense oligonucleotide having one or more additional

[0092] nucleosides relative to the antisense oligonucleotides disclosed herein.

[0093] Specification 8 / 170 pages 18 CN 121358861 A

[0094] "Locked nucleic acid" or "LNA" or "LNA nucleoside" means a nucleic acid monomer having two carbon atoms connecting the 4′ and 2′ positions of the nucleoside sugar unit to form a bridge of bicyclic sugar. Examples of such bicyclic sugars include, but are not limited to, A) α-L-methyleneoxy(4′-CH2-O-2′)LNA; (B) β-D-methyleneoxy(4′-CH2-O-2′)-LNA; (C) ethyleneoxy(4′-(CH2)2-O-2′)LNA; (D) aminooxy(4′-CH2-O-NI-2′)LNA; and (E) hydroxyamino(4′-CH2-NI-O-2′)LNA; as shown below.

[0095] As used herein, LNA oligonucleotides include, but are not limited to, oligonucleotides having at least one bridge between the 4′ and 2′ positions of the sugar, wherein each of these bridges independently comprises one or two to four linking groups independently selected from the following: -[C(R1)(R2)]n-, -C(R1)=C(R2)-, -C(R1)=N-, -C(=NR1)-, -C(=O)-, -C(=S)-, -O-, -Si(R1)2-, -S(=O)x-, and -N(R1)-; wherein: x is 0, 1, or 2; n is 1, 2, 3, or 4; each R1 and R2 is independently H, protectedGroups, hydroxyl groups, C1-C12 alkyl groups, substituted C1-C12 alkyl groups, C2-C12 alkenyl groups, substituted C2-C12 alkenyl groups, C2-C12 alkynyl groups, substituted C2-C12 alkynyl groups, C5-C20 aryl groups, substituted C5-C20 aryl groups, heterocyclic groups, substituted heterocyclic groups, heteroaryl groups, substituted heteroaryl groups, C5-C7 alicyclic groups, substituted C5-C7 alicyclic groups, halogens, OJ1, NJIJ2, SJ1, N3, COOJ1, acyl groups (C(=O)-H), substituted acyl groups, CN, sulfonyl groups (S(=O)2-J1) or hyposulfite groups (S(=O)-J1); And each J1 and J2 is independently H, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C5-C20 aryl, substituted C5-C20 aryl, acyl (C(=O)-H), substituted acyl, heterocyclic, substituted heterocyclic, C1-C12 aminoalkyl, substituted C1-C12 aminoalkyl, or protecting group.

[0096] Examples of 4′-2′ bridging groups covered within the definition of LNA include, but are not limited to, one of the following: -[C(R1)(R2)]n-, -[C(R1)(R2)]n-O-, -C(R1)(R2)-N(R1)-O-, or -C(R1)(R2)-O-N(R1)-. In addition, other bridging groups covered within the definition of LNA are 4'-CH2-2', 4'-(CH2)2-2', 4'-(CH2)3-2', 4'-CH2-O-2', 4'-(CH2)2-O-2', 4'-CH2-O-N(R1)-2', and 4'-CH2-N(R1)-O-2'-bridges, wherein each R1 and R2 is independently H, a protecting group, or a C1-C12 alkyl group.

[0097] The definition of LNA according to the invention also includes LNAs in which the 2'-hydroxyl group of the ribosyl sugar ring is attached to the 4' carbon atom of the sugar ring, thereby forming a methyleneoxy (4'-CH2-O-2') bridge to form a bicyclic sugar moiety. The bridge can also be a methylene (-CH2-) group connecting the 2′ oxygen atom and the 4′ carbon atom; for this purpose, the term methyleneoxy(4′-CH2-O-2') LNA is used. Furthermore, in the case where the bicyclic sugar moiety has an ethylene bridging group at this position, the term ethyleneoxy(4′-CH2CH2-O-2')LNA is used. As used herein, the isomer A-L-methyleneoxy(4′-CH2-O-2')LNA is also covered within the definition of LNA.

[0098] "Maximum plasma concentration" or "Cmax" refers to the highest concentration of the drug in plasma after administration of a dose of the drug to a subject.Concentration. Methods for measuring drug concentration are known to those skilled in the art, and in particular include liquid chromatography and tandem mass spectrometry.

[0099] "Mismatch" or "non-complementary nucleobase" refers to a situation where the nucleobase of the first nucleic acid cannot pair with the corresponding nucleobase of the second or target nucleic acid.

[0100] "Modified nucleoside interbond" refers to the substitution or any alteration of a naturally occurring nucleoside interbond (i.e., phosphodiester nucleoside interbond).

[0101] "Modified nucleobase" means any nucleobase other than adenine, cytosine, guanine, thymidine, or uracil. "Unmodified nucleobase" means purine bases adenine (A) and guanine (G), and pyrimidine bases thymine (T), cytosine (C), and uracil (U). Instruction manual 9 / 170 pages 19 CN 121358861 A

[0102] "Modified nucleoside" means a nucleoside that independently has a modified sugar moiety and / or a modified nucleobase.

[0103] "Modified nucleotide" means a nucleotide that independently has a modified sugar moiety, a modified nucleoside internucleotide bond, or a modified nucleobase.

[0104] "Modified oligonucleotide" means an oligonucleotide containing at least one modified nucleoside internucleotide bond, a modified sugar, and / or a modified nucleobase.

[0105] "Modified sugar" means substitution and / or any alteration of the natural sugar moiety.

[0106] "Monomer" refers to a single unit of an oligomer. Monomers include, but are not limited to, nucleosides and nucleotides, whether naturally occurring or modified.

[0107] "Modal" means the pattern of unmodified and modified nucleosides in an antisense oligonucleotide. "Natural sugar moiety" refers to a sugar moiety found in DNA (2'-H) or RNA (2'-OH). "Naturally present nucleotide internucleotide bond" refers to a 3' to 5' phosphodiester bond.

[0108] "Modified multisegment antisense oligonucleotide" refers to an antisense oligonucleotide having at least five structural segments comprising a 5' wing (W1), a 3' wing (W2), at least two nicks (at least G1 and G2), and at least one separator (at least S1). The separator is flanked by two nick regions. The wing is located at the end of the modified multisegment antisense oligonucleotide. From 5' to 3', exemplary modified multisegment antisense oligonucleotides have the formula of Formula I or Formula II. The modified multisegment antisense oligonucleotide of this disclosure also comprises at least one modified nucleoside in the 5' wing, at least one nucleoside modification in the separator, and at least one modified nucleoside in the 3' wing. "Modified multisegment antisense oligonucleotides" can be interchangeably referred to as "multisegment modified antisense oligonucleotides" or "multisegment oligonucleotides".

[0109] "Non-complementary nucleobases" refer to a pair of nucleobases that do not form hydrogen bonds with each other or otherwise support hybridization.

[0110] "Nucleic acid" refers to a molecule composed of monomeric nucleotides. Nucleic acids include, but are not limited to, ribonucleic acid (RNA), deoxyribonucleic acid (DNA), single-stranded nucleic acid, double-stranded nucleic acid, small interfering RNA (siRNA), and microRNA (miRNA).

[0111] "Nucleobase" refers to a nitrogen-containing heterocyclic base portion that can pair with a base of another nucleic acid.

[0112] "Nucleobase complementarity" refers to a nucleobase that can pair with another nucleobase. For example, in DNA, adenine (A) is complementary to thymine (T). For example, in RNA, adenine (A) is complementary to uracil (U). In some embodiments, complementary nucleobases refer to nucleobases in an antisense oligonucleotide that can pair with nucleobases of its target nucleic acid. For example, if a nucleobase at a certain position of an antisense oligonucleotide can hydrogen bond with a nucleobase at a certain position of a target nucleic acid, the position of the hydrogen bond between the oligonucleotide and the target nucleic acid is considered complementary at that nucleobase pair.

[0113] "Nucleobase sequence" means the sequence of adjacent nucleobases independent of any sugar, bond, and / or nucleobase modification.

[0114] "Nucleoside mimics" include those structures used to replace one or more sugars and bases (and not necessarily bonds) at one or more positions of an oligomer, such as nucleoside mimics having morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranoyl, bicyclic, or tricyclic sugar mimics (e.g., non-furanose units). Nucleotide mimics include those structures used to replace nucleosides and bonds at one or more positions of an oligomer, such as peptide nucleic acids or morpholino (morpholino linked by -N(H)-C(=O)-O- or other non-phosphodiester bonds). Sugar substitutions overlap with the slightly broader term nucleoside mimics, but are intended to indicate only the substitution of sugar units (furanose rings). The tetrahydropyranoyl ring provided herein is an illustration of an example of a sugar substitution in which the furanose group has been replaced by a tetrahydropyranoyl ring system. "Mimetic" refers to a group that replaces a sugar, nucleobase, and / or nucleoside bond. Typically, a mimic is used to replace a sugar or sugar-nucleoside bond combination, and the nucleobase is retained for hybridization with the selected target.

[0115] "Off-target effect" refers to unwanted or harmful biological effects associated with the regulation of RNA or protein expression of genes other than the intended target nucleic acid.

[0116] "Oligomer" means a polymer of linked monomeric subunits capable of hybridizing with at least one region of a nucleic acid molecule.

[0117] "Oligonucleotide" means a polymer of nucleosides linked by nucleoside bonds, each of which may be independently modified or unmodified.

[0118] "Parenteral administration" means administration by injection (e.g., bolus) or infusion. Parenteral administration includes subcutaneous administration,Intravenous, intramuscular, intra-arterial, intraperitoneal, or intracranial administration, for example, intrathecal or intraventricular administration.

[0119] "Peptide" means a molecule formed by linking at least two amino acids together via an amide bond. Without limitation, as used herein, "peptide" means polypeptides and proteins.

[0120] "Pharmaceutically acceptable carrier" means a medium or diluent that does not interfere with the structure of the oligonucleotide. Certain such carriers enable pharmaceutical compositions to be formulated, for example, into tablets, pills, sugar-coated pills, capsules, liquids, gels, syrups, slurries, suspensions, and lozenges for oral ingestion by a subject.

[0121] "Pharmaceutically acceptable derivative" encompasses pharmaceutically acceptable salts, conjugates, prodrugs, or isomers of the oligonucleotides described herein.

[0122] "Pharmaceutically acceptable salt" means a physiologically and pharmaceutically acceptable salt of an antisense oligonucleotide, i.e., a salt that retains the desired biological activity of the parent oligonucleotide and does not produce undesirable toxicological effects on it.

[0123] "Pharmaceutical preparation" means a substance that provides therapeutic benefit when administered to an individual.

[0124] "Pharmaceutical composition" means a mixture of substances suitable for administration to a subject. For example, a pharmaceutical composition may comprise an antisense oligonucleotide and a sterile aqueous solution. In some embodiments, the pharmaceutical composition exhibits activity in a free-uptake assay in certain cell lines.

[0125] "Thiophosphate bond" means a bond between nucleosides in which a phosphodiester bond is modified by replacing one oxygen atom of a non-bridging oxygen atom with a sulfur atom. A thiophosphate bond is a modified inter-nucleoside bond.

[0126] "Prevention" means a period of time during which the onset or development of a symptom or disease is delayed or prevented, lasting from hours to days (preferably weeks to months).

[0127] "Prodrug" means a therapeutic agent prepared in an inactive form that is converted into its active form (i.e., a drug) in vivo or within its cells by the action of endogenous enzymes or other chemicals and / or conditions.

[0128] "Prophylactic effective amount" refers to the amount of a drug agent that provides preventive or therapeutic benefits to an animal.

[0129] "Recommended therapy" means a treatment regimen recommended by a medical professional for the treatment, improvement, or prevention of disease.

[0130] "Ribbononucleotide" means a nucleotide having a hydroxyl group at the 2' position of the sugar moiety of the nucleotide. Ribonucleotides can be modified with any of a variety of substituents.

[0131] "Salt" means a physiologically and pharmaceutically acceptable salt of an antisense oligonucleotide, i.e., a salt that retains the desired biological activity of the parent oligonucleotide and does not produce undesirable toxicological effects on it.

[0132] "Segment" can be interchangeably referred to as "region" or "part".

[0133] The "segment" in the modified multi-segment antisense oligonucleotide of this disclosure is directly located in the modified multi-segment antisense oligonucleotide.The spacer is located between two gap regions in the antisense oligonucleotide and separates these two gap regions. The spacer may have one or more nucleosides, wherein these nucleosides are chemically different from the nucleosides containing the gaps. The spacer segment contains nucleosides modified to impart properties such as enhanced inhibitory activity, increased binding affinity to target nucleic acids, reduced in vivo toxicity, or resistance to in vivo nuclease degradation. The modified multi-segment antisense oligonucleotide may contain one or more spacer segments. Exemplary modified multi-segment antisense oligonucleotides of this disclosure may contain one, two, three, four, five, or six spacer segments. In some embodiments, the modified multi-segment antisense oligonucleotide contains one spacer segment. In some embodiments, the modified multi-segment antisense oligonucleotide contains two spacer segments. Specification 11 / 170 pages 21 CN 121358861 A

[0134] The “shortened” or “truncated” versions of the antisense oligonucleotides taught herein lack one, two, or more nucleosides.

[0135] “Side effect” means a physiological response attributable to treatment other than the desired effect. In some embodiments, side effects include, but are not limited to, injection site reaction, abnormal liver function tests, abnormal kidney function, hepatotoxicity, nephrotoxicity, central nervous system abnormalities, and myopathy. For example, elevated serum transaminase levels may indicate hepatotoxicity or abnormal liver function. For example, elevated bilirubin may indicate hepatotoxicity or abnormal liver function.

[0136] As used herein, “significant” means measurable or observable, e.g., a significant result, such as a significant improvement or significant reduction.

[0137] As used herein, “site” is defined as a unique nucleobase position within the target nucleic acid.

[0138] “Specifically hybridizable” means an antisense oligonucleotide that has sufficient complementarity between the antisense oligonucleotide and the target nucleic acid to induce the desired effect, while exhibiting minimal or no effect on non-target nucleic acids under conditions requiring specific binding, i.e., physiological conditions under which in vivo assays and therapeutic treatments are performed. "Strict hybridization conditions" or "strict conditions" refer to conditions under which the oligonucleotide will hybridize with its target sequence, but with a minimum number of other sequences.

[0139] "Target nucleic acid," "target RNA," "target RNA transcript," and "nucleic acid target" all refer to nucleic acids that can be targeted by antisense oligonucleotides.

[0140] "Target region" refers to a portion of the target nucleic acid targeted by one or more antisense oligonucleotides.

[0141] "Target segment" refers to the nucleotide sequence of the target nucleic acid targeted by the antisense oligonucleotide.

[0142] "Therapeutic effective amount" refers to the amount of a drug agent that provides therapeutic benefit to an individual.

[0143] "Therapeutic" means administering a composition to achieve an alteration or improvement of a disease or symptom.

[0144] "Unmodified" nucleobases refer to purine bases adenine (A) and guanine (G), and pyrimidine bases thymine (T), cytosine (C), and uracil (U).

[0145] "Unmodified nucleotide" refers to a nucleotide consisting of naturally occurring nucleobases, sugar moieties, and nucleoside bonds. In some embodiments, the unmodified nucleotide is an RNA nucleotide (i.e., (3-D-ribonucleoside) or a DNA nucleotide (i.e., (3-D-deoxyribonucleoside)).

[0146] A “validated target segment” is defined as a portion (i.e., 8 consecutive nucleotides) of at least 8 nucleotides of a target region targeted by the active oligonucleotide.

[0147] A “wing” is a terminal segment of a nicked polymer or a modified multisegmental antisense oligonucleotide modified to impart properties such as enhanced inhibitory activity, enhanced biological activity, increased binding affinity to target nucleic acids, reduced in vivo toxicity, or resistance to in vivo nuclease degradation to the oligonucleotide. A wing may be referred to as a “wing”, a “wing region”, or a “wing segment”. As used herein, a wing comprises at least two linked nucleosides; a subset thereof may comprise one or more deoxynucleosides, but the entire wing may not consist of only deoxynucleosides. In some embodiments, a wing comprises 2 to 8 linked nucleosides. In some embodiments, a wing comprises 2 to 6 linked nucleosides.

[0148] The modified multisegment antisense oligonucleotide of this disclosure comprises a 5′ wing segment (W1) located at the 5′ end of the modified multisegment antisense oligonucleotide, and the 3′ end residue of W1 is not a deoxynucleoside. The modified multisegment antisense oligonucleotide of this disclosure further comprises a 3′ wing segment (W2) located at the 3′ end of the modified multisegment antisense oligonucleotide, and the 5′ end residue of W2 is not a deoxynucleoside.

[0149] The 5′ wing (W1) begins at the 5′ end of the modified multisegment antisense oligonucleotide, extends in the 5′ to 3′ direction, and is directly connected to the deoxynucleoside of the first nick, thus indicating the 3′ end of W1 and the 5′ end of the first nick (G1).

[0150] The 3′ wing (W2) begins at the 3′ end of the modified multisegment antisense oligonucleotide, extends in the 3′ to 5′ direction. Specification 12 / 170 pages 22 CN 121358861 A The extension, and its direct connection to the deoxyribonucleotide of the nick, thus indicating the 3′ end of the last nick and the 5′ end of W2.

[0151] Exemplary Modified Multisegment Antisense Oligonucleotides

[0152] This disclosure provides at least the following exemplary modified multisegment antisense oligonucleotides. It is envisioned that the modified multisegment antisense oligonucleotides of this disclosure are complementary to the transcript of a gene, wherein, in some embodiments, the gene may be HBV, DM1 protein kinase (DMPK), α-1 antitrypsin (AAT), thyroxine transporter (TTR), proprotein convertase subtilisin / kexinOne or more of the following: type 9 (PCSK9), apolipoprotein B (ApoB), apolipoprotein C-III (ApoCIII), TNF-α, SERPINA8 (AGT), complement factor B (CFB), diacylglycerol O-acyltransferase 2 (DGAT2), Patatin-like phospholipase domain-containing protein 3 (PNPLA3), 5′-aminolevulinic acid synthase 1 (ALAS1), or hydroxy acid oxidase 1.

[0153] In some embodiments, the modified multi-segment antisense oligonucleotides of this disclosure may be complementary to the transcript of a gene, wherein the gene is one or more of the following: Mat1α, (proto)renin receptor / (P)RR, COVID-195 'UTR, Acc1, Acc2, ACE2, androgen receptor, ApoB, ASGR1, ASO, ATXN2, B1AR, B2AR, C9ORF72, cysteine ​​2, CD19, CD4, Chikungunya virus, CLPro, complement component 5, COVID19, COX2, CTGF, DGAT2, DMD, DMPK, DNM2, DUX4, E2 gene, EGFR, envelope, EphA2, epithelial sodium channel α subunit, exon 100 dystrophin, exon 101 Muscular dystrophy protein, exon 102 muscular dystrophy protein, exon 103 muscular dystrophy protein, exon 104 muscular dystrophy protein, exon 105 muscular dystrophy protein, exon 106 muscular dystrophy protein, exon 107 muscular dystrophy protein, exon 108 muscular dystrophy protein, exon 109 muscular dystrophy protein, exon 110 muscular dystrophy protein, exon 111 muscular dystrophy protein, exon 112 muscular dystrophy protein, exon 113 muscular dystrophy protein, exon 114 muscular dystrophy protein, exon 115 muscular dystrophy protein Good protein, exon 116 dystrophin, exon 117 dystrophin, exon 118 dystrophin, exon 119 dystrophin, exon 120 dystrophin, exon 121 dystrophin, exon 122 dystrophin, exon 123 dystrophin, exon 124 dystrophin, exon 125 dystrophin, exon 126 dystrophin, exon 127 dystrophin, exon 128 dystrophin, exon 129 dystrophin Exon 130 dystrophin, Exon 131 dystrophin, Exon 132 dystrophin, Exon 133 dystrophin, Exon 134 dystrophin, Exon 135 dystrophin, Exon 136 dystrophin, Exon 137 dystrophin, Exon 138 dystrophin, Exon 139 dystrophinMuscular dystrophy protein, exon 140 muscular dystrophy protein, exon 141 muscular dystrophy protein, exon 142 muscular dystrophy protein, exon 143 muscular dystrophy protein, exon 144 muscular dystrophy protein, exon 145 muscular dystrophy protein, exon 146 muscular dystrophy protein, exon 147 muscular dystrophy protein, exon 148 muscular dystrophy protein, exon 149 muscular dystrophy protein, exon 150 muscular dystrophy protein, exon 151 muscular dystrophy protein, exon 152 muscular dystrophy protein, exon 44 muscular dystrophy protein, exon 53 muscular dystrophy protein, exon 54 muscular dystrophy protein, exon 55 muscular dystrophy protein, exon 56 muscular dystrophy protein, exon 57 muscular dystrophy protein, exon 58 muscular dystrophy protein, exon 59 muscular dystrophy protein, exon 60 muscular dystrophy protein, exon 61 Muscular dystrophy protein, exon 62 muscular dystrophy protein, exon 63 muscular dystrophy protein, exon 64 muscular dystrophy protein, exon 65 muscular dystrophy protein, exon 66 muscular dystrophy protein, exon 67 muscular dystrophy protein, exon 68 muscular dystrophy protein, exon 69 muscular dystrophy protein, exon 70 muscular dystrophy protein, exon 71 muscular dystrophy protein, exon 72 muscular dystrophy protein, exon 73 muscular dystrophy protein, exon 74 muscular dystrophy protein, exon 75 muscular dystrophy protein, exon 76 muscular dystrophy protein, exon 77 muscular dystrophy protein, exon 78 muscular dystrophy protein, exon 79 muscular dystrophy protein, exon 80 muscular dystrophy protein, exon 81 muscular dystrophy protein, exon 82 muscular dystrophy protein, exon 83 muscular dystrophy protein, exon 84 muscular dystrophy protein. (Instructions 13 / 170) Page 23 CN 121358861 A muscular dystrophy protein, exon 85 muscular dystrophy protein, exon 86 muscular dystrophy protein, exon 87 muscular dystrophy protein, exon 88 muscular dystrophy protein, exon 89 muscular dystrophy protein, exon 90 muscular dystrophy protein, exon 91 muscular dystrophy protein, exon 92 muscular dystrophy protein, exon 93 muscular dystrophy protein, exon 94 muscular dystrophy protein, exon 95 muscular dystrophy protein, exon 96 muscular dystrophy protein, exon Exon 97 dystrophin, exon 98 dystrophin, exon 99 dystrophin, Fabp3, coagulation factor VII, coagulation factor XI, FAK, FGFR4, FOXP3, FUS, FXII, GFAP, GFP, glycogen synthase, H1N1, HBV, heat shock protein 47, heat shock protein 48, heat shock protein 49, heat shock protein 50, heat shock protein 51, heat shock protein 52, heat shock protein 53, heat shockProtein 54, Heat shock protein 55, Heat shock protein 56, Heat shock protein 57, Heat shock protein 58, Heat shock protein 59, Helicase, HIV, HOXB13, HPRT, HPV, Hsd1 1β1, HTT, Hydroxy acid oxidase 1, Hydroxysteroid 17β-dehydrogenase 13, Hypoxia-inducible factor 2α, Spindle kinase and vascular endothelial growth factor, KRAS, Leader sequence, Leucine-rich repeat kinase 2 (LRRK2), MERS-CoV, MGMT, miR-16, miR-21, MMP-2, MMP-9, MTL-CEBPA, MuRF1, Mycobacterium tuberculosis, COVID-19N, Rabies N123, Rabies N749, Rabies N903, Rabies N1082, Rabies N53, Rabies N8 Chikungunya virus ns1 gene, Chikungunya virus ns2 gene, Chikungunya virus ns3 gene, Chikungunya virus ns4 gene, ORF1 b, ORF1a, HIV P24, rabies P330, P53, rabies P721, rabies P91, PCSK9, PDGF, PDL1, COVID-19 PLP, PNPLA3, Polo-like kinase 1, protein kinase N3, RAF1, RAF-1, RDRP, RSV, SMN2, SNCA, Covid-19 spike protein, STAT3, TAU, TGFB1, TGFB1 and Cox2, TMPRSS2, TMPRSS6, TNFα, thyroxine transporter, VEGF, VEGFR2, VER2, xanthine dehydrogenase and YAP1.

[0154] Therefore, in some embodiments, the modified multisegment antisense oligonucleotides provided herein have one or more of the following: the ability to inhibit target gene expression, higher biological activity, low off-target binding and low toxicity, and a wider safety margin, which may be advantageous for therapeutic use. Further, in some embodiments, the modified multisegment antisense oligonucleotides of this disclosure exhibit higher target gene inhibition compared to conventional nick polymers (which are not multisegmented) having the same template sequence.

[0155] Therefore, in one aspect, this disclosure provides a modified multi-segment antisense oligonucleotide comprising, from 5′ to 3′:

[0156] 5′W1-G1-S1-G2-W2 3′ (Formula I)

[0157] wherein:

[0158] W1 is a 5′ wing segment;

[0159] W2 is a 3′ wing segment;

[0160] G1 is a first nick segment;

[0161] S1 is a first separator segment;

[0162] G2 is a second nick segment;

[0163] - is a nucleoside internucleotide bond; and

[0164] at least one nucleoside of each of W1, W2 and S1 is modified.

[0165] In some embodiments, the modified multisegment antisense oligonucleotide has Formula I, and W1 contains 2 to 8 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 to 2 nucleosides, G2 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 8 linked nucleosides.

[0166] In some embodiments, the modified multisegment antisense oligonucleotide has Formula I, and W1 contains 2 to 8 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 nucleoside, G2 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 8 linked nucleosides. Specification 14 / 170 pages 24 CN 121358861 A

[0167] In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and W1 contains 2 to 8 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 2 nucleosides, G2 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 8 linked nucleosides.

[0168] In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and W1 contains 2 to 6 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 nucleoside, G2 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 6 linked nucleosides.

[0169] In some embodiments, the modified multisegment antisense oligonucleotide has Formula I, and W1 contains 2 to 8 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 nucleoside, G2 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 8 linked nucleosides.

[0170] In some embodiments, the modified multisegment antisense oligonucleotide has Formula I, and W1 contains 4 to 6 linked nucleosides, G1 contains 1 to 6 linked deoxynucleosides, S1 contains 1 linked nucleoside, G2 contains 1 to 6 linked deoxynucleosides, and W2 contains 4 to 6 linked nucleosides.

[0171] In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and W1 contains 4 to 6 linked nucleosides, G1 contains 5 linked deoxynucleosides, S1 contains 1 linked nucleoside, G2 contains 5 linked deoxynucleosides, and W2 contains 4 to 6 linked nucleosides.

[0172] In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and W1 contains 4 linked nucleosides, G1 contains 5 linked deoxynucleosides, S1 contains 1 linked nucleoside, G2 contains 5 linked deoxynucleosides, and W2 contains 5 linked nucleosides.

[0173] In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and W1 contains 5 linked nucleosides.The nucleosides, G1 contains 4 linked deoxynucleosides, S1 contains 1 linked nucleoside, G2 contains 5 linked deoxynucleosides, and W2 contains 5 linked nucleosides.

[0174] In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and the W1-G1-S1-G2-W2 motif is 2-4-1-5-2, 3-4-1-4-2, 3-4-1-5-3, 3-4-1-5-4, 3-4-1-5-8, 3-5-1-4-2, 3-5-1-5-2, 3-5-1-5-3, 3-6-1-5-5, 3-6-1-6-4, 4-4-1-5-3, 4-4-1-5-4, 4-5-1-4-13, 4-5-1-4-6, 4-5-1- 5-1, 4-5-1-5-10, 4-5-1-5-11, 4-5-1-5-13, 4-5-1-5-3, 4-5-1-5-4, 4-5-1-5-5, 4-5-1-5-6, 4-5-1-5-7, 4-5-1-5-8, 4-5-1-5-9, 4-5-1-6-4, 4-6-1-4-5, 5-1-1-8-5, 5-2-1-7-5, 5-3-1-6-5, 5-4-1-4-6, 5-4-1-5-25, 5-4-1-5-4, 5-4-1-5-5, 5-4-1-6-4, 5-4-1-7-3, 5-4-1-8-2, 5- 4-2-4-5, 5-5-2-5-5, 5-5-2-6-5, 5-6-2-6-5, 5-5-1-4-25, 5-5-1-4-5, 5-6-1-3-5, 5-7-1-2-5, 5-8-1-1-5, 6-3-1-3-7, 6-3-1-4-6, 6-4-1-4-5, or 6-7-1-1-5, where each number represents the number of nucleosides. That is, for example, a modified multi-segment antisense oligonucleotide having formula I (W1-G1-S1-G2-W2 is 2-4-1-5-2) has 2 nucleosides in W1; 4 nucleosides in G1; 1 nucleoside in S1; 5 nucleosides in G2; and 2 nucleosides in W2.

[0175] In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and the W1-G1-S1-G2-W2 motif is 4-5-1-5-5. In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and the W1-G1-S1-G2-W2 motif is 5-4-1-5-5. In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and the W1-G1-S1-G2-W2 motif is 5-5-1-5-5. In some embodiments, the modified multi-segment antisense oligonucleotide has...Formula I is given, and the motif W1-G1-S1-G2-W2 is 5-5-1-4-5. In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and the motif W1-G1-S1-G2-W2 is 6-5-1-5-5.

[0176] In some embodiments, the modified multi-segment antisense oligonucleotide from 5′ to 3′ comprises: Specification 15 / 170 pages 25 CN 121358861 A

[0177] 5′W1-G1-S1-G2-S2-G3-W2 3′(Formula II)

[0178] Wherein:

[0179] S2 is a second separator segment;

[0180] G3 is a third nick segment;

[0181] - is a nucleoside internucleotide bond; and

[0182] at least one nucleoside of each of W1, S1, S2 and W2 is a modified nucleoside.

[0183] In some embodiments, the modified multisegment antisense oligonucleotide has Formula II, and W1 contains 2 to 8 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 linked nucleoside, G2 contains 1 to 2 linked deoxynucleosides, S2 contains 1 linked nucleoside, G3 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 8 linked nucleosides.

[0184] In some embodiments, the modified multisegment antisense oligonucleotide has Formula II, and W1 contains 2 to 8 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 linked nucleoside, G2 contains 1 linked deoxynucleoside, S2 contains 1 linked nucleoside, G3 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 8 linked nucleosides.

[0185] In some embodiments, the modified multisegment antisense oligonucleotide has Formula II, and W1 contains 2 to 8 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 linked nucleoside, G2 contains 2 linked deoxynucleosides, S2 contains 1 linked nucleoside, G3 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 8 linked nucleosides.

[0186] In some embodiments, the modified multisegment antisense oligonucleotide has Formula II, and W1 contains 2 to 6 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 linked nucleoside, G2 contains 1 to 2 linked deoxynucleosides, S2 contains 1 linked nucleoside, G3 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 6 linked nucleosides.

[0187] In some embodiments, the modified multi-segment antisense oligonucleotide has Formula II, and W1 contains 2 to 6 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 linked nucleoside, and G2 contains 1 linked deoxynucleoside.The modified multi-segment antisense oligonucleotide has Formula II, wherein S1 contains 2 to 6 linked nucleosides, G1 contains 2 to 7 linked deoxynucleosides, S1 contains 1 linked nucleoside, G2 contains 2 linked deoxynucleosides, S2 contains 1 linked nucleoside, G3 contains 2 to 7 linked deoxynucleosides, and W2 contains 2 to 6 linked nucleosides.

[0189] In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and the W1-G1-S1-G2-S2-G3-W2 motif is 5-1-1-3-1-3-6, 5-1-1-3-1-4-5, 5-1-1-6-1-1-5, 5-2-1-2-1-2-7, 5-2-1-2-1-4-5, 5-2-1-4-1-2-5, 5-3-1-1-1-4-5, 5-3-1-2-1-3-5, 5-3-1-4-1-1-5, 5-4-1-1-1-3- 5, 5-4-1-2-1-1-6, 5-4-1-2-1-2-5, 5-4-1-3-1-1-5, 6-3-1-1-1-1-7, 6-3-1-3-1-1-5, 6-4-1-1-1-2-5 or 7-2-1-2-1-2-5. That is, for example, a modified multisegment antisense oligonucleotide having formula II (W1-G1-S1-G2-S2-G3-W2 is 5-1-1-3-1-3-6) has 5 nucleosides in W1; 1 nucleoside in G1; 1 nucleoside in S1; 3 nucleosides in G2; 1 nucleoside in S2; 3 nucleosides in G3; and 2 nucleosides in W2.

[0190] In some embodiments, the modified multi-segment antisense oligonucleotide from 5′ to 3′ comprises: Specification 16 / 170 pages 26 CN 121358861 A

[0191] 5′W1-G1-S1-G2-S2-G3-S3-G4-W2 3′(Formula III)

[0192] wherein:

[0193] S3 is the third separator segment;

[0194] G4 is the fourth nick segment; and

[0195] - is a nucleoside internucleotide bond; and at least one nucleoside of each of W1, S1, S2, S3 and W2 is a modified nucleoside.

[0196] In some embodiments, the modified multi-segment antisense oligonucleotide from 5′ to 3′ comprises:

[0197] 5′W1-G1-S1-G2-S2-G3-S3-G4-S4-G5-W2 3′ (Formula IV)

[0198] wherein:

[0199] S4 is the fourth separator segment;

[0200] G5 is the fifth nick segment; and

[0201] - is a nucleoside internucleotide bond; and at least one nucleoside of each of W1, S1, S2, S3, S4 and W2 is a modified nucleoside. In some embodiments, the modified multi-segment antisense oligonucleotide from 5′ to 3′ comprises:

[0202] 5′W1-G1-S1-G2-S2-G3-S3-G4-S4-G5-S5-G6-W2 3′ (Formula V)

[0203] wherein:

[0204] S5 is the fifth separator segment;

[0205] G6 is the sixth nick segment; and

[0206] - is a nucleoside internucleotide bond; and at least one nucleoside of each of W1, S1, S2, S3, S4, S5 and W2 is a modified nucleoside.

[0207] In some embodiments, the modified multi-segment antisense oligonucleotide from 5′ to 3′ comprises:

[0208] 5′W1-G1-S1-G2-S2-G3-S3-G4-S4-G5-S5-G6-S6-G7-W2 3′

[0209] (Formula VI)

[0210] wherein:

[0211] S6 is the sixth separator segment;

[0212] G7 is the seventh nick segment; and

[0213] - is a nucleoside internucleotide bond; and at least one nucleoside of each of W1, S1, S2, S3, S4, S5, S6 and W2 is a modified nucleoside.

[0214] In some embodiments, W1 comprises 2 to 25 linked nucleosides. In some embodiments, W1 comprises one or more linked deoxynucleosides.

[0215] In some embodiments, W2 comprises 2 to 35 linked nucleosides. In some embodiments, W2 comprises one or more linked deoxynucleosides.

[0216] In some embodiments, any one or more of G1, G2, G3, G4, G5, G6 and / or G7 comprises one to ten linked deoxynucleosides.

[0217] In some embodiments, any one or more of S1, S2, S3, S4, S5 and / or S6 comprises one, two, three, four or five linked nucleosides.

[0218] In some embodiments, the length of the modified multisegment antisense oligonucleotide is 12 to 50 nucleotides, 13 to 50 nucleotides, or 18 to 50 nucleotides. In some embodiments, the length of the modified multi-segment antisense oligonucleotide is about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 nucleotides. (Specification 17 / 170, page 27, CN 121358861 A)The length is at least 16 nucleotides. In some embodiments, the length of the modified multi-segment antisense oligonucleotide is at least 17 nucleotides. In some embodiments, the length of the modified multi-segment antisense oligonucleotide is at least 18 nucleotides. In some embodiments, the length of the modified multi-segment antisense oligonucleotide is at least 19 nucleotides. In some embodiments, the length of the modified multi-segment antisense oligonucleotide is 20 nucleotides.

[0219] In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and the length of G1-S1-G2 is between 6 and 14 nucleotides. In some embodiments, the modified multi-segment antisense oligonucleotide has Formula I, and the length of G1-S1-G2 is between 8 and 12 nucleotides. In some embodiments, the modified multi-segment antisense oligonucleotide has Formula II, and the length of G1-S1-G2-S2-G3 is between 8 and 13 nucleotides. In some embodiments, the modified multisegment antisense oligonucleotide has Formula II, and the length of G1-S1-G2-S2-G3 is between 8 and 12 nucleotides.

[0220] The following embodiments relate to any one of Formulas I-VI: In some embodiments, G1, G2, G3, G4, G5, G6, and G7 may comprise nucleosides modified with 2′-deoxynucleotides. In some embodiments, any one or more of G1, G2, G3, G4, G5, G6, and G7 comprise nucleosides modified with 2′-deoxy5-methylcytidine sugar. In some embodiments, S1, S2, S3, S4, S5, and / or S6 comprise nucleosides modified with 2′-O-methoxyethyl sugar. In some embodiments, S1, S2, S3, S4, S5, and / or S6 comprise nucleosides containing 5-methylcytidine. In some embodiments, S1, S2, S3, S4, S5, and / or S6 comprise nucleosides modified with 2′-O-methyl sugar. In some embodiments, S1, S2, S3, S4, S5, and / or S6 comprise nucleosides modified with 2′-OH sugar. In some embodiments, S1, S2, S3, S4, S5, and / or S6 comprise nucleosides modified with 2′-fluorosugar. In some embodiments, S1, S2, S3, S4, S5, and / or S6 comprise nucleosides modified with 2′-fluoro-arabinonucleotide (2′-fluoro-ANA) sugar. In some embodiments, S1, S2, S3, S4, S5, and / or S6 comprise glycol nucleic acids (GNA). In some embodiments, S1, S2, S3, S4, S5, and / or S6 comprise bridging nucleic acids (e.g., LNA, cET, cMOE). In some embodiments, S1, S2, S3, S4, S5 and / or S6 comprise an LNA. In some embodiments, W1 comprises a 2′-Deoxysugar-modified nucleosides. In some embodiments, W1 comprises a nucleoside modified with a 2'-O-methoxyethyl sugar. In some embodiments, W1 comprises 2'-O-methoxyethyl 5-methylcytidine at position 2 of the 20-base polymer sequence. In some embodiments, W1 comprises a nucleoside modified with a 2'-O-methyl sugar. In some embodiments, W1 comprises 2'-O-methyl 5-methylcytidine at position 2 of the 20-base polymer. In some embodiments, W1 comprises a nucleoside modified with a 2′-fluorosugar. In some embodiments, W1 comprises a nucleoside modified with 2′-fluoro-arabinonic acid (2′-fluoro-ANA). In some embodiments, W1 comprises glycol nucleic acid (GNA). In some embodiments, W1 comprises a modified nucleoside, wherein the modified nucleoside is a bridging nucleic acid (e.g., LNA, cET, cMOE). In some embodiments, W1 comprises a modified nucleoside, wherein the modified nucleoside is a locked nucleic acid (LNA). In some embodiments, W2 comprises a nucleoside modified with a 2′-deoxy sugar. In some embodiments, W2 comprises a nucleoside modified with a 2′-O-methoxyethyl sugar (e.g., wherein the 2′-O-methoxyethyl sugar is modified at positions 15, 16, 17, 18, 19, and / or 20 of the 20-mer). In some embodiments, W2 comprises 2′-O-methoxyethyl 5-methylcytidine. In some embodiments, W2 comprises a nucleoside modified with a 2′-O-methyl sugar (e.g., wherein the 2′-O-methyl sugar is modified at positions 15, 16, 17, 18, 19, and / or 20 of the 20-mer). In some embodiments, W2 comprises a nucleoside modified with a 2′-fluoro sugar. In some embodiments, W2 comprises a nucleoside modified with 2′-fluoro-arabinonucleotide (2′-fluoro-ANA). In some embodiments, W2 comprises a modified nucleoside, wherein the modified nucleoside is ethylene glycol nucleic acid (GNA). In some embodiments, W2 comprises a modified nucleoside, and wherein the modified nucleoside is a bridging nucleic acid (e.g., LNA, cET, cMOE). In some embodiments, W2 comprises a modified nucleoside, and wherein the modified nucleoside is a locked nucleic acid (LNA) (e.g., wherein the LNA is located at positions 16, 17, 18, 19 and / or 20 of the 20-mer). Specification 18 / 170 pages 28 CN 121358861 A

[0221] Exemplary Modifications

[0222] The modified multi-segment antisense oligonucleotides of this disclosure may comprise linked nucleosides, such as linked deoxynucleosides, linked ribonucleotides, and linked deoxyribonucleotides. Therefore, the modified multi-segment antisense oligonucleotides of this disclosure may comprise deoxyribonucleotides, ribonucleotides, or a mixture of both. In some embodiments, the modified multi-segment antisense oligonucleotides may comprise a modified nucleoside, such as linked deoxyribonucleotides, linked ribonucleotides, or a mixture of both.The segmental antisense oligonucleotide is a modified multisegmental antisense oligonucleotide, for example, a modified multisegmental antisense oligonucleotide containing one or more sugar modifications, one or more modified nucleoside internucleotides, and / or one or more base modifications. The characteristics of the modified multisegmental antisense oligonucleotides of this disclosure are discussed in more detail below.

[0223] In some embodiments, the modified multisegmental antisense oligonucleotide is conjugated to a portion or conjugate, referred to as a conjugated modified multisegmental antisense oligonucleotide. The characteristics of the conjugated modified multisegmental antisense oligonucleotides of this disclosure are discussed in more detail below. The conjugated modified multisegmental antisense oligonucleotide may be modified or unmodified.

[0224] In some embodiments, the modified multi-segment antisense oligonucleotides of this disclosure comprise a sequence of any one of SEQ ID NO: 11-1453 or 5000-30983, or comprise a modified multi-segment antisense oligonucleotide with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 of its sequences modified. As used herein, the term "sequence modification" refers to the identity of the sequence (e.g., a modification from A to T).

[0225] In some embodiments, the modified multi-segment antisense oligonucleotides of this disclosure comprise a sequence of any one of SEQ ID NO: 11-1453 or 5000-30983, or comprise a modified multi-segment antisense oligonucleotide with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity with it.

[0226] In some embodiments, the vaccine contains only one unique modified multisegment antisense oligonucleotide—for clarity, the vaccine may contain a copy of the same unique modified multisegment antisense oligonucleotide. In some embodiments, the vaccine contains multiple different modified multisegment antisense oligonucleotides, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 or more different modified multisegment antisense oligonucleotides of this disclosure.

[0227] Characteristics of Modified Multisegment Antisense Oligonucleotides

[0228] As contemplated herein, modified multisegment antisense oligonucleotides encompass substitutions or alterations to nucleoside internucleotide bonds, sugar moieties, and nucleobases. Modified multisegment antisense oligonucleotides impart desired properties, such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid targets, increased stability in the presence of nucleases, or increased inhibitory activity. Chemically modified nucleosides can also be used to increase their binding affinity to their target nucleic acids.

[0229] In some embodiments, the modified multi-segment antisense oligonucleotides of this disclosure comprise one or more modified nucleoside internucleotide bonds. In some embodiments, the modified multi-segment antisense oligonucleotides of this disclosure comprise one or more...A modified nucleoside internucleotide bond, wherein the modified nucleoside internucleotide bond is a phosphoryl diamine bond between morpholino nucleoside mimics. In some embodiments, the modified multisegment antisense oligonucleotide of this disclosure comprises one or more modified nucleoside internucleotide bonds, wherein the modified nucleoside internucleotide bond is a phosphate thioester nucleoside internucleotide bond. In some embodiments, the phosphate thioester modification comprises a mixture of Sp and Rp stereoisomers. In some embodiments, the phosphate thioester modification comprises the Sp stereoisomer. In some embodiments, the phosphate thioester modification comprises the Rp stereoisomer.

[0230] In some embodiments, the modified multisegment antisense oligonucleotide of this disclosure comprises one or more sugar modifications. In some embodiments, the modified multisegment antisense oligonucleotide of this disclosure comprises one or more linked nucleosides, wherein the one or more linked nucleosides comprises a 2′ sugar modification (a sugar modification at the C2' position). In exemplary embodiments, the modified multi-segment antisense oligonucleotides of this disclosure include one or more modifications to 2′-deoxynucleosides, such as one or more nucleosides including 2′-O-methyl modification, 2′-O-ethyl modification, 2′-O-(2-methoxyethyl) modification, 2′-fluorine modification, 2′-amino modification, 2′-O-propyl modification, 2′-O-butyl modification, 2′-O-cyclopropylmethyl modification, 2′-O-(2-hydroxyethyl) modification, 2′-O-[2-(methylamino)-2-oxyethyl] modification, 2′-O-2-[2-(N,N- Modifications include: [dimethylamino]ethoxy]ethyl, 2'-O-(2-dimethylaminoethyl), 2'-O-(3-aminopropyl), 2'-O-(2-aminopropyl), 2'-O-(2-hydroxyisopropyl), 2'-O-(2-methoxyisopropyl), 2'-O-(2-dimethylaminoisopropyl), 2'-O-(2-aminobutyl), 2′-O-(2-hydroxybutyl), 2′-O-(2-methoxybutyl), 2'-O-(2-dimethylaminobutyl), and 2′-O-(2-aminocyclopropylmethyl). 2′-O-(2-hydroxycyclopropylmethyl) modification, 2′-O-(2-methoxycyclopropylmethyl) modification, 2′-O-(2-dimethylaminocyclopropylmethyl) modification, 2′-O-[(2-guanidinyl)ethyl] modification, and / or 2′-fluoro-arabinose (2′-fluoro-ANA) modification.

[0231] In some embodiments, the modified multisegment antisense oligonucleotide comprises one or more bicyclic sugar-modified nucleosides. In some embodiments, the modified multisegment antisense oligonucleotide of this disclosure comprises one or more bridging nucleosides.Acids in which the 2′-oxygen is linked to the 4′ carbon of the ribose via a bridging carbon to form a bridged nucleic acid (BNA), for example via a 2′,4′-methylene bridge to form a locked nucleic acid (LNA), or for example in a 2′,4′-restricted 2′-O-ethyl modification ((R)-cET or (S)-cET), or for example in a 2′,4′-restricted 2′-O-methoxyethyl modification ((R)-cMOE or (S)-cMOE).

[0232] In some embodiments, the modified multisegment antisense oligonucleotide comprises one or more carbocyclic LNAs (cLNAs) in which the 2′-oxygen atom in the LNA is replaced by a carbon atom. In some exemplary embodiments, the modified multisegment antisense oligonucleotides of this disclosure comprise one or more methylene carbapenems in the form of N-MC or S-MC, or 2′-F-NMC. In some embodiments, the modified multisegment antisense oligonucleotide comprises (R)-Me-cLNA, (S)-Me-cLNA, F-LNA, or methylene-cLNA as shown below.

[0233]

[0234]

[0235] In some embodiments, the modified multisegment antisense oligonucleotide comprises one or more of α-L-LNA, bcDNA, or tcDNA as shown below.

[0236]

[0237] In some embodiments, the modified multisegment antisense oligonucleotide of this disclosure comprises one or more morpholino modifications, wherein the morpholino group replaces the ribose. In some embodiments, the modified multisegment antisense oligonucleotide of this disclosure comprises phosphodiamidomorpholino modification, wherein the sugar-phosphate backbone is partially replaced by phosphodiamidomorpholino. In some embodiments, the modified multisegment antisense oligonucleotides of this disclosure comprise one or more peptide nucleic acid (PNA) modifications, wherein a sugar-phosphate backbone or sugar-thiophosphate backbone is replaced by a peptide backbone. In some embodiments, the modified multisegment antisense oligonucleotides of this disclosure comprise one or more ethylene glycol nucleic acid (GNA) modifications, sometimes also referred to as glycerol nucleic acid, wherein a propylene glycol group replaces the ribose. In some embodiments, the modified multisegment antisense oligonucleotides of this disclosure comprise one or more phosphate ester analogs E-vinyl phosphate (E-VP) and amide backbone bonds, as shown below.

[0238]

[0239] In some embodiments, the modified multisegment antisense oligonucleotides of this disclosure comprise one or more base modifications. In some embodiments, the modified multisegment antisense oligonucleotides of this disclosure comprise one or more nucleosides as 5-methylcytidine. In some embodiments, the modified multisegment antisense oligonucleotides of this disclosure comprise one or more nucleosides as N1-methyl-pseuuridine.

[0240] In some embodiments, the modified multisegmental antisense oligonucleotides of this disclosure comprise one or more modifications, such as 3′- and / or 5′-amino modifications, to the 3′ and / or 5′ ends of the oligonucleotide.

[0241] In some embodiments, the modified multisegmental antisense oligonucleotides of this disclosure comprise segmented oligonucleotides, thereby creating one or more internal regions (gap segments) having multiple nucleotides supporting RNase H cleavage, these internal regions being located between external regions (5′ and 3′ wing segments) of nucleotides having multiple nucleosides that are chemically distinct from the internal regions. Where the oligonucleotide exhibits complementarity with a target having a segmented motif, the gap segment can hybridize with the target RNA sequence for endonuclease cleavage, while the wing segments contain modified nucleosides. In some embodiments, the regions of the gap are distinguished by the type of sugar moiety comprising each distinct region. In some embodiments, the type of sugar moiety used to distinguish the region of the notch may include β-D-ribonucleoside, β-D-deoxyribonucleoside, 2′-modified nucleoside (such 2′-modified nucleoside may include 2′-MOE and 2′-O-CH3, as well as other nucleosides as described in the preceding paragraphs), and bicyclic sugar-modified nucleoside (such bicyclic sugar-modified nucleoside may include nucleoside having a constrained ethyl group). In some embodiments, the nucleoside in the wing may include modified sugar moieties, including, for example, 2′-MOE and bicyclic sugar moieties, such as constrained ethyl or LNA. In some embodiments, the wing may include several modified and unmodified sugar moieties as described in the preceding paragraphs. In some embodiments, the wing may include various combinations of 2′-MOE nucleoside, bicyclic sugar moieties (such as constrained ethyl nucleoside or LNA nucleoside), and 2′-deoxyribonucleoside. A single internal region (gap) may exist, or it may be further segmented with separator segments to create discontinuous gap segments that provide improved activity (e.g., reduced HBsAg, HBeAg, and / or HBcAg levels in serum or other body fluids or tissues) in some embodiments compared to conventional oligonucleotides with continuous gaps. One or more separator segments placed directly between gap segments may be beneficial

[0242] Exemplary modified multi-segment antisense oligonucleotides of this disclosure include, but are not limited to, those illustrated in Tables 2.1, 1A, 1B, 1C, Figures 21 and 22.

[0243] Table 2.2 shows an illustration of modifications at each residue shown in Tables 2.1, 1A, and 1B. In some implementations, the modified multi-segment antisense oligonucleotides comprise SEQ ID NO: 668-677, 679-682, 684-688, 690-692, 698-1107, 1109-1120, 1122-1125, 1127-1138, 1140, 1145-1156, 1158-1161, 1163-1174, 1176-1179, 1181-1192, 1194-1197, 1199-1210, 1212-1215, 1217-1228, 1230-1233, 1235-1246, 1248-1251, 1253-1264, 1266-1269, 1271-1282, 1284-1287, 1289-1300, 1302- A sequence of any one of the following: 1305, 1307-1318, 1320-1323, 1325-1336, 1338-1341, 1343-1354, 1356-1359, 1361-1372, 1374-1377, 1379-1390, 1392-1395, 1397-1408, 1410-1413, 1415-1426, and 1428-1431.

[0244] Table 2.1. Exemplary modified multi-segment antisense oligonucleotides of this disclosure

[0245] Specification 22 / 170 pages 32 CN 121358861 A

[0246] Specification 23 / 170 pages 33 CN 121358861 A

[0247] Specification 24 / 170 pages 34 CN 121358861 A

[0248] Specification 25 / 170 pages 35 CN 121358861 A

[0249] Specification 26 / 170 pages 36 CN 121358861 A

[0250] Specification 27 / 170 pages 37 CN 121358861 A

[0251] Specification 28 / 170 pages 38 CN 121358861 A

[0252] Specification 29 / 170 pages 39 CN 121358861 A

[0253] Specification 30 / 170 pages 40 CN 121358861 A

[0254]

[0255] Table 2.2 Illustrations of Modifications Specification 31 / 170 pages 41 CN 121358861 A

[0256]

[0257] Conjugated Oligonucleotides

[0258] The oligonucleotides of this disclosure may be further covalently linked to one or more conjugation groups / parts. In some embodiments, such groups enhance the activity, cell distribution, and / or cell uptake of the resulting vaccine. Exemplary conjugation groups include, but are not limited to, carbohydrate parts (e.g., carbohydrate chains containing N-acetylgalactosamine or containing galactose).The oligonucleotides disclosed herein may also be modified to have one or more stabilizing groups, which are typically attached to one or both ends of the oligonucleotide to enhance properties such as, for example, nuclease stability. Included in the stabilizing groups are cap structures. Other conjugation groups include, but are not limited to, phospholipids, biotin or other affinity tags (e.g., streptavidin), polymers (e.g., polyethylene glycol (PEG), polylysine), cell-penetrating peptides (e.g., Tat, Penetrantin), enzymes (e.g., horseradish peroxidase, alkaline phosphatase), antibodies or antibody fragments (e.g., anti-HER2, anti-EGFR), proteins or peptides (e.g., growth factors, cytokines), metal nanoparticles (e.g., gold nanoparticles), small molecule drugs (e.g., doxorubicin, paclitaxel), phenolazines, folic acid, phenanthridine, anthraquinones, acridine, fluorescein, rhodamine, coumarin, and dyes.

[0259] These terminal modifications can protect oligonucleotides with terminal nucleic acids from exonuclease degradation and can aid in intracellular delivery and / or localization. The cap can be present at the 5′ end (5′-cap), or at the 3′ end (3′-cap), or at both ends. Cap structures are well known in the art and include, for example, reverse deoxy-base caps.

[0260] The conjugated oligonucleotides of this disclosure can be modified as described in the foregoing sections.

[0261] A. 5′ Wing Segment, General (W1)

[0262] In some embodiments, at least one nucleotide in the 5′ wing segment comprises a 2′-O(CH2)2-OCH3 sugar. In some embodiments, each nucleotide in the 5′ wing segment comprises a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment comprises a nucleotide having a 2′-deoxy sugar. In some embodiments, the 5′ wing segment comprises a nucleoside having a 2′-deoxy sugar, and other nucleosides in the 5′ wing segment comprise a 2′-O(CH2)2-OCH3 sugar.

[0263] In some embodiments, one, two, three, or four nucleosides in the 5′ wing segment comprise the sugar modification described herein. In some embodiments, one, two, three, or four nucleosides in the 5′ wing segment comprise a bicyclic sugar. In some embodiments, one, two, three, or four nucleosides in the 5′ wing segment comprise a restricted ethyl sugar.

[0264] In some embodiments, one, two, three, or four nucleosides in the 5′ wing segment comprise a locked nucleic acid. In some embodiments, one, two, three, or four nucleosides in the 5′ wing segment comprise a 4′-CH2-O-2′ sugar. In some embodiments, two of the nucleotides in the 5′ wing segment comprise locked nucleic acids. In some embodiments, two of the nucleotides in the 5′ wing segment comprise 4′-CH2-O-2′ sugars.

[0265] B1. 5′ wing segment having 4 linked nucleotides (W1)

[0266] In some embodiments, the 5′ wing segment consists of 4 linked nucleotides. In some embodiments, the 5′ wing segment consists of 4 linked nucleotides, wherein each of the 4 linked nucleotides comprises a nucleotide having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment consists of 4 linked nucleotides, wherein 3 of the 4 linked nucleotides comprise a nucleotide having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment consists of 4 linked nucleotides, wherein 2 of the 4 linked nucleotides comprise a nucleotide having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment consists of four linked nucleosides, wherein one of the four linked nucleosides comprises a nucleoside having a 2′-O(CH2)2-OCH3 sugar.

[0267] B2. 5′ wing segment (W1) having a combination of four linked nucleosides and a 2′-deoxy sugar

[0268] In some embodiments, the 5′ wing segment consists of four linked nucleosides, wherein one of the linked nucleosides comprises a nucleoside having a 2′-deoxy sugar. In some embodiments, the 5′ wing segment consists of four linked nucleosides, wherein two of the linked nucleosides comprise a nucleoside having a 2′-deoxy sugar. In some embodiments, the 5′ wing segment consists of four linked nucleosides, wherein one of the four linked nucleosides comprises a nucleoside having a 2′-deoxy sugar, and each of the other three linked nucleosides comprises a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment is composed of four linked nucleosides, wherein one of the four linked nucleosides comprises a nucleoside having a 2′-deoxy sugar, one of the four linked nucleosides comprises a locked nucleic acid, and each of the other two linked nucleosides comprises a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment is composed of four linked nucleosides, wherein one of the four linked nucleosides comprises a nucleoside having a 2′-deoxy sugar, two of the four linked nucleosides comprise a locked nucleic acid, and the other linked nucleoside comprises a nucleoside having a 2′-O(CH2)2-OCH3 sugar.

[0269] B3. 5′ wing segment (W1) having a combination of four linked nucleosides and 2′-LNA

[0270] In some embodiments, the 5′ wing segment is composed of four linked nucleosides, wherein one of the four linked nucleosides comprises a nucleoside having a 2′-deoxy sugar, two of the four linked nucleosides comprise a locked nucleic acid, and the other linked nucleoside comprises a nucleoside having a 2′-O(CH2)2-OCH3 sugar.Each nucleoside contains a locked nucleic acid. In some embodiments, the 5′ wing segment consists of four linked nucleosides, wherein two of the four linked nucleosides contain locked nucleic acids. In some embodiments, the 5′ wing segment consists of four linked nucleosides, wherein one of the four linked nucleosides contains a 4′-CH2-O-2′ sugar. In some embodiments, the 5′ wing segment consists of four linked nucleosides, wherein two of the four linked nucleosides contain a 4′-CH2-O-2′ sugar.

[0271] In some embodiments, the 5′ wing segment consists of four linked nucleosides, wherein one of the four linked nucleosides contains a locked nucleic acid, and each of the other three linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment consists of four linked nucleosides, wherein two of the four linked nucleosides contain locked nucleic acids, and each of the other two linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment consists of four linked nucleosides, wherein one of the four linked nucleosides contains a 4′-CH2-O′2′ sugar, and each of the other three linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment consists of four linked nucleosides, wherein two of the four linked nucleosides contain a 4′-CH2-O′2′ sugar, and each of the other two linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar.

[0272] C1. 5′ Wing Segment with Five Linked Nucleosides (W1)

[0273] In some embodiments, the 5′ wing segment consists of five linked nucleosides. In some embodiments, the 5′ wing segment consists of five linked nucleosides, wherein each of the five linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein four of the five linked nucleosides comprise nucleosides having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein three of the five linked nucleosides comprise nucleosides having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein two of the five linked nucleosides comprise nucleosides having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein one of the five linked nucleosides comprises nucleosides having a 2′-O(CH2)2-OCH3 sugar.

[0274] C2. 5′ wing segment (W1) having a combination of five linked nucleosides and a 2′-deoxy group

[0275] In some embodiments, the 5′ wing segment consists of five linked nucleosides, wherein one of the linked nucleosides contains a nucleoside having a 2′-deoxy sugar. In some embodiments, the 5′ wing segment consists of five linked nucleosides, wherein two of the linked nucleosides contain a nucleoside having a 2′-deoxy sugar. In some embodiments, the 5′ wing segment consists of five linked nucleosides, wherein one of the five linked nucleosides contains a nucleoside having a 2′-deoxy sugar, and each of the other four linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment consists of five linked nucleosides, wherein one of the five linked nucleosides contains a nucleoside having a 2′-deoxy sugar, one of the five linked nucleosides contains a locked nucleic acid, and each of the other three linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein one of the five linked nucleosides contains a nucleoside having a 2′-deoxy sugar, two of the five linked nucleosides contain locked nucleic acids, and the other two linked nucleosides contain nucleosides having a 2′-O(CH2)2-OCH3 sugar.

[0276] C3. 5′ wing segment (W1) having a combination of five linked nucleosides and 2′-LNA Specification 34 / 170 pages 44 CN 121358861 A

[0277] In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein one of the five linked nucleosides contains a locked nucleic acid. In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein two of the five linked nucleosides contain locked nucleic acids. In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein one of the five linked nucleosides contains a 4′-CH2-O-2′ sugar. In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein two of the five linked nucleosides contain a 4′-CH2-O′ sugar.

[0278] In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein one of the five linked nucleosides contains a locked nucleic acid, and each of the other four linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein two of the five linked nucleosides contain a locked nucleic acid, and each of the other three linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 5′ wing segment is composed of five linked nucleosides, wherein one of the five linked nucleosides contains a 4′-CH2-O′ sugar, and each of the other four linked nucleosides contains a 2′-O(CH2)2-OCH3 sugar.Nucleosides of sugars. In some embodiments, the 5′ wing segment consists of five linked nucleosides, wherein two of the five linked nucleosides contain 4′-CH2-O-2′ sugars, and each of the other three linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar.

[0279] D. 3′ Wing segment, generally (W2)

[0280] In some embodiments, at least one nucleoside in the 3′ wing segment contains a 2′-O(CH2)2-OCH3 sugar. In some embodiments, each nucleoside in the 3′ wing segment contains a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment contains a nucleoside having a 2′-deoxy sugar. In some embodiments, the 3′ wing segment contains a nucleoside having a 2′-deoxy sugar, and the other nucleosides in the 3′ wing segment contain a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment further comprises two nucleotides, each having a 2′-deoxy sugar.

[0281] In some embodiments, one, two, three, or four nucleotides in the 3′ wing segment comprise the sugar modification described herein. In some embodiments, one, two, three, or four nucleotides in the 3′ wing segment comprise a bicyclic sugar. In some embodiments, one, two, three, or four nucleotides in the 3′ wing segment comprise a restricted ethyl sugar.

[0282] In some embodiments, one, two, three, or four nucleotides in the 3′ wing segment comprise a locked nucleic acid. In some embodiments, one, two, three, or four nucleotides in the 3′ wing segment comprise a 4′-CH2-O-2′ sugar. In some embodiments, two nucleotides in the 3′ wing segment comprise locked nucleic acids. In some embodiments, two nucleotides in the 3′ wing segment comprise a 4′-CH2-O-2′ sugar. In some embodiments, three nucleotides in the 3′ wing segment comprise locked nucleic acids. In some embodiments, three of the nucleotides in the 3′ wing segment comprise a 4′-CH2-O-2′ sugar.

[0283] E1. 3′ Wing Segment (W2) with 4 linked nucleotides

[0284] In some embodiments, the 3′ wing segment consists of 4 linked nucleotides. In some embodiments, the 3′ wing segment consists of 4 linked nucleotides, wherein each of the 4 linked nucleotides comprises a nucleotide having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of 4 linked nucleotides, wherein 3 of the 4 linked nucleotides comprise a nucleotide having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of 4 linked nucleotides, wherein 2 of the 4 linked nucleotides comprise a nucleotide having a 2′-O(CH2)2-OCH3 sugar. In some embodimentsIn the 3′ wing segment, the 3′ wing segment is composed of four linked nucleosides, wherein one of the four linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar.

[0285] E2. 3′ wing segment (W2) having four linked nucleosides and a 2′-deoxy combination Specification 35 / 170 pages 45 CN 121358861 A

[0286] In some embodiments, the 3′ wing segment is composed of four linked nucleosides, wherein one of the linked nucleosides contains a nucleoside having a 2′-deoxy sugar. In some embodiments, the 3′ wing segment is composed of four linked nucleosides, wherein two of the linked nucleosides contain a nucleoside having a 2′-deoxy sugar. In some embodiments, the 3′ wing segment consists of four linked nucleosides, wherein one of the four linked nucleosides contains a nucleoside having a 2′-deoxy sugar, and each of the other three linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of four linked nucleosides, wherein one of the four linked nucleosides contains a nucleoside having a 2′-deoxy sugar, one of the four linked nucleosides contains a locked nucleic acid, and each of the other two linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of four linked nucleosides, wherein one of the four linked nucleosides contains a nucleoside having a 2′-deoxy sugar, two of the four linked nucleosides contain locked nucleic acids, and the other linked nucleoside contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar.

[0287] E3. 3′ Wing segment (W2) having a combination of 4 linked nucleosides and 2′-LNA

[0288] In some embodiments, the 3′ wing segment consists of 4 linked nucleosides, wherein one of the 4 linked nucleosides contains a locked nucleic acid. In some embodiments, the 3′ wing segment consists of 4 linked nucleosides, wherein two of the 4 linked nucleosides contain a locked nucleic acid. In some embodiments, the 3′ wing segment consists of 4 linked nucleosides, wherein one of the 4 linked nucleosides contains a 4′-CH2-O-2′ sugar. In some embodiments, the 3′ wing segment consists of 4 linked nucleosides, wherein two of the 4 linked nucleosides contain a 4′-CH2-O-2′ sugar.

[0289] In some embodiments, the 3′ wing segment consists of 4 linked nucleosides, wherein one of the 4 linked nucleosides contains a locked nucleic acid, and each of the other 3 linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of four linked nucleosides, two of which are...The nucleosides comprise locked nucleic acids, and each of the other two linked nucleosides comprises a nucleoside having a 2'-O(CH2)2-OCH3 sugar. In some embodiments, the 3'-wing segment consists of four linked nucleosides, wherein three of the four linked nucleosides comprise locked nucleic acids, and the other linked nucleoside comprises a nucleoside having a 2'-O(CH2)2-OCH3 sugar. In some embodiments, the 3'-wing segment consists of four linked nucleosides, wherein one of the four linked nucleosides comprises a 4'-CH2-O-2' sugar, and each of the other three linked nucleosides comprises a nucleoside having a 2'-O(CH2)2-OCH3 sugar. In some embodiments, the 3'-wing segment consists of four linked nucleosides, wherein two of the four linked nucleosides comprise a 4'-CH2-O-2' sugar, and each of the other two linked nucleosides comprises a nucleoside having a 2'-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of four linked nucleosides, wherein three of the four linked nucleosides contain a 4′-CH2-O-2′ sugar, and the other linked nucleoside contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar.

[0290] F1. 3′ wing segment with five linked nucleosides (W2)

[0291] In some embodiments, the 3′ wing segment consists of five linked nucleosides. In some embodiments, the 3′ wing segment consists of five linked nucleosides, wherein each of the five linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of five linked nucleosides, wherein four of the five linked nucleosides contain a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of 5 linked nucleosides, wherein 3 of the 5 linked nucleosides comprise nucleosides having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of 5 linked nucleosides, wherein 2 of the 5 linked nucleosides comprise nucleosides having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of 5 linked nucleosides, wherein 1 of the 5 linked nucleosides comprises a nucleoside having a 2′-O(CH2)2-OCH3 sugar.

[0292] F2. 3′ wing segment (W2) having 5 linked nucleosides and a 2′-deoxy combination

[0293] In some embodiments, the 3′ wing segment consists of 5 linked nucleosides, wherein one of the linked nucleosides comprises a nucleoside having a 2′-deoxy sugar. In some implementations, the 3′ wing segment consists of five linked nucleosides, among which...Two of the linked nucleosides comprise nucleosides having a 2′-deoxy sugar. In some embodiments, the 3′-wing segment consists of five linked nucleosides, wherein one of the five linked nucleosides comprises a nucleoside having a 2′-deoxy sugar, and each of the other four linked nucleosides comprises a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′-wing segment consists of five linked nucleosides, wherein one of the five linked nucleosides comprises a nucleoside having a 2′-deoxy sugar, one of the five linked nucleosides comprises a locked nucleic acid, and each of the other three linked nucleosides comprises a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of five linked nucleosides, wherein one of the five linked nucleosides contains a nucleoside having a 2′-deoxy sugar, two of the five linked nucleosides contain locked nucleic acids, and the other two linked nucleosides contain nucleosides having a 2′-O(CH2)2-OCH3 sugar.

[0294] F3. 3′ wing segment (W2) having a combination of five linked nucleosides and 2′-LNA

[0295] In some embodiments, the 3′ wing segment consists of five linked nucleosides, wherein one of the five linked nucleosides contains a locked nucleic acid. In some embodiments, the 3′ wing segment consists of five linked nucleosides, wherein two of the five linked nucleosides contain locked nucleic acids. In some embodiments, the 3′ wing segment consists of five linked nucleosides, wherein one of the five linked nucleosides contains a 4′-CH2-O-2′ sugar. In some embodiments, the 3′ wing segment consists of five linked nucleosides, wherein two of the five linked nucleosides contain a 4′-CH2-O-2′ sugar.

[0296] In some embodiments, the 3′ wing segment consists of five linked nucleosides, wherein one of the five linked nucleosides contains a locked nucleic acid, and each of the other four linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of five linked nucleosides, wherein two of the five linked nucleosides contain a locked nucleic acid, and each of the other three linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of five linked nucleosides, wherein three of the five linked nucleosides contain a locked nucleic acid, and each of the other two linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of five linked nucleotides, one of which contains a 4′-CH2-O-2′ sugar, and each of the other four linked nucleotides contains a 2′-O(CH2)2-OCH3 sugar.The 3′ wing segment consists of 5 linked nucleotides, wherein two of the 5 linked nucleotides contain 4′-CH2-O-2′ sugars, and each of the other 3 linked nucleotides contains a nucleotide having a 2′-O(CH2)2-OCH3 sugar

[0297] G1 3′ wing segment (W2) having 6 linked nucleotides

[0298] In some embodiments, the 3′ wing segment consists of 6 linked nucleotides. In some embodiments, the 3′ wing segment consists of 6 linked nucleotides, wherein each of the 6 linked nucleotides contains a nucleotide having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of 6 linked nucleotides, wherein 5 of the 6 linked nucleotides contain a nucleotide having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein four of the six linked nucleosides comprise a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein three of the six linked nucleosides comprise a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein two of the six linked nucleosides comprise a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein one of the six linked nucleosides comprises a nucleoside having a 2′-O(CH2)2-OCH3 sugar.

[0299] G2. 3′ Wing segment (W2) having a 6-linked nucleotide combination and a 2′-deoxy sugar

[0300] In some embodiments, the 3′ wing segment consists of 6 linked nucleotides, wherein one of the linked nucleotides contains a nucleotide having a 2′-deoxy sugar. In some embodiments, the 3′ wing segment consists of 6 linked nucleotides, wherein two of the linked nucleotides contain a nucleotide having a 2′-deoxy sugar. In some embodiments, the 3′ wing segment consists of 6 linked nucleotides, wherein one of the 6 linked nucleotides contains a nucleotide having a 2′-deoxy sugar, and each of the other 5 linked nucleotides contains a nucleotide having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein one of the six linked nucleosides contains a nucleoside having a 2′-deoxy sugar, one of the six linked nucleosides contains a locked nucleic acid, and each of the other four linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein five of the six linked nucleosides contain a 2′-deoxy sugar.One of the linked nucleosides contains a nucleoside having a 2′-deoxy sugar, two of the six linked nucleosides contain locked nucleic acids, and the other three linked nucleosides contain nucleosides having a 2′-O(CH2)2-OCH3 sugar.

[0301] G3. 3′ Wing segment (W2) having a combination of six linked nucleosides and 2′-LNA

[0302] In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein one of the six linked nucleosides contains a locked nucleic acid. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein two of the six linked nucleosides contain locked nucleic acids. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein one of the six linked nucleosides contains a 4′-CH2-O-2′ sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein two of the six linked nucleosides contain a 4′-CH2-O-2′ sugar.

[0303] In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein one of the six linked nucleosides contains a locked nucleic acid, and each of the other five linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein two of the six linked nucleosides contain a locked nucleic acid, and each of the other four linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein three of the six linked nucleosides contain a locked nucleic acid, and each of the other three linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein one of the six linked nucleosides contains a 4′-CH2-O-2′ sugar, and each of the other five linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein two of the six linked nucleosides contain a 4′-CH2-O-2′ sugar, and each of the other four linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the 3′ wing segment consists of six linked nucleosides, wherein three of the six linked nucleosides contain a 4′-CH2-O-2′ sugar, and each of the other three linked nucleosides contains a nucleoside having a 2′-O(CH2)2-OCH3 sugar.

[0304] H-O. Gap Segment

[0305] In some embodiments, the modified multi-segment antisense oligonucleotide comprises at least one gap segment or consists of up toThe modified multi-segment antisense oligonucleotide comprises at least two nick segments or is composed of at least two nick segments. In some embodiments, the modified multi-segment antisense oligonucleotide comprises at least three nick segments or is composed of at least three nick segments. In some embodiments, the modified multi-segment antisense oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nick segments. The nick segments are consecutively referred to as the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth nick segments, wherein the first nick segment is closest to the 5′ end of the modified multi-segment antisense oligonucleotide, and the last nick segment is closest to the 3′ end of the modified multi-segment antisense oligonucleotide. In some embodiments, the modified multi-segment antisense oligonucleotide comprises two nick segments or is composed of two nick segments. In some embodiments, the modified multi-segment antisense oligonucleotide comprises three nick segments or is composed of three nick segments. In some embodiments, the modified multi-segment antisense oligonucleotide comprises or consists of 4 nick segments. In some embodiments, the modified multi-segment antisense oligonucleotide (specification page 38 / 170, CN 121358861 A) comprises or consists of 5 nick segments. In some embodiments, the modified multi-segment antisense oligonucleotide comprises or consists of 6 nick segments. In some embodiments, the modified multi-segment antisense oligonucleotide comprises or consists of 7 nick segments.

[0306] In some embodiments, the nick segment comprises or consists of 1 to 20 linked nucleosides. In some embodiments, the nick segment comprises or consists of 2 to 7 linked nucleosides. In some embodiments, the nick segment consists of 1 nucleoside. In some embodiments, the nick segment consists of 2 linked nucleosides. In some embodiments, the nick segment consists of 3 linked nucleosides. In some embodiments, the gap segment consists of 4 linked nucleosides. In some embodiments, the gap segment consists of 5 linked nucleosides. In some embodiments, the gap segment consists of 6 linked nucleosides. In some embodiments, the gap segment consists of 7 linked nucleosides. In some embodiments, the gap segment consists of 8 linked nucleosides. In some embodiments, the gap segment consists of 9 linked nucleosides. In some embodiments, the gap segment consists of 10 linked nucleosides.

[0307] H-1. First Gap Segment (G1)

[0308] In some embodiments, the first gap segment comprises 1, 2, 3, 4, 5, 6, 7, or 8 linked nucleosides.The nucleotide may be composed of 1, 2, 3, 4, 5, 6, 7, or 8 linked nucleotides. In some embodiments, the first nick segment contains 2 to 7 linked nucleotides or is composed of 2 to 7 linked nucleotides. In some embodiments, the first nick segment contains 4 or 5 linked nucleotides or is composed of 4 or 5 linked nucleotides. In some embodiments, the first nick segment contains 4 linked nucleotides or is composed of 4 linked nucleotides. In some embodiments, the first nick segment contains 5 linked nucleotides or is composed of 5 linked nucleotides.

[0309] In some embodiments, the first nick segment contains 1, 2, 3, 4, 5, 6, 7, or 8 linked nucleotides or is composed of 1, 2, 3, 4, 5, 6, 7, or 8 linked nucleotides, each nucleotide having a 2′-deoxy sugar. In some embodiments, the first nick segment comprises or consists of 2 to 7 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the first nick segment comprises or consists of 4 or 5 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the first nick segment comprises or consists of 4 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the first nick segment comprises or consists of 5 linked nucleosides, each nucleoside having a 2′-deoxy sugar.

[0310] H-2. Second nick segment (G2)

[0311] In some embodiments, the second nick segment comprises or consists of 1, 2, 3, 4, 5, 6, 7 or 8 linked nucleosides, or consists of 1, 2, 3, 4, 5, 6, 7 or 8 linked nucleosides. In some embodiments, the second gap segment comprises or consists of 2 to 7 linked nucleosides. In some embodiments, the second gap segment comprises or consists of 1 or 2 linked nucleosides. In some embodiments, the second gap segment comprises or consists of 4 or 5 linked nucleosides. In some embodiments, the second gap segment comprises 1 nucleoside. In some embodiments, the second gap comprises or consists of 2 linked nucleosides. In some embodiments, the second gap segment comprises or consists of 4 linked nucleosides. In some embodiments, the second gap segment comprises or consists of 5 linked nucleosides.

[0312] In some embodiments, the second gap segment comprises or is composed of 1, 2, 3, 4, 5, 6, 7 or 8 linked nucleosides, each nucleoside having a 2′-deoxySugar. In some embodiments, the second nick segment comprises or consists of 2 to 7 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the second nick segment comprises or consists of 1 or 2 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the second nick segment comprises 1 nucleoside, each nucleoside having a 2′-deoxy sugar. In some embodiments, the second nick segment comprises or consists of 2 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the second nick segment comprises or consists of 4 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the second nick segment comprises or consists of 5 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the second nick segment comprises or consists of 6 linked nucleosides, each nucleoside having a 2′-deoxy sugar.

[0313] H-3. Third nick segment (G3)

[0314] In some embodiments, the third nick segment comprises or consists of 1, 2, 3, 4, 5, 6, 7, or 8 linked nucleosides. In some embodiments, the third nick segment comprises or consists of 2 to 7 linked nucleosides. In some embodiments, the third nick segment comprises or consists of 4 or 5 linked nucleosides. In some embodiments, the third nick segment comprises or consists of 4 linked nucleosides. In some embodiments, the third nick segment comprises or consists of 5 linked nucleosides.

[0315] In some embodiments, the third nick segment comprises or consists of 1, 2, 3, 4, 5, 6, 7, or 8 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the third nick segment comprises or consists of 2 to 7 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the third nick segment comprises or consists of 4 or 5 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the third nick segment comprises or consists of 4 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the third nick segment comprises or consists of 4 linked nucleosides, each nucleoside having a 2′-deoxy sugar. In some embodiments, the third nick segment comprises or consists of 5 linked nucleosides, each nucleoside having a 2′-deoxy sugar.

[0316] J. Separator Section

[0317] In some embodiments, the separator segment comprises one, two, three, four, or five linked nucleosides. In some embodiments, the separator segment comprises one nucleoside. In some embodiments, the separator segment comprises two nucleosides.

[0318] In some embodiments, the nucleoside comprises a modification. Exemplary modifications include any of the modifications shown in the section entitled Exemplary Modifications, including but not limited to 2′-O-methoxyethyl nucleoside, 2′-O-methoxyethyl cytidine, 2′-O-methyl nucleoside, 2′-O-methyl nucleoside, 2′-OH nucleoside, GNA, LNA, LNA having a cytosine base, 2′-fluoro2′-deoxynucleoside, 2′-fluoro2′-deoxycytidine, 2′-F-arabinose (2′-F-ANA), or 2′-F-arabinose (2′-F-ANA), or combinations thereof.

[0319] In some embodiments, the separator segment consists of a nucleoside comprising a 2′-OCH3 sugar. In some embodiments, the separator segment consists of a nucleotide comprising a 2'-O(CH2)2-OCH3 sugar.

[0320] In some embodiments, the separator segment is located at position 7, 8, 9, 10, 11, 12, 13, or 14 of a modified multi-segment antisense oligonucleotide of length 16 residues. In some embodiments, the separator segment is located at position 7, 8, 9, 10, 11, 12, 13, or 14 of a modified multi-segment antisense oligonucleotide of length 17 residues. In some embodiments, the separator segment is located at position 7, 8, 9, 10, 11, 12, 13, or 14 of a modified multi-segment antisense oligonucleotide of length 18 residues. In some embodiments, the separator segment is located at position 7, 8, 9, 10, 11, 12, 13, or 14 of a modified multi-segment antisense oligonucleotide of length 19 residues. In some embodiments, the separator segment is located at position 7, 8, 9, 10, 11, 12, 13, or 14 of a modified multi-segment antisense oligonucleotide of length 20 residues. In some embodiments, as described on pages 40 / 170 of CN 121358861 A, the separator segment is located at position 7, 8, 9, 10, 11, 12, 13, or 14 of a modified multi-segment antisense oligonucleotide of length 21 residues. In some embodiments, the separator segment is located at position 7, 8, 9, 10, 11, 12, 13, or 14 of a modified multi-segment antisense oligonucleotide of length 22 residues.

[0321] In some embodiments, the separator segment is located at position 9, 10, 11, or 12 of a modified multi-segment antisense oligonucleotide of length 20 residues.

[0322] In some embodiments, the separator segment is located at position 10 of a modified multi-segment antisense oligonucleotide of length 20 residues.

[0323] In some embodiments, the separator segment is located at position 10 of a modified multisegmental antisense oligonucleotide of length 20 residues and is composed of a nucleoside containing a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the separator segment is composed of a nucleoside containing a 2′-OCH3 sugar. In some embodiments, the separator segment is located at position 7, 8, 9, 10, 11, 12, 13, or 14 of a modified multisegmental antisense oligonucleotide of length 20 residues. In some embodiments, the separator segment is located at position 9, 10, or 11 of a modified multisegmental antisense oligonucleotide of length 20 residues. In some embodiments, the separator segment is located at position 10 of a modified multisegmental antisense oligonucleotide of length 20 residues.

[0324] In some embodiments, the separator segment is composed of a nucleoside containing a 2′-O(CH2)2-OCH3 sugar. In some embodiments, the separator segment consists of a nucleoside containing a 2′-OCH3 sugar. In some embodiments, the separator segment is located at position 7, 8, 9, 10, 11, 12, 13, or 14 of a modified multisegment antisense oligonucleotide of length 20 residues. In some embodiments, the separator segment is located at position 9, 10, or 11 of a modified multisegment antisense oligonucleotide of length 20 residues. In some embodiments, the separator segment is located at position 10 of a modified multisegment antisense oligonucleotide of length 20 residues.

[0325] K. Oligonucleotide backbone

[0326] In some embodiments, the modified multisegment antisense oligonucleotide is single-stranded. In some embodiments, at least one internucleotide bond is a modified internucleotide bond. In some embodiments, each internucleotide bond is a phosphate thioester internucleotide bond. In some embodiments, the modified multisegment antisense oligonucleotide of this disclosure comprises one or more modified internucleotide bonds, wherein the modified internucleotide bond is a phosphoryldiamine bond between morpholinonucleotide mimics.

[0327] L. Modified nucleobase

[0328] In some embodiments, the modified multisegment antisense oligonucleotide comprises at least one modified nucleobase. In some embodiments, the modified multisegment antisense oligonucleotide comprises one, two, or three modified nucleobases. In some embodiments, the modified nucleobase is 5-methylcytosine.

[0329] In some embodiments, one or more modified nucleosides in the wing segment have modified sugars. In some embodiments, the modified sugar is a bicyclic sugar. In some embodiments, the modified nucleoside is an LNA nucleoside. In some embodiments, the modified nucleoside is a 2′-substituted nucleoside. In some embodiments, the 2′-substituted nucleoside includes nucleosides modified with bicyclic sugars. In some embodiments, the modified nucleoside is a 2'-MOE nucleoside. In some embodiments,The modified nucleoside is a restricted ethyl (cEt) nucleoside. In some embodiments, each modified nucleoside in each wing segment is independently a 2'-MOE nucleoside or a nucleoside with bicyclic sugar modification, such as a restricted ethyl (cEt) nucleoside or LNA nucleoside.

[0330] 4-5-1-5-5 modified multi-segment antisense oligonucleotide

[0331] In some embodiments, the modified multi-segment antisense oligonucleotide comprises: a 5' wing segment consisting of 4 linked nucleosides; a first nick segment consisting of 5 linked nucleosides having 2'-deoxy sugar; a separator segment located at position 10 of the modified multi-segment antisense oligonucleotide of length 20 residues; a second nick segment consisting of 5 linked nucleosides having 2'-deoxy sugar; and a 3' wing segment consisting of 5 linked nucleosides. In one exemplary embodiment, the modified multisegment antisense oligonucleotide of this paragraph further includes: cytosine at positions 2, 13, and 20 of the modified multisegment antisense oligonucleotide of length 20 residues is 5-methylcytosine. In an exemplary embodiment of the modified multisegment antisense oligonucleotide of this paragraph, each cytosine of the modified multisegment antisense oligonucleotide is 5-methylcytosine. In an exemplary embodiment, the modified multisegment antisense oligonucleotide of this paragraph further includes a nucleoside internucleotide bond, wherein each nucleoside internucleotide bond is a phosphate thioester nucleoside internucleotide bond. In an exemplary embodiment, the modified multisegment antisense oligonucleotide of this paragraph further includes: cytosine at positions 2, 13, and 20 of the modified multisegment antisense oligonucleotide of length 20 residues is 5-methylcytosine, and further includes a nucleoside internucleotide bond, wherein each nucleoside internucleotide bond is a phosphate thioester nucleoside internucleotide bond.

[0332] In some embodiments, the modified multi-segment antisense oligonucleotide comprises: a 5′ wing segment as described in portions B1, B2, or B3; a first nick segment consisting of five linked nucleotides having a 2′-deoxy sugar; a separator segment located at position 10 of the modified multi-segment antisense oligonucleotide of length 20 residues; a second nick segment consisting of five linked nucleotides having a 2′-deoxy sugar; and a 3′ wing segment as described in portions F1, F2, or F3. In one exemplary embodiment, the modified multi-segment antisense oligonucleotide of this paragraph further comprises: cytosine at positions 2, 13, and 20 of the modified multi-segment antisense oligonucleotide of length 20 residues, each being 5-methylcytosine. In one exemplary embodiment, the modified multi-segment antisense oligonucleotide of this paragraph further comprises internucleotide bonds, wherein each internucleotide bond is a phosphate thioester internucleotide bond. In one exemplary embodiment, the modified multi-segment antisense oligonucleotide of this paragraph further comprises:The cytosine at positions 2, 13, and 20 of the modified multisegment antisense oligonucleotide of length 20 residues is 5-methylcytosine, and also contains nucleoside internucleotides, wherein each nucleoside internucleotide is a phosphate thioester nucleoside internucleotide.

[0333] Exemplary notes of positions and segments of AUS1493 or SEQ ID NO: 456 are shown below.

[0334]

[0335] In some embodiments, the oligonucleotide or composition comprises a salt of the modified multisegment antisense oligonucleotide.

[0336] In some embodiments, the oligonucleotide or composition further comprises a pharmaceutically acceptable carrier or diluent.

[0337] In some embodiments, the compound or modified multisegment antisense oligonucleotide is single-stranded.

[0338] In some embodiments, at least one nucleoside of the modified multisegment antisense oligonucleotide comprises a modified sugar. In some embodiments, at least one modified sugar comprises 2′-O-methoxyethyl(2′-O(CH2)2-OCH3). In some embodiments, the modified sugar comprises a 2′-O-CH3 group. In some embodiments, the modified nucleobase is '-O-methoxyethyl 5-methylcytidine.

[0339] In some embodiments, at least one modified sugar is a bicyclic sugar. In some embodiments, at least one modified sugar of the bicyclic sugar comprises a 4′-(CH2)-O-2′ bridge, wherein n is 1 or 2. In some embodiments, the bicyclic sugar comprises a 4′-CH2-O-2′ bridge. In some embodiments, the bicyclic sugar comprises a 4′-CH(CH3)-O-2′ bridge.

[0340] Methods

[0341] This disclosure provides methods for treating a subject suffering from a disease or disorder involving a target.

[0342] In some embodiments, the disease or disorder is a DMPK-related disease or disorder. In some embodiments, the disease or disorder is an AAT-related disease or disorder. In some embodiments, the disease or disorder is a TTR-related disease or disorder. In some embodiments, the disease or disorder is a PCSK9-related disease or disorder. In some embodiments, the disease or disorder is an ApoB-related disease or disorder. In some embodiments, the disease or disorder is a TNFα-related disease or disorder. In some embodiments, the disease or disorder is an ApoCIIIα-related disease or disorder. In some embodiments, the disease or disorder is a DMPK-related disease or disorder. In some embodiments, the disease or disorder is an AGT-related disease or disorder. In some embodiments, the disease or disorder is a CFB-related disease or disorder. In some embodiments, the disease or disorder is a DGAT2-related disease or disorder. In some embodiments, the disease or disorder is a PNPLA3-related disease or disorder. In some embodiments...In this context, the disease or disorder is an ALAS1-related disease or disorder. In some implementations, the disease or disorder is a hydroxy acid oxidase 1-related disease or disorder.

[0343] In some embodiments, the disease or disorder is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), COVID-19, skin aging conditions, prostate cancer, atherosclerosis, chronic kidney disease, chikungunya virus, amyotrophic lateral sclerosis, advanced malignant solid tumors, non-arteritis anterior ischemic optic neuropathy, HIV, immunoglobulin A nephropathy, inflammation and injury, human Tenon's cystic fibroblasts, antifibrotic agents, cystic fibrosis, Duchenne muscular dystrophy (DMD), myotonic dystrophy, central nucleus myopathy, facioscapulohumeral muscular dystrophy (FSHD), pancreatic cancer, solid tumors, cystic fibrosis, antithrombotic agents, coagulation disorders, thrombotic disorders, Alexander disease, Pompe disease, H1N1 influenza, HBV, liver fibrosis, HPV, Huntington's disease. The following diseases are considered as potential causes of cancer: clear cell renal cell carcinoma, pancreatic cancer, Parkinson's disease, MERS-CoV, inflammatory bowel disease, Alport's syndrome, advanced liver cancer, muscular atrophy and myotonic dystrophy, Mycobacterium tuberculosis, rabies, hypercholesterolemia, pulmonary fibrosis, primary or secondary liver cancer, breast cancer, RSV, spinal muscular atrophy, multiple system atrophy, cancer, Alzheimer's disease and frontotemporal lobe degeneration, thalassemia / low-risk myelodysplastic syndrome, autoimmune diseases, hATTR, hereditary thyroxine transporter (ATTRv) amyloidosis, or gout.

[0344] In some embodiments, the disease or disorder is Mat1α, (proto)renin receptor / (P)RR, COVID-195'UTR, Acc1, Acc2, ACE2, androgen receptor, ApoB, ASGR1, ASO, ATXN2, B1AR, B2AR, C9ORF72, cysteine ​​2, CD19, CD4, Chikungunya virus, CLPro, complement component 5, COVID19, COX2, CTGF, DGAT2, DMD, DMPK, DNM2, DUX4, E2 gene, EGFR, envelope, EphA2, epithelial sodium channel α subunit, exon 100 dystrophin, exon 101 Muscular dystrophy protein, exon 102 muscular dystrophy protein, exon 103 muscular dystrophy protein, exon 104 muscular dystrophy protein, exon 105 muscular dystrophy protein, exon 106 muscular dystrophy protein, exon 107 muscular dystrophy proteinGood protein, exon 108 dystrophin, exon 109 dystrophin, exon 110 dystrophin, exon 111 dystrophin, exon 112 dystrophin, exon 113 dystrophin, exon 114 dystrophin, exon 115 dystrophin, exon 116 dystrophin, exon 117 dystrophin, exon 118 dystrophin, exon 119 dystrophin, exon 120 dystrophin, exon 121 dystrophin, exon 122 dystrophin, exon 123 dystrophin, exon 124 dystrophin, exon 125 dystrophin, exon 126 dystrophin, exon 127 dystrophin, exon 128 dystrophin, exon 129 dystrophin. Exon 130 dystrophin, Exon 131 dystrophin, Exon 132 dystrophin, Exon 133 dystrophin, Exon 134 dystrophin, Exon 135 dystrophin, Exon 136 dystrophin, Exon 137 dystrophin, Exon 138 dystrophin, Exon 139 dystrophin, Exon 140 dystrophin, Exon 141 dystrophin, Exon 142 dystrophin. (Instructions 43 / 170 pages, 53 CN 121358861 A) Good protein, exon 143 muscular dystrophy protein, exon 144 muscular dystrophy protein, exon 145 muscular dystrophy protein, exon 146 muscular dystrophy protein, exon 147 muscular dystrophy protein, exon 148 muscular dystrophy protein, exon 149 muscular dystrophy protein, exon 150 muscular dystrophy protein, exon 151 muscular dystrophy protein, exon 152 muscular dystrophy protein, exon 44 muscular dystrophy protein, exon 53 muscular dystrophy protein, exon 54 muscular dystrophy protein, exon 55 muscular dystrophy protein, exon 56 muscular dystrophy protein, exon 57 muscular dystrophy protein Good protein, exon 58 muscular dystrophy protein, exon 59 muscular dystrophy protein, exon 60 muscular dystrophy protein, exon 61 muscular dystrophy protein, exon 62 muscular dystrophy protein, exon 63 muscular dystrophy protein, exon 64 muscular dystrophy protein, exon 65 muscular dystrophy protein, exon 66 muscular dystrophy protein, exon 67 muscular dystrophy protein, exon 68 muscular dystrophy protein, exon 69 muscular dystrophy protein, exon 70 muscular dystrophy protein, exon 71 muscular dystrophy protein, exon 72 muscular dystrophy protein, exon 73 muscular dystrophy protein, exon 74 muscular dystrophy proteinMuscular dystrophy protein, exon 75 muscular dystrophy protein, exon 76 muscular dystrophy protein, exon 77 muscular dystrophy protein, exon 78 muscular dystrophy protein, exon 79 muscular dystrophy protein, exon 80 muscular dystrophy protein, exon 81 muscular dystrophy protein, exon 82 muscular dystrophy protein, exon 83 muscular dystrophy protein, exon 84 muscular dystrophy protein, exon 85 muscular dystrophy protein, exon 86 muscular dystrophy protein, exon 87 muscular dystrophy protein, exon 88 muscular dystrophy protein, exon 89 muscular dystrophy protein, exon 90 muscular dystrophy protein, exon 91 muscular dystrophy protein, exon 92 muscular dystrophy protein, exon 93 muscular dystrophy protein, exon 94 muscular dystrophy protein, exon 95 muscular dystrophy protein, exon 96 muscular dystrophy protein, exon 97 muscular dystrophy protein White, exon 98 dystrophin, exon 99 dystrophin, Fabp3, coagulation factor VII, coagulation factor XI, FAK, FGFR4, FOXP3, FUS, FXII, GFAP, GFP, glycogen synthase, H1N1, HBV, heat shock protein 47, heat shock protein 48, heat shock protein 49, heat shock protein 50, heat shock protein 51, heat shock protein 52, heat shock protein 53 Heat shock protein 54, heat shock protein 55, heat shock protein 56, heat shock protein 57, heat shock protein 58, heat shock protein 59, helicase, HIV, HOXB13, HPRT, HPV, Hsd11β1, HTT, hydroxy acid oxidase 1, hydroxysteroid 17β-dehydrogenase 13, hypoxia-inducible factor 2α, spindle kinase and vascular endothelial growth factor, KRAS, leader sequence, leucine-rich repeat kinase 2 (LRRK2), MERS-CoV, MGMT, miR-16, miR-21, MMP-2, MMP-9, MTL-CEBPA, MuRF1, Mycobacterium tuberculosis, COVID-19N, Rabies N123, Rabies N749, Rabies N903, Rabies N1082, Rabies N53, Rabies N8, Chikungunya virus ns1 gene, Chikungunya virus ns2 gene, Chikungunya virus ns3 gene, Chikungunya virus ns4 gene, ORF1b, ORF1a, HIV P24, Rabies P330, P53, Rabies P721, Rabies P91, PCSK9, PDGF, PDL1, COVID-19 PLP, PNPLA3, Polo-like kinase 1, Protein kinase N3, RAF1, RAF-1, RDRP, RSV, SMN2, SNCA Covid-19 spike protein, STAT3, TAU, TGFB1, TGFB1 and Cox2, TMPRSS2, TMPRSS6, TNFα, thyroxine transportDiseases or disorders related to cytokines, VEGF, VEGFR2, VER2, xanthine dehydrogenase, or YAP1.

[0345] In some embodiments, the subject is a human.

[0346] In some embodiments, the subject is a non-human primate, such as a monkey, for example, a cynomolgus monkey.

[0347] In some embodiments, the subject is a rodent, such as a mouse or rat.

[0348] In some embodiments, the modified multisegment antisense oligonucleotide of this disclosure increases in vivo activity (compared to a sequence having the same nucleobase sequence but unmodified).

[0349] In some embodiments, the modified multisegment antisense oligonucleotide of this disclosure results in reduced off-target binding (compared to a sequence having the same nucleobase sequence but unmodified).

[0350] In some embodiments, the use of the modified multisegment antisense oligonucleotide of this disclosure results in reduced toxicity (compared to a sequence having the same nucleobase sequence but unmodified). Specification 44 / 170 pages 54 CN 121358861 A

[0351] In some embodiments, the modified multisegment antisense oligonucleotide or pharmaceutical composition is designated as a first agent. In some embodiments, these methods include administering the first agent and one or more second agents. In some embodiments, the first agent and one or more second agents are administered together. In some embodiments, the first agent and one or more second agents are administered sequentially or simultaneously. In some embodiments, the first agent and one or more second agents are not administered together.

[0352] The modified multisegment antisense oligonucleotides of this disclosure and pharmaceutical compositions comprising them can be administered to a subject via any suitable route of administration. Examples of routes of administration include parenteral, such as intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), intraocular, intramuscular, intraperitoneal (into body cavities), and transmucosal administration.

[0353] In some embodiments, administration includes parenteral administration. In some embodiments, administration includes subcutaneous administration. In some embodiments, administration includes intravenous injection or infusion.

[0354] In some embodiments, the EC50 in cells treated with the modified multi-segment antisense oligonucleotide is measured as a representative of the effectiveness of the modified multi-segment antisense oligonucleotide. In some embodiments, the EC50 is from about 0.1 nM to about 250 nM. In some embodiments, the EC50 is less than 250 nM, less than 200 nM, less than 150 nM, less than 100 nM, less than 90 nM, less than 80 nM, less than 70 nM, less than 65 nM, less than 60 nM, less than 55 nM, less than 50 nM, less than 49 nM, less than 47 nM, less than 46 nM, less than 45 nM, less than 44 nM, less than 43 nM, less than 42 nM, less than 41 nM, less than 40 nM, less than 39 nM, less than 38 nM.Less than 37nM, less than 36nM, less than 35nM, less than 34nM, less than 33nM, less than 32nM, less than 31nM, less than 30nM, less than 29nM, less than 28nM, less than 27nM, less than 26nM, less than 25nM, less than 24nM, less than 23nM, less than 22nM, less than 21nM, less than 20nM, less than 19nM, less than 18nM, less than 17nM, less than 16nM, less than 15nM, less than 14nM, less than 13nM, less than 12nM, less than 11nM, less than 10nM, less than 9nM, less than 8nM, less than 7nM, less than 6nM, less than 5nM, less than 4nM, less than 3nM, less than 2nM, less than 1nM, less than 0.9nM, less than 0.8nM, less than 0.7nM, less than 0 <0.6 nM, <0.5 nM, <0.4 nM, <0.3 nM, <0.2 nM, or <0.1 nM.

[0355] In some embodiments, the ratio of EC50 in cells treated with a modified multi-segment antisense oligonucleotide to EC50 in cells treated with a reference oligonucleotide (e.g., a modified antisense oligonucleotide having the same template nucleotide sequence but without the separator segment) is calculated as a measure of efficacy in reducing target protein expression levels. In some embodiments, the ratio is from about 0.05 to about 250. In some embodiments, the ratio is from about 0.05 to about 100. In some implementations, the EC50 ratio is less than 250, less than 150, less than 100, less than 90, less than 80, less than 70, less than 65, less than 60, less than 55, less than 50, less than 49, less than 47, less than 46, less than 45, less than 44, less than 43, less than 42, less than 41, less than 40, less than 39, less than 38, less than 37, less than 36, less than 35, less than 34, less than 33, less than 32, less than 31, less than 30, less than 29, less than 28, less than 27, less than 26, less than 25, less than 24, less than 23, less than 22, less than 21, less than 20, less than 19, less than 18, less than 17. Less than 16, less than 15, less than 14, less than 13, less than 12, less than 11, less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, less than 2, less than 1, less than 0.9, less than 0.8, less than 0.7, less than 0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2, or less than 0.1.

[0356] In some embodiments, the MTT CC25 value (nM) is used as a measure of cytotoxicity. In some embodiments, the MTT CC25 of cells treated with the modified multisegment antisense oligonucleotides described herein is from about 10 nM to about 250 nM. In some embodiments, the MTTCC25 > 10nM, > 15nM, > 20nM, > 25nM, > 30nM, > 35nM, > 40nM, > 45nM, > 50nM, > 55nM, > 60nM, > 65nM, > 70nM, > 75nM, > 80nM, > 85nM, > 90nM, > 95nM, > 100nM, > 110nM, > 120nM, > 130nM, > 140nM, > 150nM, > 160nM, > 170nM, > 180nM, > 190nM, > 200nM, > 210nM, > 220nM, > 230nM, > 240nM, or > 250nM. Specification 45 / 170 pages 55 CN 121358861 A

[0357] In some embodiments, CCK8 CC30 (nM) is used as a measure of cytotoxicity. In some embodiments, the CCK8 CC30 of cells treated with the modified multisegment antisense oligonucleotides described herein is about 10 nM to about 250 nM. In some implementations, CCK8 CC30 is greater than 10nM, greater than 15nM, greater than 20nM, greater than 25nM, greater than 30nM, greater than 35nM, greater than 40nM, greater than 45nM, greater than 50nM, greater than 55nM, greater than 60nM, greater than 65nM, greater than 70nM, greater than 75nM, greater than 80nM, greater than 85nM, greater than 90nM, greater than 95nM, greater than 100nM, greater than 110nM, greater than 120nM, greater than 130nM, greater than 140nM, greater than 150nM, greater than 160nM, greater than 170nM, greater than 180nM, greater than 190nM, greater than 200nM, greater than 210nM, greater than 220nM, greater than 230nM, greater than 240nM, or greater than 250nM.

[0358] In some embodiments, the ratio of MTT CC25 or CCK8 CC30 of cells treated with the modified multi-segment antisense oligonucleotide to MTT CC25 or CCK8 CC30 of cells treated with a reference oligonucleotide (e.g., a modified antisense oligonucleotide having the same template nucleotide sequence but without a separator segment) is calculated as a measure of cytotoxicity (relative cytotoxicity). In some embodiments, the ratio of MTT CC25 or CCK8 CC30 of cells treated with the modified multi-segment antisense oligonucleotide to MTT CC25 or CCK8 CC30 of cells treated with a reference oligonucleotide (e.g., a modified antisense oligonucleotide having the same template nucleotide sequence but without a separator segment) is less than 250, less than 150, less than100, less than 90, less than 80, less than 70, less than 65, less than 60, less than 55, less than 50, less than 49, less than 47, less than 46, less than 45, less than 44, less than 43, less than 42, less than 41, less than 40, less than 39, less than 38, less than 37, less than 36, less than 35, less than 34, less than 33, less than 32, less than 31, less than 30, less than 29, less than 28, less than 27, less than 26, less than 25, less than 2 4. Less than 23, less than 22, less than 21, less than 20, less than 19, less than 18, less than 17, less than 16, less than 15, less than 14, less than 13, less than 12, less than 11, less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, less than 2, less than 1, less than 0.9, less than 0.8, less than 0.7, less than 0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2, or less than 0.1.

[0359] In some embodiments, the "C / E ratio" is used as a measure of the efficacy of cytotoxicity in reducing the expression level of target proteins. In some implementations, the C / E ratio is calculated by taking the ratio of the MTT CC25(nM) of the modified multi-segment antisense oligonucleotide to the MTT CC25(nM) of a reference oligonucleotide (e.g., a modified antisense oligonucleotide having the same template nucleotide sequence but without a separator segment) and dividing it by the ratio of the EC50 of the modified multi-segment antisense oligonucleotide to the EC50 of a reference oligonucleotide (e.g., a modified antisense oligonucleotide having the same template nucleotide sequence but without a separator segment). In some embodiments, the C / E ratio is calculated as follows: the ratio of the CCK8 CC25(nM) of the modified multi-segment antisense oligonucleotide to the CCK8 CC25(nM) of a reference oligonucleotide (e.g., a modified antisense oligonucleotide having the same template nucleotide sequence but without a separator segment), and then divided by the ratio of the EC50 of the modified multi-segment antisense oligonucleotide to the EC50 of a reference oligonucleotide (e.g., a modified antisense oligonucleotide having the same template nucleotide sequence but without a separator segment). In some embodiments, the C / E ratio is from about 0.01 to about 50. In some implementations, the C / E ratio is greater than 1, greater than 1.1, greater than 1.2, greater than 1.3, greater than 1.4, greater than 1.5, greater than 1.6, greater than 1.7, greater than 1.8, greater than 1.9, greater than 2.0, greater than 2.1, greater than 2.2, greater than 2.3, greater than 2.4, greater than 2.5, greater than 2.6, greater than 2.7, greater than 2.8, greater than 2.9, greater than 3.0, greater than 10, greater than 11, greater than 12, greater than 13, and greater than...14, greater than 15, greater than 16, greater than 17, greater than 18, greater than 19, greater than 20, greater than 21, greater than 22, greater than 23, greater than 24, greater than 25, greater than 30, greater than 35, greater than 40, greater than 45, greater than 50, greater than 55, greater than 65, greater than 70, greater than 80, greater than 90, or greater than 100.

[0360] In some embodiments, the melting temperature of the modified multi-segment antisense oligonucleotide is used as a measure of stability. In some embodiments, the melting temperature of the modified multi-segment antisense oligonucleotide described herein is at least 0.01 times lower than that of a reference oligonucleotide (e.g., a modified antisense oligonucleotide having the same template nucleobase sequence but not containing a separator segment). In some embodiments, the melting temperature is about 0.01 times, about 0.02 times, about 0.03 times, and about 0.04 times lower than that of a reference oligonucleotide (e.g., a modified antisense oligonucleotide having the same template nucleobase sequence but excluding the separator segment). Approximately 0.05 times, approximately 0.06 times, approximately 0.07 times, approximately 0.08 times, approximately 0.09 times, approximately 0.1 times, approximately 0.15 times, approximately 0.2 times, approximately 0.25 times, approximately 0.3 times, approximately 0.35 times, approximately 0.4 times, approximately 0.45 times, approximately 0.5 times, approximately 0.55 times, approximately 0.6 times, approximately 0.65 times, approximately 0.7 times, approximately 0.75 times, approximately 0.8 times, approximately 0.85 times, approximately 0.9 times, approximately 0.95 times, approximately 1 time, approximately 1.1 times, approximately 1.15 times, approximately 1.2 times, approximately 1.25 times, approximately 1.3 times, approximately 1.35 times, approximately 1.4 times, approximately 1.45 times, approximately 1.5 times, approximately 1.55 times, approximately 1.6 times, approximately 1.65 times. Approximately 1.7 times, approximately 1.75 times, approximately 1.8 times, approximately 1.85 times, approximately 1.9 times, approximately 1.95 times, approximately 2 times, approximately 2.1 times, approximately 2.15 times, approximately 2.2 times, approximately 2.25 times, approximately 2.3 times, approximately 2.35 times, approximately 2.4 times, approximately 2.45 times, approximately 2.5 times, approximately 2.55 times, approximately 2.6 times. Approximately 2.65 times, approximately 2.7 times, approximately 2.75 times, approximately 2.8 times, approximately 2.85 times, approximately 2.9 times, approximately 2.95 times, approximately 3 times, approximately 3.1 times, approximately 3.15 times, approximately 3.2 times, approximately 3.25 times, approximately 3.3 times, approximately 3.35 times, approximately 3.4 times, approximately 3.45 times, approximately 3.5 times, approximately 3.55 times, approximately 3.6 times, approximately 3.65 times, approximately 3.7 times, approximately 3.75 times, approximately 3.8 times, approximately 3.85 times, approximately 3.9 times, approximately 3.95 times, approximately 4 times, approximately 4.1 times, approximately 4.15 times, approximately 4.2 times, approximately 4.25 times, approximately 4.3 times, approximately 4.35 times, approximately 4.4 times, approximately 4.45 times, approximately 4.5 times, approximately 4.55 times.Approximately 4.6 times, approximately 4.65 times, approximately 4.7 times, approximately 4.75 times, approximately 4.8 times, approximately 4.85 times, approximately 4.9 times, approximately 4.95 times, or approximately 5 times.

[0361] In some embodiments, the ability of the modified multi-segment antisense oligonucleotide to recruit endonucleases (e.g., RNase H) and degrade the template sequence is used as a measure of biological function. In some embodiments, the modified multi-segment oligonucleotide degrades the template sequence at least 0.01 times more than a reference oligonucleotide (e.g., a modified antisense oligonucleotide having the same template nucleobase sequence but not containing a separator segment). In some embodiments, the modified multi-segment oligonucleotide degrades the template sequence by approximately 0.01 times, approximately 0.02 times, approximately 0.03 times, approximately 0.04 times, approximately 0.05 times, approximately 0.06 times, approximately 0.07 times, approximately 0.08 times, approximately 0.09 times, approximately 0.1 times, approximately 0.15 times, approximately 0.2 times, approximately 0.25 times, approximately 0.3 times, approximately 0.35 times, approximately 0.4 times, approximately 0.45 times, approximately 0.5 times, approximately 0.55 times, approximately 0.6 times, approximately 0.65 times, approximately 0.7 times, approximately 0.75 times, approximately 0.8 times, approximately 0.85 times, approximately 0.9 times, approximately 0.95 times, approximately 1 time, approximately 1.1 times, and approximately 1 0.15 times, approximately 1.2 times, approximately 1.25 times, approximately 1.3 times, approximately 1.35 times, approximately 1.4 times, approximately 1.45 times, approximately 1.5 times, approximately 1.55 times, approximately 1.6 times, approximately 1.65 times, approximately 1.7 times, approximately 1.75 times, approximately 1.8 times, approximately 1.85 times, approximately 1.9 times, approximately 1.95 times, approximately 2 times, approximately 2.1 times, approximately 2.15 times, approximately 2.2 times, approximately 2.25 times, approximately 2.3 times, approximately 2.35 times, approximately 2.4 times, approximately 2.45 times, approximately 2.5 times, approximately 2.55 times, approximately 2.6 times, approximately 2.65 times. Approximately 2.7 times, approximately 2.75 times, approximately 2.8 times, approximately 2.85 times, approximately 2.9 times, approximately 2.95 times, approximately 3 times, approximately 3.1 times, approximately 3.15 times, approximately 3.2 times, approximately 3.25 times, approximately 3.3 times, approximately 3.35 times, approximately 3.4 times, approximately 3.45 times, approximately 3.5 times, approximately 3.55 times, approximately 3.6 times. Approximately 3.65 times, approximately 3.7 times, approximately 3.75 times, approximately 3.8 times, approximately 3.85 times, approximately 3.9 times, approximately 3.95 times, approximately 4 times, approximately 4.1 times, approximately 4.15 times, approximately 4.2 times, approximately 4.25 times, approximately 4.3 times, approximately 4.35 times, approximately 4.4 times, approximately 4.45 times, approximately 4.5 times, approximately 4.55 times, approximately 4.6 times, approximately 4.65 times, approximately 4.7 times, approximately 4.75 times, approximately 4.8 times, approximately 4.85 times, approximately 4.9 times, approximately 4.95 times, or approximately 5 times.

[0362] Reagent kits and products

[0363] This disclosure provides kits comprising the modified multisegment antisense oligonucleotides described herein, and pharmaceutical compositions comprising these oligonucleotides. In some embodiments, the modified multisegment antisense oligonucleotides comprise the structure of any of the oligonucleotide sequences described herein.

[0364] Target Nucleic Acid, Target Region, and Nucleotide Sequence

[0365] The modified multisegment antisense oligonucleotides can target any target of interest.

[0366] The target can be any target for which reduced activity is desired. In some embodiments, the target is a mammalian target, such as a human or other animal target; targeting oncogenic targets, inflammatory targets, metabolic targets, cardiovascular targets, neural targets, neuropsychiatric targets, etc. In some embodiments, the target is a gene transcript (e.g., mRNA) or RNA that regulates gene expression. Exemplary genes include, but are not limited to, DMPK, AAT, TTR, PCSK9, ApoB, ApoCIII, TNF-α, AGT, CFB, DGAT2, PNPLA3, ALAS1, or hydroxy acid oxidase 1. In some embodiments, the gene is DMPK, AAT, TTR, or PCSK9.

[0367] In some embodiments, the gene is Mat1α, (proto)renin receptor / (P)RR, COVID-195 'UTR, Acc1, Acc2, ACE2, androgen receptor, ApoB, ASGR1, ASO, ATXN2, B1AR, B2AR, C9ORF72, caspase 2, CD19, CD4, chikungunya virus, CLPro, complement component 5, COVID19, COX2, CTGF, DGAT2, DMD, DMPK, DNM2, DUX4. E2 gene, EGFR, envelope, EphA2, epithelial sodium channel α subunit, exon 100 dystrophin, exon 101 dystrophin, exon 102 dystrophin, exon 103 dystrophin, exon 104 dystrophin, exon 105 dystrophin, exon 106 dystrophin, exon 107 dystrophin, exon 108 dystrophin, exon 109 dystrophin, exon 110 dystrophin White, exon 111 dystrophin, exon 112 dystrophin, exon 113 dystrophin, exon 114 dystrophin, exon 115 dystrophin, exon 116 dystrophin, exon 117 dystrophin, exon 118 dystrophin, exon 119 dystrophin, exon 120 dystrophin, exon 121 dystrophin, exon 122 dystrophin, exon 123 dystrophinProteins, exon 124 dystrophin, exon 125 dystrophin, exon 126 dystrophin, exon 127 dystrophin, exon 128 dystrophin, exon 129 dystrophin, exon 130 dystrophin, exon 131 dystrophin, exon 132 dystrophin, exon 133 Muscular dystrophy protein, exon 134 muscular dystrophy protein, exon 135 muscular dystrophy protein, exon 136 muscular dystrophy protein, exon 137 muscular dystrophy protein, exon 138 muscular dystrophy protein, exon 139 muscular dystrophy protein, exon 140 muscular dystrophy protein, exon 141 muscular dystrophy protein, exon 142 muscular dystrophy protein, exon 143 muscular dystrophy protein, exon 144 muscular dystrophy protein, exon 145 muscular dystrophy protein, exon 146 muscular dystrophy protein, exon 147 muscular dystrophy protein, exon Myotrophic lateral sclerosis protein 148, 149, 150, 151, 152, 44, 53, 54, 55, 56, 57, 58, 59, 60, 61, and 62 of exon 148. White, exon 63 muscular dystrophy protein, exon 64 muscular dystrophy protein, exon 65 muscular dystrophy protein, exon 66 muscular dystrophy protein, exon 67 muscular dystrophy protein, exon 68 muscular dystrophy protein, exon 69 muscular dystrophy protein, exon 70 muscular dystrophy protein, exon 71 muscular dystrophy protein, exon 72 muscular dystrophy protein, exon 73 muscular dystrophy protein, exon 74 muscular dystrophy protein, exon 75 muscular dystrophy protein, exon 76 muscular dystrophy protein, exon 77 muscular dystrophy protein, exon 78 muscular dystrophy protein Muscular dystrophy protein, exon 79 muscular dystrophy protein, exon 80 muscular dystrophy protein, exon 81 muscular dystrophy protein, exon 82 muscular dystrophy protein, exon 83 muscular dystrophy protein, exon 84 muscular dystrophy protein, exon 85 muscular dystrophy protein, exon 86 muscular dystrophy protein, exon 87 muscular dystrophy protein, exon 88 muscular dystrophy protein, exon 89 muscular dystrophy protein, exon 90 muscular dystrophy protein, exon 91 muscular dystrophy protein, exon 92 muscular dystrophy protein, exon 93 muscular dystrophy protein, exon 94 muscular dystrophy proteinProteins, exon 95 dystrophin, exon 96 dystrophin, exon 97 dystrophin, exon 98 dystrophin, exon 99 dystrophin, Fapp3, coagulation factor VII, coagulation factor XI, FAK, FGFR4, FOXP3, FUS, FXII, GFAP, GFP, glycogen synthase, H1N1, HBV, heat shock protein 47, heat shock protein 48, heat shock protein 49, heat shock protein 50, heat shock protein 51, heat shock protein 52, heat shock protein 53, heat shock protein 54, instruction manual 48 / 170 pages 58 CN 121358861 A heat shock protein 55, heat shock protein 56, heat shock protein 57, heat shock protein 58, heat shock protein 59, helicase, HIV, HOXB13, HPRT, HPV, Hsd1 1β1, HTT, hydroxy acid oxidase 1, hydroxysteroid 17β-dehydrogenase 13, hypoxia-inducible factor 2α, spindle kinase and vascular endothelial growth factor, KRAS, leader sequence, leucine-rich repeat kinase 2 (LRRK2), MERS-CoV, MGMT, miR-16, miR-21, MMP-2, MMP-9, MTL-CEBPA, MuRF1, Mycobacterium tuberculosis, COVID-19N, rabies N123, rabies N749, rabies N903, rabies N1082, rabies N53, rabies N8, chikungunya virus ns1 gene, chikungunya virus ns2 gene, chikungunya virus ns3 gene, chikungunya virus ns4 gene, ORF1b, ORF1a, HIV P24, rabies P330, P53, rabies P721, rabies P91, PCSK9, PDGF, PDL1, COVID-19 PLP, PNPLA3, Polo-like kinase 1, protein kinase N3, RAF1, RAF-1, RDRP, RSV, SMN2, SNCA, Covid-19 spike protein, STAT3, TAU, TGFB1, TGFB1 and Cox2, TMPRSS2, TMPRSS6, TNFα, thyroxine carrier protein, VEGF, VEGFR2, VER2, xanthine dehydrogenase or YAP1.

[0368] Exemplary nucleic acid target sequences include, but are not limited to, the sequences shown in Tables 8.1, 8.2 and 8.3. In some embodiments, the nucleic acid target comprises the sequence of any one of the sequences described in Tables 8.1, 8.2 and 8.3. Each of the residues in Tables 8.1, 8.2 and 8.3 reflects only sequence information and does not contain any modified nucleosides.

[0369] Table 8.1. Exemplary modified multi-segment antisense oligonucleotide nucleobase sequences and gene target sequences

[0370] Specification 49 / 170 pages 59 CN 121358861A

[0371]

[0372] Table 8.2. Exemplary HBV target sequences

[0373] Specification 50 / 170 pages 60 CN 121358861 A

[0374] Specification 51 / 170 pages 61 CN 121358861 A

[0375] Specification 52 / 170 pages 62 CN 121358861 A

[0376] Specification 53 / 170 pages 63 CN 121358861 A

[0377]

[0378] HBV

[0379] Some embodiments provide methods, modified multi-segment antisense oligonucleotides, and compositions for inhibiting HBV mRNA expression.

[0380] Some embodiments provide modified multi-segment antisense oligonucleotides targeting HBV nucleic acid sequences. Exemplary HBV nucleic acid sequences include, but are not limited to, the sequences shown in Table 8.3.

[0381] Table 8.3 Exemplary HBV Sequences

[0382] Specification 54 / 170 pages 64 CN 121358861 A

[0383] Specification 55 / 170 pages 65 CN 121358861 A

[0384] Specification 56 / 170 pages 66 CN 121358861 A

[0385] Specification 57 / 170 pages 67 CN 121358861 A

[0386] Specification 58 / 170 pages 68 CN 121358861 A

[0387] Specification 59 / 170 pages 69 CN 121358861 A

[0388] Specification 60 / 170 pages 70 CN 121358861 A

[0389] Specification 61 / 170 pages 71 CN 121358861 A

[0390] Specification 62 / 170 pages 72 CN 121358861 A

[0391] Specification 63 / 170 pages 73 CN 121358861 A

[0392] Specification 64 / 170 pages 74 CN 121358861 A

[0393] Specification 65 / 170 pages 75 CN 121358861 A

[0394] Specification 66 / 170 pages 76 CN 121358861 A

[0395]

[0396] In some embodiments, the HBV nucleic acid is the sequence shown in GENBANK accession number U95551.1 (incorporated herein as SEQ ID NO: 3). In some embodiments, the modified multi-segment antisense oligonucleotide targets SEQ ID NO: 3.The sequence or a portion thereof. In some embodiments, the modified multi-segment antisense oligonucleotide targets the sequence at position 1583-1602 of SEQ ID NO: 3.

[0397] PCSK9

[0398] The proprotein convertase subtilisin / kexin type 9 (PCSK9) may also be referred to as subtilisin / kexin-like protease PC9. The cytogenetic position of human PCSK9 is 1p32.3, and the genomic coordinates are on chromosome 1 on the positive strand, at positions 55, 039, 548-55, 064, 852. The NCBI gene ID of human PCSK9 is 255738, reference sequence specification page 67 / 170 77 CN 121358861 A accession number is NM_174936.4, reference sequence accession number is NP_777596.2, and the Ensembl gene ID is ENSG00000169174.

[0399] PCSK9 activity is primarily in the liver, and PCSK9 is associated with dyslipidemia, PCSK9-associated familial hypercholesterolemia, hypercholesterolemia (familial), papillary gastric carcinoma, homozygous familial hypercholesterolemia, and nasopharyngitis. PCSK9-associated familial hypercholesterolemia is a hereditary (autosomal dominant) disorder in which the body dangerously develops high blood cholesterol levels due to a lack of receptors for low-density lipoprotein cholesterol. PCSK9-associated familial hypercholesterolemia affects approximately 1 in 500 heterozygotes to 1 in 1,000,000 homozygotes worldwide, and is more common in Afrikaans, French Canadians, Lebanese Christians, and Finns. Common symptoms of PCSK9-associated familial hypercholesterolemia include elevated circulating cholesterol in only low-density lipoprotein or also in very low-density lipoprotein. Current treatment for PCSK9-associated familial hypercholesterolemia includes the administration of statins to inhibit HMG-CoA-reductase in the liver. Another option for treating PCSK9-associated familial hypercholesterolemia is ezetimibe, which inhibits cholesterol absorption in the intestine.

[0400] In some embodiments, the PCSK9 nucleic acid is the sequence or a portion thereof shown in NCBI gene ID NM_174936.4.

[0401] In some embodiments, the PCSK9 target comprises the sequence or a portion thereof or a variant thereof described in SEQ ID NO: 1454, 1458, or 1472. In some embodiments, the modified multi-segment antisense oligonucleotide comprises at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, or at least65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% complementary.

[0402] In some embodiments, the modified multi-segment antisense oligonucleotide comprises the nucleobase sequence of SEQ ID NO: 1432, 1436, or 1450. In some embodiments, the modified multi-segment antisense oligonucleotide is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1432, 1436, or 1450.

[0403] DMPK

[0404] DM1 protein kinase (DMPK) can also be called DM, DM1, DMK, MDPK, DM1PK, MT-PK. The cytogenetic location of human DMPK is 19q 13.32, and its genomic coordinates are on chromosome 19 on the reverse strand, at positions 45, 769, 70% 45, 782, 490. The NCBI gene ID of human DMPK is 1760, the reference sequence accession number is NM_004409.5, the reference sequence accession number is NP_004400.4, and the Ensembl gene ID is ENSG00000104936.

[0405] DMPK activity is mainly in muscle, and DMPK is associated with myotonic dystrophy 1 and adult-onset Steinert myotonic dystrophy. The genetic defect of DM1 is caused by a trinucleotide repeat sequence amplified in the 3′ untranslated region of the protein kinase gene. Disease severity varies with the number of repeats: normal individuals have 5 to 37 repeats, mildly affected individuals have 50 to 150 repeats, patients with classic DM have 100 to 1,000 repeats, and those with birth-onset DM may have more than 2,000 repeats. This disorder shows early genetic presentation, with repeat amplification depending on the sex of the transmitting parent. Alleles with 40 to 80 repeats typically amplify in male-transmitted DM, while only alleles with more than 80 repeats tend to amplify in maternal-transmitted DM. Repeat retraction events occur in 4.2% to 6.4% of cases. The prevalence of DM1 exceeds 1 / 1000 in certain populations and is 1–9 / 100,000 globally, particularly in Europe, Italy, Japan, Ireland, Norway, and the United States. DM1 is characterized primarily by myotonia, muscular dystrophy, cataracts, hypogonadism, frontal alopecia, and ECG changes. Currently approved DM1 drugs include methylphenidate, dopamine, lamotrigine, mexiletine, and metformin (see product information page 68 / 170, CN 121358861 A).

[0406] In some embodiments, the DMPK nucleic acid is the sequence or a portion thereof shown in NCBI gene ID NM_004409.5.

[0407] In some embodiments, the DMPK target comprises the sequence or a portion thereof or a variant thereof described in SEQ ID NO: 1455, 1459, 1460 or 1461. In some embodiments, the modified multi-segment antisense oligonucleotide is complementary to at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% of SEQ ID NO: 1455, 1459, 1460 or 1461.

[0408] In some embodiments, the modified multi-segment antisense oligonucleotide has the nucleobase sequence of SEQ ID NO: 1433, 1437, 1438 or 1439. In some embodiments, the modified multisegment antisense oligonucleotide is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1433, 1437, 1438, or 1439.

[0409] TTR

[0410] Thyroxine transporter (TTR) may also be referred to as CTS, TTN, ATTR, CTS1, PALB, TBPA, HEL111, HsT2651. The cytogenetic location of human TTR is 18q12.1, and its genomic coordinates are on chromosome 18 on the positive strand, at position 31,591,877–31,598,821. The NCBI gene ID for human TTR is 7276, the reference sequence accession number is NM_000371.4, the reference sequence accession number is NP_000362.1, and the Ensemb1 gene ID is ENSG00000118271.

[0411] Thyroxine transporter protein synthesized in the liver is secreted into the blood, while thyroxine transporter protein originating from the choroid plexus is transported to the CSF (cerebrospinal fluid). Thyroxine transporter protein is associated with both localized amyloidosis and systemic amyloidosis, the latter being a disorder characterized by the extracellular deposition of mutant or wild-type thyroxine transporter protein as amyloid fibrils throughout the body. Senile systemic amyloidosis is an intermittent disorder caused by the extracellular deposition of wild-type thyroxine transporter protein fibrils in the heart and other tissues. More than 80 mutations in thyroxine transporter protein are associated with familial amyloid polyneuropathy and cardiomyopathy. Variants Val122Ile, Val30Met, and Gluo.1Lys areAmyloidosis is a common mutation worldwide. In most cases, the inheritance is autosomal dominant. The prevalence of Val30Met amyloidosis is 6–9 / 10,000 in Portugal and 1–9 / 1,000,000 in Japan and Cyprus. Patients with thyroxine amyloidosis typically present with polyneuropathy, carpal tunnel syndrome, autonomic dysfunction, cardiomyopathy, and gastrointestinal features, occasionally accompanied by vitreous opacities and renal insufficiency. In later stages of the disease, severe diarrhea with malabsorption, cachexia, disabling neuropathy, severe cardiac disturbances, and significant orthostatic hypotension dominate the clinical presentation. Death usually occurs 5 to 15 years after symptom onset. The FDA has approved wutracyline (Amvuttra), partecilline (Onpattro), and enoxacin (Tegsedi) for the treatment of polyneuropathy caused by hATTR in adults. Vyndamax and Vyndaqel are FDA approved for use in thyroxine-mediated amyloid cardiomyopathy (ATTR-CM).

[0412] In some embodiments, the TTR nucleic acid is the sequence or a portion thereof shown in NCBI gene ID NM_000371.4.

[0413] In some embodiments, the TTR target comprises the sequence or a portion thereof or a variant thereof described in SEQ ID NO: 1456, 1462 or 1474. In some embodiments, the modified multi-segment antisense oligonucleotide is complementary to at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% of SEQ ID NO: 1456, 1462 or 1474. Specification page 69 / 170 79 CN 121358861 A

[0414] In some embodiments, the modified multi-segment antisense oligonucleotide has the nucleobase sequence of SEQ ID NO: 1434, 1440 or 1452. In some embodiments, the modified multi-segment antisense oligonucleotide is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or 100% identical to SEQ ID NO: 1434, 1440 or 1452.

[0415] AAT

[0416] Serine protease inhibitor family A member 1 (SERPINA1) may also be referred to as PI, A1A, AAT, PI1, A1AT,nNIF, PRO2275, α1AT. The cytogenetic location of human SERPINA1 is 14q32.13, and its genomic coordinates are on chromosome 14 on the reverse strand, at positions 94, 376, 747-94, 390, 635. The NCBI gene ID of human SERPINA1 is 5265, the reference sequence accession number is NM_000295.5, the reference sequence accession number is NP_000286.3, and the Ensembl gene ID is ENSG00000197249.

[0417] AAT is mainly produced by hepatocytes and secreted into the blood; however, low levels of AAT expression have also been detected in the lungs and intestines. Diseases associated with SERPINA1 include α-1-antitrypsin deficiency and hemorrhagic diseases caused by α-1-antitrypsin Pittsburgh mutations. α-1-antitrypsin deficiency is a genetic disorder that can cause lung and liver disease. Alpha-1 antitrypsin deficiency occurs globally, but its prevalence varies by population. This disorder affects approximately 1 in 1,500 to 3,500 individuals of European descent. It is uncommon in populations of Asian descent. Many individuals with alpha-1 antitrypsin deficiency may go undiagnosed, particularly those with a lung condition known as chronic obstructive pulmonary disease (COPD). COPD can be caused by alpha-1 antitrypsin deficiency; however, alpha-1 antitrypsin deficiency is often never diagnosed. Some people with alpha-1 antitrypsin deficiency are misdiagnosed with asthma. Treatment for lung disease may include bronchodilators, inhaled steroids, and antibiotics when infections occur. Intravenous infusion of A1AT protein or lung transplantation may also be recommended in cases of severe illness. Liver transplantation may be an option in patients with severe liver disease. Smoking avoidance and vaccination against influenza, pneumococcal disease, and hepatitis are also recommended.

[0418] In some embodiments, the AAT nucleic acid is the sequence or a portion thereof shown in NCBI gene ID NM_000295.5.

[0419] In some embodiments, the AAT target comprises the sequence or a portion thereof or a variant thereof described in SEQ ID NO: 1457 or 1463. In some embodiments, the modified multi-segment antisense oligonucleotide is complementary to SEQ ID NO: 1457 or 1463 by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100%.

[0420] In some embodiments, the modified multi-segment antisense oligonucleotide has the nucleobase sequence of SEQ ID NO: 1435 or 1441. In some embodiments, the modified multi-segment antisense oligonucleotide is complementary to SEQ ID NO: 1435 or 1441.At least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical.

[0421] Generally, the targets of the modified multi-segment antisense oligonucleotides of this disclosure are transcripts of genes. In some embodiments, the target region is a structurally defined region of the target nucleic acid. For example, the target region may encompass the 3′UTR, 5′UTR, exons, introns, exon / intron junctions, coding regions, translation initiation regions, translation termination regions, or other defined nucleic acid regions. The structurally defined regions of the target can be obtained from sequence databases (such as NCBI) by accession number, and such information is incorporated herein by reference. In some embodiments, the target region may encompass a sequence from the 5′ target site of one target segment within the target region to the 3′ target site of another target segment within the same target region.

[0422] Targeting includes identifying at least one target segment, with an antisense compound hybridizing to the at least one target segment such that the desired effect occurs. In some embodiments, the desired effect is a reduction in the level of the target nucleic acid in mRNA. In some embodiments, the desired effect is a reduction in the level of the protein encoded by the target nucleic acid or a phenotypic change associated with the target nucleic acid.

[0423] The target region may contain one or more target segments. Multiple target segments within the target region may overlap. Alternatively, they may not overlap. In some embodiments, the target segments within the target region are separated by no more than about 300 nucleotides. In some embodiments, the target segment within the target region is separated by a number of nucleotides on the target nucleic acid, which is, is about, is no more than, is no more than about 250, 200, 150, 100, 90, 80, 70, 60, 50, 40, 30, 20, or 10 nucleotides, or a range defined by any two of the foregoing values. In some embodiments, the target segment within the target region is separated by no more than or no more than about 5 nucleotides on the target nucleic acid. In some embodiments, the target segments are contiguous. Target regions defined by a range having a starting nucleic acid, which is any of the 5′ or 3′ target sites listed herein.

[0424] Suitable target segments may be present in the 5′ UTR, coding region, 3′ UTR, intron, exon, or exon / intron junction. Target segments containing a start codon or stop codon are also suitable target segments. Suitable target segments can specifically exclude certain structurally defined regions, such as start codons or stop codons.

[0425] Determining suitable target segments may include comparing the sequence of the target nucleic acid with other sequences throughout the genome.Comparison. For example, the BLAST algorithm can be used to identify similar regions between different nucleic acids. This comparison can prevent the selection of antisense oligonucleotide sequences that may hybridize in a non-specific manner with sequences other than the selected target nucleic acid (i.e., non-target or off-target sequences).

[0426] Hybridization

[0427] In some embodiments, hybridization occurs between the antisense oligonucleotide disclosed herein and the target nucleic acid. The most common hybridization mechanism involves hydrogen bonding between complementary nucleobases of nucleic acid molecules (e.g., Watson-Crick, Hough, or reverse Hough hydrogen bonding).

[0428] Hybridization can occur under different conditions. Strict conditions are sequence-dependent and determined by the nature and composition of the nucleic acid molecule to be hybridized.

[0429] Methods for determining whether a sequence can specifically hybridize with a target nucleic acid are well known in the art. In some embodiments, the antisense oligonucleotides provided herein can specifically hybridize with a target nucleic acid.

[0430] Complementarity

[0431] The antisense oligonucleotide and the target nucleic acid are complementary to each other when a sufficient number of nucleobases of the antisense oligonucleotide can hydrogen-bond with the corresponding nucleobases of the target nucleic acid such that the desired effect (e.g., antisense inhibition of the target nucleic acid) occurs.

[0432] Non-complementary nucleobases between the antisense oligonucleotide and the target nucleic acid can be tolerated, provided that the antisense oligonucleotide is still able to specifically hybridize with the target nucleic acid. In addition, the antisense oligonucleotide can hybridize on one or more segments of the target nucleic acid such that the middle or adjacent segments do not participate in the hybridization event (e.g., loop structures, mismatches, or hairpin structures).

[0433] In some embodiments, the antisense oligonucleotides provided herein, or designated portions thereof, are 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to a target nucleic acid, target region, target segment, or designated portion thereof, or at least 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary. The percentage of complementarity between the antisense oligonucleotide and the target nucleic acid can be determined using conventional methods.

[0434] For example, an antisense oligonucleotide in which 18 of the 20 nucleotides are complementary to the target region and thus specifically hybridize will represent 90% complementarity. In this example, the remaining non-complementary nucleotides may aggregate or interweave with complementary nucleotides and do not necessarily need to be adjacent to each other or to complementary nucleotides. Therefore, an antisense oligonucleotide of 18 nucleotides in length (having four non-complementary nucleotides flanking two regions that are completely complementary to the target nucleic acid) will have 77.8% overall complementarity to the target nucleic acid and will therefore fall within the scope of the invention.The percentage of complementarity between the oligonucleotide and the target nucleic acid region can be routinely determined using BLAST (Basic Local Alignment Search Tool) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol., 1990, 215, 403410; Zhang and Madden, Genome Res., 1997, 7, 649656). The percentage of homology, sequence identity, or complementarity can be determined, for example, using the Gap program (Wisconsin Sequence Analysis Package, Unix Version 8, Genetics Computer Group, University Research Park, Madison Wisconsin) with default settings, which uses Smith and Waterman (Adv. Appl. Math., 1981, 2, 482489).

[0435] In some embodiments, the antisense oligonucleotide or a designated portion thereof provided herein is completely complementary (i.e., 100% complementary) to the target nucleic acid or a designated portion thereof. As used herein, "perfect complementarity" means that each nucleobase of the antisense oligonucleotide is perfectly complementary to the corresponding nucleobase of the target nucleic acid. For example, a 20-nucleobase antisense oligonucleotide is perfectly complementary to a 400-nucleobase-long target sequence, provided that the target nucleic acid contains a corresponding 20-nucleobase portion that is perfectly complementary to the antisense oligonucleotide. Perfect complementarity can also refer to a specific portion of the first and / or second nucleic acid. For example, a 20-nucleobase portion of a 30-nucleobase antisense oligonucleotide can be "perfectly complementary" to a 400-nucleobase-long target sequence. If the target sequence has a corresponding 20-nucleobase portion, where each nucleobase is complementary to the 20-nucleobase portion of the antisense oligonucleotide, then the 20-nucleobase portion of the 30-nucleobase oligonucleotide is perfectly complementary to the target sequence. Simultaneously, the entire 30-nucleobase antisense oligonucleotide may or may not be perfectly complementary to the target sequence, depending on whether the remaining 10 nucleobases of the antisense oligonucleotide are also complementary to the target sequence.

[0436] The non-complementary nucleobases may be located at the 5′ or 3′ end of the antisense oligonucleotide. Alternatively, the non-complementary nucleobases may be located inside the antisense oligonucleotide. When two or more non-complementary nucleobases are present, they may be adjacent (i.e., linked) or non-adjacent. In one embodiment, the non-complementary nucleobases are located in the wing segments of the nicked polymer antisense oligonucleotide. In one embodiment, the non-complementary nucleobases are located in the wing segments of the multi-segment antisense oligonucleotide.

[0437] The provided antisense oligonucleotides also include oligonucleotides complementary to a portion of the target nucleic acid. As used herein, “portion” refers to a specific number of adjacent (i.e. linked) nucleobases within a region or segment of the target nucleic acid. “Portion” may also refer toA defined number of adjacent nucleobases for the antisense oligonucleotide. In some embodiments, the antisense oligonucleotide is complementary to at least 8 nucleobases of the target segment. In some embodiments, the antisense oligonucleotide is complementary to at least 9 nucleobases of the target segment. In some embodiments, the antisense oligonucleotide is complementary to at least 10 nucleobases of the target segment. In some embodiments, the antisense oligonucleotide is complementary to at least 11 nucleobases of the target segment. In some embodiments, the antisense oligonucleotide is complementary to at least 12 nucleobases of the target segment. In some embodiments, the antisense oligonucleotide is complementary to at least 13 nucleobases of the target segment. In some embodiments, the antisense oligonucleotide is complementary to at least 14 nucleobases of the target segment. In some embodiments, the antisense oligonucleotide is complementary to at least 15 nucleobases of the target segment. Antisense oligonucleotides complementary to at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more nucleotides of a target segment, or a range defined by any two of these values, are also envisioned.

[0438] Identity

[0439] The antisense oligonucleotides provided herein may also have a defined percentage of identity with a specific nucleotide sequence (i.e., SEQ ID NO: 11-1453 or 5000-30983, or an oligonucleotide, or a portion thereof). As used herein, if an antisense oligonucleotide has the same nucleotide pairing ability, it is identical to the sequence disclosed herein. For example, RNA containing uracil instead of thymidine in a disclosed DNA sequence would be considered identical to the DNA sequence because both uracil and thymidine pair with adenine. Shortened and extended versions of the antisense oligonucleotides described herein, as well as oligonucleotides having non-identical bases relative to the antisense oligonucleotide specification provided herein, page 72 / 170, 82 CN 121358861 A nucleotide. Non-identical bases may be adjacent to each other or scattered throughout the antisense oligonucleotide. The identity percentage of the antisense oligonucleotide is calculated based on the number of bases with identical base pairs relative to the sequence with which it is being compared.

[0440] As used herein, a “complementary” polynucleotide is one of those oligonucleotides capable of base pairing according to the standard Watson-Crick complementarity rules. Specifically, a purine will pair with a pyrimidine base to form a combination of guanine and cytosine (G:C) and, in the case of DNA, adenine and thymine (A:T), or, in the case of RNA, adenine and uracil (A:U). For example, the sequence “A-G-T” binds to the complementary sequence “T-C-A”. It should be understood that even when two polynucleotides are not perfectly complementary, the two polynucleotides...They can also hybridize with each other, provided that each polynucleotide has at least one region substantially complementary to the other polynucleotide.

[0441] As used herein, the terms “substantially complementary” or “partially complementary” mean that at least about 50%, 60%, 70%, 80%, or 90% of the nucleotides in the two nucleic acid sequences are complementary.

[0442] In some embodiments, at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more of the nucleotides in the two nucleic acid sequences may be complementary. In some embodiments, the two nucleic acid sequences may be 60% to 100% complementary, 70% to 100% complementary, 80% to 100% complementary, 90% to 100% complementary, 60% to 90% complementary, 60% to 80% complementary, 60% to 70% complementary, 70% to 90% complementary, 70% to 80% complementary, 80% to 100% complementary, or 80% to 90% complementary.

[0443] The terms “substantially complementary” and “partially complementary” may also mean that the two nucleic acid sequences can hybridize under highly stringent conditions, and such conditions are well known in the art.

[0444] As used herein, the term “identity” means that the sequences are compared to each other as follows. To determine the percentage of identity between two nucleic acid sequences, the sequences may first be aligned relative to each other so that the sequences can subsequently be compared. For this purpose, for example, a gap may be inserted into the sequence of the first nucleic acid sequence, and the nucleotides may be compared to corresponding positions in the second nucleic acid sequence. If a position in the first nucleic acid sequence is occupied by the same nucleotide as that at a position in the second sequence, then the two sequences are identical at that position. The percentage of identity between the two sequences is a function of the number of identical positions divided by the total number of positions compared in the sequence under study.

[0445] The "percentage of identity" of the aligned segments of the test and reference sequences is the percentage of identical components shared by the two aligned sequences divided by the total number of components in the reference sequence segment (i.e., the entire reference sequence or a smaller defined portion of the reference sequence).

[0446] The percentage of identity between the two sequences can be determined by means of a mathematical algorithm. An example of a mathematical algorithm that can be used to compare two sequences is the algorithm of Karlin et al. (1993), PNAS USA, 90: 5873-5877. Integrating such an algorithm into the NBLAST program allows for the identification of sequences with the desired identity to the sequences of the present invention. To obtain alignments with gaps as described herein, a "BLAST with gaps" procedure can be used, as described by Altschul et al. (1997), Nucleic Acids Res, 25:3389-3402. If both BLAST and BLAST with gaps are used, then...Preset parameters of a specific program (e.g., NBLAST). Sequences can be further aligned using version 9 of the GAP (Global Alignment Program) of "Genetic Computational Groups" with a preset (BLOSUM62) matrix (values ​​from -4 to +11), where the gap opening penalty is -12 (for the first zero of the gap) and the gap extension penalty is -4 (for each additional consecutive zero in the gap). After alignment, the percentage of identity is calculated by expressing the number of similarities as a percentage of the nucleic acid content in the claimed sequence. If desired, the method for determining the percentage of identity between two nucleic acid sequences can also be applied accordingly to the encoded amino acid sequences.

[0447] Available methods for determining sequence identity are also disclosed in Guide to Huge Computers (Martin, specification 73 / 170 pages 83 CN 121358861 A J. Bishop, edited, Academic Press, San Diego (1994)) and Carillo, H. and Lipton, D. (Applied Math 48: 1073 (1988)). More specifically, preferred computer programs for determining sequence identity include, but are not limited to, the Basic Local Alignment Search Tool (BLAST) program, which is publicly available from the National Center for Biotechnology Information (NCBI) at the National Library of Medicine, National Institute of Health, Bethesda, Md 20894, Maryland; see BLAST Manual, Altschul et al., NCBI, NLM, NIH; (Altschul et al., J.Mol.Biol.215:403-410(1990)); version 2.0 or later of the BLAST program allows gaps (deletions and insertions) to be introduced into the alignment; for peptide sequences, BLASTX can be used to determine sequence identity; and for polynucleotide sequences, BLASTN can be used to determine sequence identity. The identity percentage can be 70% or higher, for example, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, at least 98% identity, at least 99% identity, or 100% identity.

[0448] Modifications

[0449] Nucleosides are base-sugar combinations. The nucleobase (also called base) portion of a nucleoside is typically a heterocyclic base portion. NucleosidesAn acid is a nucleoside that also includes a phosphate group covalently linked to the sugar moiety of the nucleoside. For those nucleosides that include pentofuranosyl sugars, the phosphate group may be linked to the 2′, 3′, or 5′ hydroxyl moiety of the sugar. Oligonucleotides are formed by the covalent linkage of adjacent nucleosides to each other to form linear polymeric oligonucleotides. Within the oligonucleotide structure, the phosphate group is generally referred to as the nucleoside internucleotide bond that forms the oligonucleotide.

[0450] Modification of antisense oligonucleotides encompasses substitution or alteration of the nucleoside internucleotide bond, sugar moiety, or nucleobase. Modified antisense oligonucleotides are generally superior to their native forms because they possess desired properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid targets, increased stability in the presence of nucleases, or increased inhibitory activity.

[0451] Chemically modified nucleosides can also be used to increase the binding affinity of shortened or truncated antisense oligonucleotides to their target nucleic acids. Therefore, shorter antisense oligonucleotides with such chemically modified nucleosides generally yield comparable results.

[0452] Modified Nucleoside Interbonds

[0453] Naturally occurring nucleoside interbonds in RNA and DNA are 3′ to 5′ phosphodiester bonds. Antisense oligonucleotides having one or more modified (i.e., non-naturally occurring) nucleoside interbonds are generally superior to antisense oligonucleotides having naturally occurring nucleoside interbonds because they have desired properties, such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.

[0454] Oligonucleotides having modified nucleoside interbonds include nucleoside interbonds that retain a phosphorus atom and those that do not. Representative phosphorus-containing nucleoside interbonds include, but are not limited to, phosphodiester, phosphotriester, methylphosphonate, aminophosphate, and thiophosphate. Methods for preparing phosphorus-containing and phosphorus-free oligonucleotides are well known.

[0455] In some embodiments, the antisense oligonucleotide targeting the target nucleic acid comprises one or more modified nucleoside interbonds. In some embodiments, the modified nucleoside interbond is a thiophosphate bond. In some embodiments, each nucleoside internucleotide of the antisense oligonucleotide is a phosphate thioester nucleoside internucleotide. In some embodiments, the modified multi-segment antisense oligonucleotides of this disclosure comprise one or more modified nucleoside internucleotides, wherein the modified nucleoside internucleotide is a phosphoryl diamine bond between morpholino nucleoside mimics.

[0456] Modified sugar moiety

[0457] The antisense oligonucleotides provided herein may optionally contain one or more nucleosides, wherein the glycosyl group has been modified. Such sugar-modified nucleosides can confer on the antisense oligonucleotide enhanced nuclease stability, increased binding affinity, or some other beneficial biological properties. In some embodiments, the nucleoside comprises a chemically modified furanose ring moiety.Examples of chemically modified furanose rings include, but are not limited to, the addition of substituents (including 5′ and 2′ substituents); bridging of non-twinned ring atoms to form bicyclic nucleic acids (BNAs); substitution of ribosyl epoxide atoms with S, N(R) or C(R1)(R2) (R = H, C1-C12 alkyl or protecting groups); and combinations thereof. Examples of chemically modified sugars include 2′-F-5′-methyl substituted nucleosides (for other disclosed 5′,2′-disubstituted nucleosides, see PCT International Application WO 2008 / 101157, published August 21, 2008), by further substituting S for the ribosyl epoxy atom at the 2′-position (see published U.S. Patent Application US2005 / 0130923, published June 16, 2005), or alternatively, 5′-substituted BNA (see PCT International Application WO 2007 / 134181, published November 22, 2007, wherein LNA is substituted, for example, with 5′-methyl or 5′-vinyl).

[0458] Examples of nucleosides having a modified sugar moiety include, but are not limited to, nucleosides containing 5′-vinyl, 5′-methyl (R or S), 4′-S, 2′-F, 2′-OCH3, and 2′-O(CH2)2OCH3 substituents. The substituent at the 2′ position may also be selected from allyl, amino, azide, thio, O-allyl, O-C1-C10 alkyl, OCF3, O(CH2)2SCH3, O(CH2)2-O-N(Rm)(Rn), and O-CH2-C(=O)-N(Rm)(Rn), wherein each Rm and Rn is independently H or a substituted or unsubstituted C1-C10 alkyl group.

[0459] As used herein, “bicyclic nucleoside” refers to a modified nucleoside containing a bicyclic sugar moiety. Examples of bicyclic nucleosides include, but are not limited to, nucleosides containing a bridge between the 4′ and 2′ ribosyl ring atoms. In some embodiments, the antisense oligonucleotides provided herein comprise one or more bicyclic nucleotides, wherein the bridge comprises a 4′ to 2′ bicyclic nucleotide. Examples of such 4′ to 2′ bicyclic nucleotides include, but are not limited to, one of the following formulas: 4′-(CH2)-O-2′ (LNA); 4′-(CH2)-S-2′; 4′-(CH2)2-O-2′ (ENA); 4′-CH(CH3)-O-2′ (cEt) and 4′-CH(CH2OCH3)-O-2′ and analogs thereof (see U.S. Patent 7,399,845, published July 15, 2008); 4′-C(CH3)(CH3)-O-2′ and analogs thereof (see published PCT International Application WO2009 / 006478, published January 8, 2009); 4′-CH2-N(OCH3)-2′ and analogs thereof (see published PCT International Application WO2009 / 006478, published January 8, 2009); 4′-CH2-N(OCH3)-2′ and analogs thereof (see published PCT International Application WO2009 / 006478).International application WO2008 / 150729, published December 11, 2008; 4'-CH2-O-N(CH3)-2′ (see published U.S. patent application US2004 / 0171570, published September 2, 2004); 4′-CH2-N(R)-O-2′, wherein R is H, C1-C12 alkyl or protecting group (see U.S. Patent 7,427,672, published September 23, 2008); 4'-CH2-C(H)(CH3)-2′ (see Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4'-CH2-C(=CH2)-2′ and the like (see published PCT international application WO 2008 / 154401, published December 8, 2008). See also, for example: Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U.S. A., 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem., 1998, 63, 10035- 10039; Srivastava et al., J. Am. Chem. Soc., 129(26) 8362-8379 (July 4, 2007); Elayadi et al., Curr. Opinion Invens. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; Orum et al., Curr. Opinion Mol. Ther., 2001, 3, 239-243; US Patent Nos. 6,670,461, 7,053,207, 6,268,490, 6,770,748, 6,794,499, 7,034,133, 6,525,191, 7,399,845; Published PCT International Application WO 2004 / 106356, WO 94 / 14226, WO 2005 / 021570 and WO 2007 / 134181; US ​​Patent Publications Nos. US2004 / 0171570, US2007 / 0287831 and US2008 / 0039618; and USThe patents listed are in the following patent series: National Patent Nos. 12 / 129,154, 60 / 989,574, 61 / 026,995, 61 / 026,998, 61 / 056,564, 61 / 086,231, 61 / 097,787, and 61 / 099,844; and PCT International Applications Nos. PCT / US2008 / 064591, PCT / US2008 / 066154, and PCT / US2008 / 068922. Each of the aforementioned bicyclic nucleosides can be prepared to have one or more stereochemical sugar configurations, including, for example, α-L-ribose and β-D-ribose (see PCT International Application PCT / DK98 / 00393, published on March 25, 1999 as WO 99 / 14226).

[0460] In some embodiments, the bicyclic sugar moiety of the BNA nucleotide includes, but is not limited to, oligonucleotides having at least one bridge between the 4′ and 2′ positions of the pentofuranosyl sugar moiety as described on page 75 / 170 of CN 121358861 A, wherein such bridge independently comprises one or two to four linking groups independently selected from the following: -[C(Ra)(Rb)]n-, -C(Ra)=C(Rb)-, -C(Ra)=N-, -C(=NRa)-, -C(=O)-, -C(=S)-, -O-, -Si(Ra)2-, -S(=O)x-, and -N(Ra)-;

[0461] wherein:

[0462] x is 0, 1, or 2;

[0463] n is 1, 2, 3, or 4;

[0464] Each Ra and Rb is independently H, a protecting group, a hydroxyl group, a C1-C12 alkyl group, a substituted C1-C12 alkyl group, a C2-C12 alkenyl group, a substituted C2-C12 alkenyl group, a C2-C12 ynyl group, a substituted C2-C12 ynyl group, a C5-C20 aryl group, a substituted C5-C20 aryl group, a heterocyclic group, a substituted heterocyclic group, a heteroaryl group, a substituted heteroaryl group, a C5-C7 alicyclic group, a substituted C5-C7 alicyclic group, a halogen, OJ1, NJ1J2, SJ1, N3, COOJ1, an acyl group (C(=O)-H), a substituted acyl group, CN, a sulfonyl group (S(=O)2-J1) or a hyposulfite group (S(=O)-J1); and

[0465] Each J1 and J2 is independently H, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 ynyl, substituted C2-C12 ynyl, C5-C20 aryl, substituted C5-C20 aryl, acyl (C(=O)-H), substituted acyl, heterocyclic, substituted heterocyclic, C1-C12 aminoalkyl, substituted C1-C12 aminoalkyl, or a protecting group.

[0466] In some embodiments, the bridge of the bicyclic sugar moiety is -[C(Ra)(Rb)]n-, -[C(Ra)(Rb)]n-O-, -C(Ra)(Rb)-N(R)-O-, or -C(Ra)(Rb)-O-N(R)-. In some embodiments, the bridge is 4′-CH2-2', 4′-(CH2)2-2', 4′-(CH2)3-2', 4′-CH2-O-2', 4′-(CH2)2-O-2', 4′-CH2-O-N(R)-2', and 4′-CH2-N(R)-O-2'-, wherein each R is independently H, a protecting group, or a C1-C12 alkyl group.

[0467] In some embodiments, the bicyclic nucleoside is further defined by isomer configuration. For example, nucleosides containing a 4′–2′ methylene-oxy group can be in the α–L or β–D configuration. Previously, α–L-methyleneoxy (4′–CH2–O–2′)BNA has been incorporated into antisense oligonucleotides exhibiting antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 63 656372).

[0468] In some embodiments, the bicyclic nucleosides include, but are not limited to, (A) α-L-methyleneoxy(4′-CH2-O-2′)BNA, (B) β-D-methyleneoxy(4′-CH2-O-2′)BNA, (C) ethyloxy(4′-(CH2)2-O-2′)BNA, (D) aminooxy(4′-CH2-O-N(R)-2′)BNA, (E) hydroxyamino(4′-CH2-N(R)-O-2′)BNA, (F) methyl(methyleneoxy)(4′-CH(CH3)-O-2′)BNA, (G) methylene-thio(4′-CH2-S-2′)BNA, and (H) methylene-amino(4′-CH2-N (R)-2′)BNA, (I) methyl carbocyclic (4′-CH2-CH(CH3)-2′)BNA, and (J) propylene carbocyclic (4′-(CH2)3-2′)BNA, as shown below. Specification 76 / 170 pages 86 CN 121358861 A

[0469]

[0470] wherein Bx is a base moiety, and R is independently H, a protecting group, or a C1-C12 alkyl group.

[0471] In some embodiments, the bicyclic nucleoside is according to Formula I:

[0472]

[0473] wherein:

[0474] Bx is a heterocyclic base moiety;

[0475] -Qa-Qb-Qc- is -CH2-N(Rc)-CH2-, -C(=O)-N(Rc)-CH2-, -CH2-O-N(Rc)-, -CH2-N(Rc)-O- or -N(Rc)-O-CH2;

[0476] Rc is a C1-C12 alkyl or amino protecting group; and

[0477] Ta and Tb are each independently H, a hydroxyl protecting group, a conjugated group, a reactive phosphorus group, a phosphorus moiety, or covalently linked to a supporting medium.

[0478] In some embodiments, the bicyclic nucleoside has Formula II: Specification 77 / 170 pages 87 CN 121358861 A

[0479]

[0480] wherein:

[0481] Bx is a heterocyclic base moiety;

[0482] Ta and Tb are each independently H, a hydroxyl protecting group, a conjugated group, a reactive phosphorus group, a phosphorus moiety, or covalently linked to a supporting medium;

[0483] Za is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, substituted C1-C6 alkyl, substituted C2-C6 alkenyl, substituted C2-C6 alkynyl, acyl, substituted acyl, substituted amide, thiol, or substituted thio.

[0484] In one embodiment, each of the substituted groups is independently selected from the following substituents: halogen, oxy, hydroxy, OJc, NJcJd, SJc, N3, OC(=X)Jc and NJeC(=X)NJcJd, wherein each Jc, Jd and Je is independently H, C1-C6 alkyl or substituted C1-C6 alkyl, and X is O or NJc.

[0485] In some embodiments, the bicyclic nucleoside has formula III:

[0486]

[0487] wherein:

[0488] Bx is a heterocyclic base moiety;

[0489] Ta and Tb are each independently H, a hydroxyl protecting group, a conjugated group, a reactive phosphorus group, a phosphorus moiety, or covalently linked to a supporting medium;

[0490] Zb is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, substituted C1-C6 alkyl, substituted C2-C6 alkenyl, substituted C2-C6 alkynyl, or substituted acyl (C(=O)-).

[0491] In some embodiments, the bicyclic nucleoside has formula IV: Specification 78 / 170 pages 88 CN 121358861 A

[0492]

[0493] wherein:

[0494] Bx is a heterocyclic base moiety;

[0495] Ta and Tb are each independently H, a hydroxyl protecting group, a conjugated group, a reactive phosphorus group, a phosphorus moiety, or covalently linked to a supporting medium;

[0496] Rd is a C1-C6 alkyl, a substituted C1-C6 alkyl, a C2-C6 alkenyl, a substituted C2-C6 alkenyl, a C2-C6 ynyl, or a substituted C2-C6 ynyl;

[0497] Each qa, qb, qc, and qd is independently H, a halogen, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C2-C6 alkenyl, a substituted ...Substituted C2-C6 alkenyl, C2-C6 alkynyl or substituted C2-C6 alkynyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, acyl, substituted acyl, C1-C6 aminoalkyl or substituted C1-C6 aminoalkyl;

[0498] In some embodiments, the bicyclic nucleoside has formula V:

[0499]

[0500] wherein:

[0501] Bx is a heterocyclic base moiety;

[0502] Ta and Tb are each independently H, a hydroxyl protecting group, a conjugated group, a reactive phosphorus group, a phosphorus moiety or covalently linked to a supporting medium;

[0503] qa, qb, qe and qf are each independently hydrogen, halogen, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl, Substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C1-C12 alkoxy, substituted C1-C12 alkoxy, OJj, SJj, SOjj, SO2Jj, NJjJk, N3, CN, C(=O)OJj, C(=O)NJjJk, C(=O)Jj, O-C(=O)NJjJk, N(H)C(=NH)NJjJk, N(H)C(=O)NJjJk or N(H)C(=S)NJjJk;

[0504] Or qe and qf together are =C(qg)(qh);

[0505] qg and qh are each independently H, halogen, C1-C12 alkyl or substituted C1-C12 alkyl.

[0506] The synthesis and preparation of methyleneoxy (4′-CH2-O-2′)BNA monomers adenine, cytosine, guanine, 5-methylcytosine, thymine, and uracil, as well as their oligomerization and nucleic acid recognition properties, have been described (see, for example, Koshkin et al., Tetrahedron, 1998, 54, 3607-3630). BNA and its preparation are also described in WO 98 / 39352 and WO specification 79 / 170 pages, 89 CN 121358861 A 99 / 14226.

[0507] Analogs of methyleneoxy(4′-CH2-O-2′)BNA, methyleneoxy(4′-CH2-O-2′)BNA, and 2′-thio-BNA have also been prepared (see, for example, Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222). The preparation of locked nucleoside analogs comprising oligodeoxyribonucleotide duplexes as substrates for nucleic acid polymerases has also been described (see, for example, Wengel et al., WO 99 / 14226). Furthermore, 2′-amino-BNA (a novel construct) has been described in the art.Synthesis of restricted high-affinity oligonucleotide analogs (see, for example, Singh et al., J. Org. Chem., 1998, 63, 10035-10039). Furthermore, 2′-amino- and 2′-methylamino-BNAs have been prepared, and their thermal stability in duplexes with complementary RNA and DNA strands has been previously reported.

[0508] In some embodiments, the bicyclic nucleoside has formula VI:

[0509]

[0510] wherein:

[0511] Bx is a heterocyclic base moiety;

[0512] Ta and Tb are each independently H, a hydroxyl protecting group, a conjugated group, a reactive phosphorus group, a phosphorus moiety, or covalently linked to a supporting medium;

[0513] each qi, qj, qk, and ql is independently H, a halogen, a C1-C12 alkyl, a substituted C1-C12 alkyl, a C2-C12 alkenyl, a substituted C2-C12 alkenyl, a C2-C12 alkynyl, a substituted C2-C12 alkynyl, a C1-C12 alkoxy, a substituted C1-C12 alkoxy, OJj, SJj, SOJj, SO2J j, NJjJk, N3, CN, C(=O)OJj, C(=O)NJjJk, C(=O)Jj, O-C(=O)NJjJk, N (H)C(=NH)NJjJk, N(H)C(=O)NJjJk or N(H)C(=S)NJjJk; and

[0514] qi and qj or ql and qk together are =C(qg)(qh), wherein qg and qh are each independently H, halogen, C1-C12 alkyl or substituted C1-C12 alkyl.

[0515] A carbocyclic bicyclic nucleoside having a 4′-(CH2)3-2′ bridge and an alkenyl analog (bridge 4′-CH=CH-CH2-2′) has been described (see, for example, Freier et al., Nucleic Acids Research, 1997, 25(22), 44294443 and Albaek et al., J. Org. Chem., 2006, 71, 7731-7740). The synthesis and preparation of carbocyclic bicyclic nucleosides, as well as their oligomerization and biochemical studies, have also been described (see, for example, Srivastava et al., J. Am. Chem. Soc. 2007, 129(26), 8362-8379).

[0516] As used herein, “bicyclic nucleoside” refers to a nucleoside containing a bridge connecting two carbon atoms of the sugar ring to form a bicyclic sugar moiety. In some embodiments, the bridge connects the 2′ carbon of the sugar ring and another carbon.

[0517] As used herein, "4′-2′ bicyclic nucleoside" or "4′ to 2′ bicyclic nucleoside" refers to a bicyclic nucleoside comprising a furanose ring containing a bridge connecting the 2′ carbon atom and the 4′ carbon atom.

[0518] As used herein, “monocyclic nucleoside” means a nucleoside that includes a modified sugar moiety that is not a bicyclic sugar moiety. In some embodiments, the sugar moiety of the nucleoside or a sugar moiety analogue may be modified or substituted at any position.

[0519] As used herein, “2′-modified sugar” means a furanyl sugar modified at the 2′ position. In some embodiments, such modifications include substituents selected from: halides, including but not limited to substituted and unsubstituted alkoxy groups, substituted and unsubstituted thioalkyl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkyl groups, substituted and unsubstituted allyl groups, and substituted and unsubstituted alkynyl groups. In some embodiments, the 2′ modification is selected from substituents including, but not limited to, O[(CH2)nO]mCH3, O(CH2)nNH2, O(CH2)nCH3, O(CH2)nONH2, OCH2C(=O)N(H)CH3 and O(CH2)nON[(CH2)nCH3]2, wherein n and m are 1 to about 10. Other 2′-substituents may also be selected from: C1-C12 alkyl; substituted alkyl; alkenyl; alkynyl; alkylaryl; aralkyl; O-alkylaryl or O-aralkyl; SH; SCH3; OCN; Cl; Br; CN; CF3; OCF3; SOCH3; SO2CH3; ONO2; NO2; N3; NH2; heterocyclic alkyl; heterocyclic alkylaryl; aminoalkylamino; polyalkylamino; substituted silyl; RNA cleaving group; reporter group; intercalator; group for improving pharmacokinetic properties; and group for improving the pharmacodynamic properties of antisense oligonucleotides, as well as other substituents with similar properties. In some embodiments, the modified nucleoside comprises a 2′-MOE side chain (see, for example, Baker et al., J. Biol. Chem., 1997, 272, 11944-12000). This 2'-MOE substitution has been described as having improved binding affinity compared to unmodified nucleosides and other modified nucleosides, such as 2'-O-methyl, O-propyl, and O-aminopropyl. Oligonucleotides with 2'-MOE substituents have also been shown to be antisense inhibitors of gene expression, with promising characteristics for in vivo use (see, for example, Martin, P., Helv. Chim. Acta, 1995, 78, 486-504; Altmann et al., Chimia, 1996, 50, 168-176; Altmann et al., Biochem. Soc. Trans., 1996, 24, 630-637; and Altmann et al., Nucleosides Nucleotides, 1997, 16, 917-926).

[0520] As used herein, "modified tetrahydropyranoside" or "modified THP nucleoside" refers to a nucleoside (sugar substitute) in which the pentofuranose residue in a normal nucleoside is replaced by a hexavalent tetrahydropyranose "sugar". Modified THP nucleosides include, but are not limited to, nucleosides known in the art as hexitol nucleosides (HNA), anisole nucleic acids (ANA), mannitol nucleic acids (MNA) (see Leumann, CJ. Bioorg. & Med. Chem. (2002) 10: 841-854), fluoroHNA (F-HNA), or those oligonucleotides having formula X:

[0521] wherein for each of the at least one tetrahydropyran nucleoside analogue of formula X, independently:

[0522]

[0523] Bx is a heterocyclic base moiety;

[0524] T3 and T4 are each independently an internucleotide linker group connecting the tetrahydropyran nucleoside analogue to the antisense oligonucleotide, or one of T3 and T4 is an internucleotide linker group connecting the tetrahydropyran nucleoside analogue to the antisense oligonucleotide, and the other of T3 and T4 is an H, a hydroxyl protecting group, a linked conjugate group, or a 5′ or 3′ terminal group;

[0525] q1, q2, q3, q4, q5, q6 and q7 are each independently H, C1-C6 alkyl, substituted C1-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 ynyl or substituted C2-C6 ynyl; and

[0526] one of R1 and R2 is hydrogen, and the other is selected from halogen, substituted or unsubstituted alkoxy, NJ1J2, SJ1, N3, OC(=X)J1, OC(=X)NJ1J2, NJ3C(=X)NJ1J2 and CN, wherein X is O, S or NJ1, and each J1, J2 and J3 is independently H or C1-C6 alkyl.

[0527] In some embodiments, a modified THP nucleoside of formula X is provided, wherein qm, qn, qp, qr, qs, qt, and qu are each H. In some embodiments, at least one of qm, qn, qp, qr, qs, qt, and qu is not H. In some embodiments, at least one of qm, qn, qp, qr, qs, qt, and qu is methyl. In some embodiments, a THP nucleoside of formula X is provided, wherein one of R1 and R2 is F. In some embodiments, R1 is fluorine and R2 is H, R1 is methoxy and R2 is H, and R1 is methoxyethoxy and R2 is H.

[0528] As used herein, "2′-modified nucleoside" or "2′-substituted nucleoside" refers to a nucleoside containing a sugar having a substituent other than H or OH at the 2′ position of the furanose ring. 2′-modified nucleosides include, but are not limited to, bicyclic nucleosides.A bridge connecting two carbon atoms of the sugar ring connects the 2′ carbon of the sugar ring to another carbon, and a nucleoside having a non-bridged 2′-substituent, such substituents as allyl, amino, azide, thio, O-allyl, O-C1-C10 alkyl, -OCF3, O-(CH2)2-OCH3, 2′-O(CH2)2SCH3, O-(CH2)2-O-N(Rm)(Rn) or O-CH2-C(=O)-N(Rm)(Rn), wherein each Rm and Rn is independently H or a substituted or unsubstituted C1-C10 alkyl group. 2′-modified nucleosides may also contain other modifications, for example, at other positions of the sugar and / or at the nucleobase.

[0529] As used herein, "2′-F" refers to a sugar containing a fluorine group at the 2′ position.

[0530] As used herein, "2′-OMe", "2′-OCH3", or "2′-O-methyl" each refers to a nucleoside containing a sugar having an -OCH3 group at the 2′ position of the sugar ring.

[0531] As used herein, "oligonucleotide" refers to a compound containing a plurality of linked nucleosides. In some embodiments, one or more of the plurality of nucleosides are modified. In some embodiments, the oligonucleotide contains one or more ribonucleosides (RNA) and / or deoxyribonucleosides (DNA).

[0532] Many other bicyclic and tricyclic sugar substitute ring systems are also known in the art, which can be used to modify nucleosides for incorporation into antisense oligonucleotides (see, for example, review article: Leumann, J.C., Bioorganic & Medicinal Chemistry, 2002, 10, 841-854). Such ring systems can undergo various additional substitutions to enhance activity.

[0533] Methods for preparing modified sugars are well known to those skilled in the art.

[0534] In nucleotides having modified sugar moieties, nucleobase moieties (natural, modified, or combinations thereof) are maintained for hybridization with suitable nucleic acid targets.

[0535] In some embodiments, the antisense oligonucleotide comprises one or more nucleotides having modified sugar moieties. In some embodiments, the modified sugar moieties are 2'-MOE. In some embodiments, 2'-MOE-modified nucleotides are arranged in a nicked polymer motif or a multisegment antisense oligonucleotide motif. In some embodiments, the modified sugar moieties are cEt. In some embodiments, cEt-modified nucleotides are arranged in the entire wing of a nicked polymer motif or a multisegment antisense oligonucleotide motif.

[0536] Compositions and methods for formulating pharmaceutical compositions

[0537] The oligonucleotides of this disclosure can be mixed with pharmaceutically acceptable active or inert substances to prepare pharmaceutical compositions or formulations. Compositions and methods for formulating pharmaceutical compositions depend on many criteria, including but not limited to administration.The path, severity of disease, or dosage to be administered.

[0538] Pharmaceutical compositions comprising antisense oligonucleotides encompass any pharmaceutically acceptable salt, ester, or salt of such esters, or any other oligonucleotide that, when administered to animals (including humans), is capable of (directly or indirectly) providing a biologically active metabolite or its residue. Thus, for example, this disclosure also relates to pharmaceutically acceptable salts of antisense oligonucleotides, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.

[0539] Prodrugs may include additional nucleosides incorporated at one or both ends of the antisense compound, which are cleaved by endogenous nucleases in vivo to form an active antisense compound. Specification 82 / 170 pages 92 CN 121358861 A

[0540] This disclosure provides pharmaceutical compositions comprising the modified multi-segment antisense oligonucleotides of this disclosure and a pharmaceutically acceptable carrier, diluent, or excipient. In some embodiments, the modified multisegment antisense oligonucleotide comprises the structure of any of the oligonucleotide sequences described herein.

[0541] The modified multisegment antisense oligonucleotide may be mixed with pharmaceutically acceptable active or inert substances to prepare pharmaceutical compositions or formulations. The compositions and methods used to formulate pharmaceutical compositions depend on a number of criteria, including but not limited to the route of administration, disease severity, or dose to be administered.

[0542] Pharmaceutical compositions of this disclosure may optionally comprise therapeutic agents, pharmaceutical formulations, carriers, adjuvants, dispersants, diluents, etc.

[0543] Pharmaceutical compositions comprising modified multisegment antisense oligonucleotides encompass any pharmaceutically acceptable salt, ester, or salt of such esters, or any other oligonucleotide that, when administered to animals (including humans), is capable of providing (directly or indirectly) a biologically active metabolite or its residue. Thus, for example, this disclosure also relates to pharmaceutically acceptable salts of antisense oligonucleotides, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.

[0544] Modified multisegment antisense oligonucleotides formulated as prodrugs are considered to be within the scope of this disclosure. Prodrugs may include additional nucleosides incorporated at one or both ends of the antisense oligonucleotide, which are cleaved by endogenous nucleases in vivo to form an active antisense oligonucleotide.

[0545] Pharmaceutical compositions may contain any of the agents discussed above, and one or more of pharmaceutically acceptable carriers, diluents, or excipients.

[0546] A "pharmaceutical composition" is a formulation comprising the modified multisegment antisense oligonucleotides described herein, in a form suitable for administration to a subject. In some embodiments, the pharmaceutical composition is in bulk or unit dosage form. A unit dosage form is...Any of the various forms, including, for example, capsules, IV bags, tablets, disposable syringes, single-pump inhalers, or vials. The amount of active ingredient (e.g., a formulation of a modified multisegment antisense oligonucleotide) in a unit dose composition is an effective amount and varies depending on the specific treatment involved. Those skilled in the art will understand that dose variations may sometimes be necessary based on the patient's age and condition. The dose will also depend on the route of administration. A variety of routes are envisioned, including oral, pulmonary, rectal, parenteral, percutaneous, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, buccal, sublingual, intrapleural, intrathecal, intranasal, etc. Dosage forms for topical or percutaneous application of the present invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalers. In some embodiments, the modified multisegment antisense oligonucleotide is mixed under sterile conditions with a pharmaceutically acceptable carrier and with any desired preservatives, buffers, or propellants.

[0547] "Pharmaceutically acceptable excipient" means an excipient suitable for preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically desired nor otherwise undesirable, and includes excipients acceptable for both veterinary and human pharmaceutical use. As used herein, "pharmaceutically acceptable excipient" includes one or more such excipients.

[0548] The pharmaceutical composition is formulated to conform to its intended route of administration. Examples of routes of administration include parenteral, such as intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), intraperitoneal (into body cavities), and transmucosal administration. Solutions or suspensions intended for parenteral, intradermal, intraperitoneal, or subcutaneous administration may contain the following components: sterile diluents such as water for injection, saline solution, non-volatile oils, polyethylene glycol, glycerol, propylene glycol, or other synthetic solvents; antimicrobial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates, or phosphates; and agents for adjusting tension such as sodium chloride or dextrose. The pH value may be adjusted with an acid or base such as hydrochloric acid or sodium hydroxide. Parenteral or subcutaneous preparations may be encapsulated in ampoules, disposable syringes, or multi-dose vials made of glass or plastic. These preparations may contain antioxidants, buffers, antimicrobial agents, and solutes that make the formulation isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions may contain suspending agents and thickeners. The formulation can be presented in single / dose or multi-dose containers (e.g., sealed ampoules, syringes, and vials) and can be stored under lyophilized (freeze-dried) conditions where a sterile liquid carrier (e.g., saline or water for injection) only needs to be added just before use.

[0549] The pharmaceutical compositions described herein can be manufactured in a manner commonly known, such as by conventional processes of mixing, dissolving, granulation, coating, grinding, emulsifying, encapsulating, embedding, or lyophilizing. The pharmaceutical compositions can be formulated using one or more pharmaceutically acceptable carriers in a conventional manner, the one or more of which include excipients and / or adjuvants that facilitate the processing of the active agent into a pharmaceutically usable formulation. Of course, the appropriate formulation depends on the chosen route of administration.

[0550] Pharmaceutical compositions suitable for injection include sterile aqueous solutions (water-soluble) or dispersions and sterile powders for the provisional preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, antibacterial water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and flowable to the point of being injectable. It must be stable under manufacturing and storage conditions and must be protected against contamination by microorganisms such as bacteria and fungi. It must be stable under manufacturing and storage conditions and must be preserved against contamination by microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium, comprising, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Appropriate flowability can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size in the case of a dispersion, and by using a surfactant. Prevention of microbial action can be achieved by various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenols, ascorbic acid, thimerosal, and the like. In many cases, the composition will preferably contain isotonic agents, such as sugars, polyols (e.g., mannitol and sorbitol), and sodium chloride. The absorption of injectable compositions can be prolonged by including a delayed absorption agent (e.g., aluminum monostearate and gelatin) in the composition.

[0551] Oral compositions typically contain an inert diluent or an edible, pharmaceutically acceptable carrier. They can be encapsulated in gelatin capsules or compressed into tablets. For oral therapeutic administration, the active agent may be combined with excipients and administered in the form of tablets, lozenges, or capsules. Oral compositions may also be prepared using a fluid carrier used as a mouthwash, wherein the agent in the fluid carrier is administered orally and rinsed in the mouth, then spit out or swallowed. Pharmaceutically compatible binder and / or adjuvant materials may be included as part of the composition. Tablets, pills, capsules, lozenges, etc., may contain any of the following ingredients or agents with similar properties: binders such as microcrystalline cellulose, tragacanth gum, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate or sterotes; and flow aids such as colloidal dioxide.Silicon; sweeteners such as sucrose or saccharin; or flavorings such as peppermint, methyl salicylate, or orange flavoring.

[0552] For inhalation administration, the agent is delivered as an aerosol spray from a pressurized container or dispenser or nebulizer containing a suitable propellant such as a gas such as carbon dioxide.

[0553] The pharmaceutical composition can be prepared with a pharmaceutically acceptable carrier (such as controlled-release formulations, including implants and microencapsulated delivery systems) that protects the modified multisegment antisense oligonucleotide from rapid elimination from the body. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such formulations will be apparent to those skilled in the art, and the materials are commercially available. Liposome suspensions (containing liposomes targeting infected cells with monoclonal antibodies against viral antigens) can also be used as pharmaceutically acceptable carriers. These liposome suspensions can be prepared according to methods known to those skilled in the art, such as those described in U.S. Patent No. 4,522,811, page 84 / 170.

[0554] For ease of administration and dosage uniformity, it is particularly advantageous to formulate oral or parenteral compositions in dose-unit form. As used herein, dose-unit form refers to a physically discrete unit suitable as a single dose to a subject to be treated; each unit contains a predetermined amount of modified multisegment antisense oligonucleotides calculated to associate with the desired drug carrier to produce the desired therapeutic effect. The specifications of the dose-unit form of this disclosure are determined by and directly depend on the unique characteristics of the active agent and the specific therapeutic effect to be achieved.

[0555] The pharmaceutical composition may be included in a container, package, or dispenser along with instructions for administration.

[0556] Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues (such as amines), basic or organic salts of acidic residues (such as carboxylic acids), etc. Pharmaceutically acceptable salts include, for example, conventional non-toxic salts or quaternary ammonium salts of parent compounds formed from non-toxic inorganic or organic acids.

[0557] Techniques for formulating and administering the disclosed compositions of the present invention can be found in Remington: the Science and Practice of Pharmacy, 19th edition, Mack Publishing Co., Easton, PA (1995).

[0558] Unless otherwise specified, all percentages and ratios used herein are by weight. Other features and advantages of the invention are apparent from various examples. The examples provided illustrate different components that can be used to carry out the invention.Methods and techniques. These examples do not limit the scope of the claimed invention. Based on this disclosure, those skilled in the art can identify and use other components and methods that can be used to carry out the invention. The modified multisegment antisense oligonucleotides of this disclosure can be covalently linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the resulting antisense oligonucleotide. Typical conjugate groups include cholesterol moieties and lipid moieties. Other conjugate groups include carbohydrates, phospholipids, biotin, phenazine, folic acid, phenanthridine, anthraquinone, acridine, fluorescein, rhodamine, coumarin, and dyes.

[0559] The modified multisegment antisense oligonucleotides can also be modified to have one or more stabilizing groups, which are typically linked to one or both ends of the antisense oligonucleotide to enhance properties such as, for example, nuclease stability. Included in the stabilizing groups is a cap structure. These end modifications protect the antisense oligonucleotide with terminal nucleic acids from exonuclease degradation and can aid in intracellular delivery and / or localization. The cap may be present at the 5′-end (5′-cap), or at the 3′-end (3′-cap), or at both ends. Cap structures are well known in the art and include, for example, a reverse deoxy-base cap. Additional 3′ and 5′-stabilizing groups that can be used to cap one or both ends of the antisense oligonucleotide to impart nuclease stability include those disclosed in WO 03 / 004602, published January 16, 2003.

[0560] The modified multi-segment antisense oligonucleotides of this disclosure may be encapsulated within particles or incorporated into the surface of particles. In some embodiments, the particles are nanoparticles. Exemplary nanoparticles include liposomes, micelles, polymer-based nanoparticles, lipid-polymer-based nanoparticles, and polymeric micelles.

[0561] In some embodiments, the nanoparticles comprise liposomes. Liposomes are spherical vesicles having at least one lipid bilayer and, in some embodiments, have an aqueous core. In some embodiments, the lipid bilayer of the liposome may comprise phospholipids. An exemplary but non-limiting example of a phospholipid is phosphatidylcholine, but the lipid bilayer may contain other lipids, such as phosphatidylethanolamine. Liposomes may be multilayered liposomes (i.e., composed of several lamellar phase lipid bilayers) or monolayered liposomes (having a single lipid bilayer). Liposomes may be formulated in specific size ranges to make them viable targets for phagocytosis. The size range of liposomes may be 20 nm to 100 nm, 100 nm to 400 nm, 1 μM and larger, or 200 nm to 3 μM. Examples of liposomes and lipid-based formulations are provided in U.S. Publication 20090023673. In other embodiments, one or more lipids are one or more cationic lipids. Those skilled in the art will recognize which liposomes are suitable for encapsulating the modified multisegmental antisense oligonucleotides described herein.

[0562] In some embodiments, the nanoparticles comprise micelles. Micelles are aggregates of surfactant molecules. Exemplary specification 85 / 170 pages 95 CN 121358861 A Micelles comprise aggregates of amphiphilic macromolecules, polymers, or copolymers in aqueous solutions, wherein the hydrophilic head is in contact with the surrounding solvent, while the hydrophobic tail is isolated at the center of the micelle.

[0563] In some embodiments, the nanoparticles comprise polymer-based nanoparticles. Polymer-based nanoparticles comprise one or more polymers, such as polyesters, poly(orthoesters), poly(ethyleneimine), poly(caprolactone), polyanhydrides, poly(acrylic acid), polyglycolic acid, or poly(polyurethane). In other embodiments, one or more polymers comprise poly(lactic acid) (PLA) or poly(lactic acid-co-glycolic acid) (PLGA). In exemplary embodiments, one or more polymers comprise polyalkylene glycols, such as polyethylene glycol (PEG), or polyepoxides, such as polyethylene oxide (PEO).

[0564] In some embodiments, the nanoparticles or portions thereof are biodegradable. In other embodiments, the lipids and / or polymers of the nanoparticles are degradable.

[0565] Conjugated Antisense Oligonucleotides

[0566] Antisense oligonucleotides may be covalently linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the resulting antisense oligonucleotide. Typical conjugation groups include cholesterol moieties and lipid moieties. Other conjugation groups include carbohydrates, phospholipids, biotin, phenazine, folic acid, phenanthridine, anthraquinone, acridine, fluorescein, rhodamine, coumarin, and dyes.

[0567] Antisense oligonucleotides may also be modified to have one or more stabilizing groups, which are typically linked to one or both ends of the antisense oligonucleotide to enhance properties such as, for example, nuclease stability. Included in the stabilizing groups is a cap structure. These end modifications protect antisense compounds with terminal nucleic acids from exonuclease degradation and can aid in intracellular delivery and / or localization. The cap may be present at the 5′ end (5′-cap), or at the 3′ end (3′-cap), or at both ends. The cap structure is well known in the art and includes, for example, a reverse deoxy-base cap. Additional 3′ and 5′-stabilizing groups that can be used to cap one or both ends of an antisense oligonucleotide to confer nuclease stability include those disclosed in WO 03 / 004602, published January 16, 2003.

[0568] Cell Culture and Treatment of Antisense Oligonucleotides

[0569] The effects of antisense oligonucleotides on the level, activity, or expression of target nucleic acids can be tested in vitro in a variety of cell types. Cell types used for such analyses are available from commercial suppliers (e.g., the American Type Culture Collection in Manassas, Virginia).Cells were obtained from Zen-Bio, Inc., Research Triangle Park, NC, North Carolina, and Clonetics Corporation, Walkersville, MD, and cultured using commercially available reagents (e.g., Invitrogen Life Technologies, Carlsbad, CA) according to the supplier’s instructions. Illustrative cell types include, but are not limited to, HuVEC cells, b.END cells, HepG2 cells, Hep3B cells, and primary hepatocytes.

[0570] In Vitro Assay of Antisense Oligonucleotides

[0571] Methods for treating cells with antisense oligonucleotides are described herein, which may be appropriately modified to suit other antisense oligonucleotide treatments.

[0572] Cells can be treated with antisense oligonucleotides when they reach approximately 60%–80% confluence in culture.

[0573] One reagent commonly used to introduce antisense oligonucleotides into cultured cells includes the cationic lipid transfection reagent LIPOFECTIN (Ingenieur, Carlsbad, California). Antisense oligonucleotides can be mixed with LIPOFECTIN in OPTI-MEM 1 (Ingenieur, Carlsbad, California) to achieve the desired final concentration of antisense oligonucleotides and a LIPOFECTIN concentration that may range from 2 μg / mL to 12 μg / mL per 100 nM antisense oligonucleotides.

[0574] Another reagent used to introduce antisense oligonucleotides into cultured cells includes LIPOFECTAMINE (Ingenieur, Carlsbad, California, 86 / 170 pages, CN 121358861 A). Antisense oligonucleotides were mixed with LIPOFECTAMINE in OPTI-MEM 1 serum-depleted medium (Ingenie, Carlsbad, California) to achieve the desired concentration of antisense oligonucleotides and a LIPOFECTAMINE concentration that may be in the range of 2 μg / mL to 12 μg / mL per 100 nM antisense oligonucleotides.

[0575] Another technique for introducing antisense oligonucleotides into cultured cells includes electroporation.

[0576] Cells were treated with antisense oligonucleotides using conventional methods. Cells could be harvested 16 to 24 hours after antisense oligonucleotide treatment, at which time the RNA or protein levels of the target nucleic acid were measured using methods known in the art and described herein. Generally, when treatment was performed in multiple replicates, the data are presented as the average of the replicates.

[0577] The concentration of antisense oligonucleotides used varies depending on the cell line. Methods for determining the optimal concentration of antisense oligonucleotides for a particular cell line are well known in the art. When transfected with LIPOFECTAMINE, antisense oligonucleotides are typically used at concentrations ranging from 1 nM to 300 nM. When transfected using electroporation, antisense oligonucleotides are used at higher concentrations ranging from 625 nM to 20,000 nM.

[0578] RNA Isolation

[0579] Total cellular RNA or poly(A)+ mRNA can be analyzed. RNA isolation methods are well known in the art. RNA is prepared using methods well known in the art, for example, using TRIZOL reagents (Ingenieur, Carlsbad, California) according to the manufacturer's recommended protocol.

[0580] Target Level or Inhibition Analysis

[0581] The level of target nucleic acid or inhibition of its expression can be determined in a variety of ways known in the art. For example, the level of target nucleic acid can be quantified by, for example, RNA blot analysis, competitive polymerase chain reaction (PCR), or quantitative real-time PCR. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. RNA isolation methods are well known in the art. RNA blotting analysis is also a routine technique in the art. Quantitative real-time PCR can be conveniently performed using a commercially available ABIPRISM 7600, 7700 or 7900 sequence detection system (available from PE-Applied Biosystems, Foster City, CA) and according to the manufacturer's instructions.

[0582] Quantitative Real-Time PCR Analysis of Target RNA Levels

[0583] Quantification of target RNA levels can be performed by quantitative real-time PCR using an ABIPRISM 7600, 7700 or 7900 sequence detection system (PE-Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Quantitative real-time PCR methods are well known in the art.

[0584] Prior to real-time PCR, the isolated RNA is subjected to a reverse transcriptase (RT) reaction, which produces complementary DNA (cDNA), which is then used as a substrate for real-time PCR amplification. RT and real-time PCR reactions are performed sequentially in the same sample well. RT and real-time PCR reagents are available from Ingenium Corporation (Carlsbad, California). RT real-time PCR reactions are performed using methods well known to those skilled in the art.

[0585] The gene (or RNA) target levels obtained by real-time PCR are normalized using the expression levels of genes expressing constant values ​​(such as cyclophilin A), or by quantifying total RNA using RIBOGREEN (Ingenium Corporation, Carlsbad, California). Cyclophilin A expression is quantified by real-time PCR, by running simultaneously with the target, by multiplexing, or by using alone.Total RNA was quantified using RIBOGREEN RNA quantification reagent (Invitrogen, Inc., Eugene, OR). Jones, LJ. et al. (Analytical Biochemistry, 1998, 265, 368-374) taught a method for quantifying RNA using RIBOGREEN. RIBOGREEN fluorescence was measured using a CYTOFLUOR 4000 instrument (PE Applied Biosystems, Inc.).

[0586] Probes and primers were designed to hybridize with target nucleic acids. Methods for designing real-time PCR probes and primers are well known in the art and may include the use of software such as PRIMER EXPRESS software (Applied Biosystems, Inc., Foster City, CA, 87 / 170 pages, 97 CN 121358861 A).

[0587] Quantitative Real-Time PCR Analysis of Target DNA Levels

[0588] Quantification of target DNA levels can be performed by quantitative real-time PCR using an ABIPRISM 7600, 7700, or 7900 sequence detection system (PE Applied Biosystems, Foster City, California) according to the manufacturer's instructions. Quantitative real-time PCR methods are well known in the art.

[0589] The gene (or DNA) target levels obtained by real-time PCR are normalized using the expression levels of genes with constant expression (such as cyclic protein A) or by quantifying total DNA using RIBOGREEN (Ingenie, Carlsbad, California). Cyclic protein A expression is quantified by real-time PCR, by running simultaneously with the target, by multiplexing, or by using alone. Total DNA is quantified using RIBOGREEN RNA Quantification Reagent (Ingenie, Eugene, Oregon). Jones, LJ. et al. (Analytical Biochemistry, 1998, 265, 368-374) taught a method for quantifying DNA using RIBOGREEN. RIBOGREEN fluorescence was measured using a CYTOFLUOR 4000 instrument (PE Applied Biosystems, Inc.).

[0590] Probes and primers were designed to hybridize with the target nucleic acid. Methods for designing real-time PCR probes and primers are well known in the art and may include the use of software such as PRIMER EXPRESS software (Applied Biosystems, Foster City, California).

[0591] Protein Level Analysis

[0592] Antisense inhibition of the target nucleic acid can be assessed by measuring the target protein level. The target protein level can be evaluated or quantified in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), enzyme-linked immunosorbent assay (ELISA).Immunosorbent assay (ELISA), quantitative protein assay, protein activity assay (e.g., cysteine ​​activity assay), immunohistochemistry, immunocytochemistry, or fluorescence activated cell sorting (FACS). Antibodies against the target can be identified and obtained from a variety of sources, such as the MSRS Antibody Catalog (Aerie Corporation, Birmingham, MI), or can be prepared using conventional monoclonal or polyclonal antibody production methods well known in the art.

[0593] In vivo testing of antisense oligonucleotides

[0594] Antisense oligonucleotides, such as antisense oligonucleotides, are tested in animals to assess their ability to inhibit target expression and produce phenotypic changes. The test can be performed in normal animals or in experimental disease models. For administration to animals, the antisense oligonucleotides are formulated in a pharmaceutically acceptable diluent (such as phosphate-buffered saline). Administration includes parenteral routes, such as intraperitoneal, intravenous, subcutaneous, intrathecal, and intraventricular administration. Administration also includes intraocular and intramuscular routes. The calculation of antisense oligonucleotide dosage and dosing frequency is within the capabilities of those skilled in the art and depends on factors such as route of administration and animal weight.

[0595] Certain Combination Therapies

[0596] In some embodiments, one or more pharmaceutical compositions provided herein are administered in combination with one or more other pharmaceutical agents. In some embodiments, such one or more other pharmaceutical agents are designed to treat the same disease, disorder, or condition as the one or more pharmaceutical compositions provided herein. In some embodiments, such one or more other pharmaceutical agents are designed to treat a different disease, disorder, or condition than the one or more pharmaceutical compositions provided herein.

[0597] In some embodiments, such one or more other pharmaceutical agents are designed to treat undesirable side effects of the one or more pharmaceutical compositions provided herein. In some embodiments, one or more pharmaceutical compositions provided herein are administered in combination with another pharmaceutical agent to treat undesirable effects of that other pharmaceutical agent. In some embodiments, one or more pharmaceutical compositions provided herein are administered in combination with another pharmaceutical agent to produce a combination effect. In some embodiments, one or more pharmaceutical compositions provided herein are administered in combination with another pharmaceutical agent to produce a synergistic effect. Instructions for Use, pages 88 / 170, CN 121358861 A

[0598] : In some embodiments, one or more pharmaceutical compositions provided herein and one or more other pharmaceutical agents are administered simultaneously. In some embodiments, one or more pharmaceutical compositions provided herein and one or more other pharmaceutical agents are administered at different times. In some embodiments, one or more pharmaceutical compositions provided herein and one or more other pharmaceutical agents are administered simultaneously.Multiple other pharmaceutical agents are prepared together in a single formulation. In some embodiments, one or more pharmaceutical compositions and one or more other pharmaceutical agents provided herein are prepared separately.

[0599] Although certain oligonucleotides, compositions and methods described herein have been specifically described according to certain embodiments, the following examples are for illustrative purposes only and are not intended to limit the oligonucleotides described herein.

[0600] Examples

[0601] Example 1: Synthesis and Evaluation of Modified Multisegment Antisense Oligonucleotides

[0602] The following examples describe experimental methods for synthesizing modified oligonucleotides and evaluating the in vitro inhibition of target nucleotides.

[0603] Modified Oligonucleotide Sequences and Preparation Methods

[0604] Exemplary modified multisegment antisense oligonucleotides are shown in Tables 1A, 1B, 1C and Figure 22. Specifically, Table 1A shows modified multisegment antisense oligonucleotides for inhibiting HBV. Table 1B shows modified multisegment antisense oligonucleotides for inhibiting PCSK9, DMPK, TTR or AAT. Table 2.2 shows illustrations of individual modifications at each position of the modified multi-segment antisense oligonucleotides in Tables 1A and 1B.

[0605] Tables 2.1, 1C, and Figure 22 show further exemplary modified multi-segment antisense oligonucleotides. Table 2.2 shows illustrations of individual modifications at each position of the modified multi-segment antisense oligonucleotides in Table 2.1. In Table 1C and Figure 22, lowercase letters denote 21-deoxynucleosides, and uppercase letters denote nucleosides having any of the modifications shown in the section titled Exemplary Modifications, such as 2'-O-methoxyethyl nucleoside, 2'-O-methoxyethyl cytidine, 2'-O-methyl nucleoside, 2'-O-methyl nucleoside, 2′-OH nucleoside, GNA, LNA, LNA having a cytosine base, 2′-fluoro2′-deoxynucleoside, 2′-fluoro2′-deoxycytidine, 2′-F-arabinose (2′-F-ANA), or 2'-F-arabinose (2′-F-ANA), or combinations thereof. In Table 1C and Figure 22, lowercase "c" denotes 2′-deoxycytidine or 2′-deoxy5-methylcytidine, and uppercase "C" denotes cytidine or 5-methylcytidine with or without the aforementioned sugar modifications.

[0606] Modified multi-segment antisense oligonucleotides with various structural motifs were generated. For example, a motif from 5′ to 3′ includes a 5′ wing of 4 nucleotides, a first nick of 5 nucleotides, a separator of 1 nucleotide, a second nick of 5 nucleotides, and a 3′ wing of 5 nucleotides, collectively referred to herein as the "4-5-1-5-5" motif. In Tables 1A, 1B, and 1C, the separators are shown in bold text.

[0607] Synthesis: Solid-phase synthesis is used to produce modified multi-segment antisense oligonucleotides. The oligonucleotides are bound to a solid surface during preparation. In other words, in solid-phase synthesis, the assembled oligonucleotide is covalently bound to a solid support material via its 3′-terminal hydroxyl group and remains attached to it throughout the chain assembly process. This synthetic process begins with the 3′-terminal nucleotide and proceeds through a series of four-step cycles, repeated until the 5′-terminal nucleotide is attached. The four steps are deprotection (A), condensation (B), end capping (C), and oxidation (D), as described below:

[0608] Step 1: Remove the DMTr attached to the 5'-OH group of the first base on the CPG monomer and prepare to attach the next new base;

[0609] Step 2: Activate the new base monomer and prepare to react with the first base;

[0610] Step 3: The second base undergoes a coupling reaction with the first base;

[0611] Step 4: End cap the 5'-OH of the unreacted first base so that it no longer participates in the reaction;

[0612] Step 5: Oxidize the nucleoside phosphite to a more stable nucleoside phosphate; Specification 89 / 170 pages 99 CN 121358861 A

[0613] Step 6: Repeat the cycle of steps 1-5 until the desired oligonucleotide DNA sequence is synthesized.

[0614] Ammonolysis: The synthesized modified multisegment antisense oligonucleotides were chemically cleaved from the solid carrier (CPG) and the protecting groups were removed by ammonolysis.

[0615] Purification: The improved primer purification method is as follows:

[0616] (1) PAGE purification: The primer DNA was separated by denaturing polyacrylamide gel electrophoresis and the target DNA was then recovered from the gel. The purity of the purified DNA was greater than 90%.

[0617] (2) HPLC purification: The primer DNA was purified to a purity greater than 90% using the principle of high performance liquid chromatography.

[0618] Antisense inhibition of HBV in HepG2.2.15 cells

[0619] The antiviral effect of the modified multisegment antisense oligonucleotides targeting HBV was evaluated by measuring the levels of hepatitis B virus (HBV) surface antigen (HBsAg) and HBV e antigen (HBeAg) in HepG2.2.15 cells. HBsAg levels were measured by chemiluminescent immunoassay, HBeAg levels were measured by enzyme-linked immunosorbent assay (ELISA), and cell viability was determined by MTT assay. Results are expressed as mean and SD.

[0620] HepG2.2.15 cells stably expressing HBsAg and HBeAg were purchased from the China Center for Type Culture Collection (CCTCC No.: GDC0141). Each compound was prepared by dissolving it in saline or RNase-free double-distilled H2O (dd H2O).Prepare a 50 μM target stock solution to prepare a modified multisegment antisense oligonucleotide solution.

[0621] The modified multisegment antisense oligonucleotides were set to a series of concentrations (0 nM, 0.037 nM, 0.11 nM, 0.34 nM, 1 nM, 3.1 nM, 9.3 nM, 27.8 nM, 83.3 nM, 250 nM) and used in conjunction with HepG2.2.15 cells via reverse transfection. First, each well of a 96-well cell culture plate was covered with 50 μL of rat tail collagen I and the plate was removed after one hour. Second, P3000 and 3000 reagents were diluted with Opti-MEM™ serum-depleted medium and mixed with the serially diluted compound solutions, and then incubated at room temperature for 10 minutes. Third, 10 μL of a transfection reagent mixture of P3000, Lipo3000, and modified multisegment antisense oligonucleotides, and 100 μL of a cell suspension with a concentration of 3.5 × 10⁵ cells were added to each well.

[0622] The mixture was pipetted 4 or 5 times and the plate was placed in a 37°C incubator. After 24 hours of reverse transfection, the culture medium was replaced with fresh cell culture medium. After 48 hours of culture, the supernatant was collected for detection. The remaining cells were used for viability testing. The obtained data are shown in Table 1A as EC50 (nM) and MTT CC25 (nM). The EC50 (nM) ratio was calculated by dividing the EC50 value determined after treatment with the modified multisegment antisense oligonucleotides shown in Table 1A by the EC50 value determined after treatment with the reference oligonucleotide (SEQ ID NO: 10) of AUS1233, which is a "gap polymer" oligonucleotide lacking the separator sequence. A lower EC50 ratio indicates that the modified multisegment antisense oligonucleotide has an increased ability to reduce HBsAg levels relative to the reference oligonucleotide. The MTT CC25 (nM) ratio was calculated by dividing the MTT CC25 value determined after treatment with the modified multisegment antisense oligonucleotide shown in Table 1A by the MTT CC25 value determined after treatment with the reference oligonucleotide (SEQ ID NO: 10) of AUS1233. A higher MTT CC25 ratio indicates increased cell viability relative to the reference oligonucleotide. The C / E ratio was calculated by dividing the MTT CC25 ratio by the EC50 value. A higher C / E ratio indicates a balanced reduction in HBsAg levels while maintaining high cell viability.

[0623] Antisense inhibition of PCSK9, DMPK, AAT and TTR

[0624] The effects of modified multisegment antisense oligonucleotides targeting PCSK9, DMPK, AAT or TTR were evaluated as follows. The obtained data are presented in Table 1B as EC25 (nM), EC50 (nM), and maximum inhibition rate (%).

[0625] Stability of modified multi-segment antisense oligonucleotides

[0626] Tables 1A and 1B also provide melting temperature data for representative modified multisegment antisense oligonucleotides as an assessment of their stability, as described in Example 11 below. Specification 90 / 170 pages 100 CN 121358861 A

[0627] Example 7: Inhibition of mouse PCSK9 expression in Hepa1-6 cells using modified multisegment antisense oligonucleotides

[0628] Modified multisegment antisense oligonucleotides of 20 nucleotides in length were designed to target PCSK9 nucleic acid, and their effects on PCSK9 mRNA in vitro were tested.

[0629] The modified multisegment antisense oligonucleotides were tested in a series of experiments with similar culture conditions. The results of each experiment are presented in separate tables below.

[0630] Cultured Hepa1-6 cells at a density of 18,000 cells / well were transfected using Lipofectamine 3000 reagent according to the manufacturer's protocol. Reverse transfection of cells on ASO is a powerful alternative for high-throughput transfection.

[0631] Cells were treated with serial dilutions starting at 60 nM. After a treatment period of approximately 48 hours, RNA was isolated from the cells and PCSK9 mRNA levels were measured by quantitative real-time PCR. PCSK9 mRNA levels were measured using mouse PCSK9 primer probes and normalized relative to housekeeping gene GAPDH mRNA levels. Results are expressed as a percentage of PCSK9 inhibition relative to untreated control cells. ISIS 394816 (AB-1648) as described in US 9,650,636B2 and WO2009148605A2 was tested as a control. Several newly designed modified multi-segment antisense oligonucleotides were more effective than the reference control ISIS 394816 (AUS-P1000) (Table 7A, Figures 1A-1E and 2A-2F). Table 2.2 shows an illustration of the modifications at each residue shown in Table 7A.

[0632] Compared to the control nick polymer sequence without a separator, the separator placed at position 10 of the modified multi-segment antisense oligonucleotide with a length of 20 residues resulted in greater maximum inhibition. Furthermore, the LNA modification in the 3′ wing also increased maximum inhibition compared to the control nick polymer sequence without modification at the 3′ wing. The combination of the separator at position 10 with the LNA modifications at positions 17 and 18 (SEQ ID NO: 671 and SEQ ID NO: 675) resulted in the greatest maximum inhibition.

[0633] Table 7A. Antisense inhibition of PCSK9 in mouse cells

[0634]

[0635] *Modal shows the region from 5′ to 3′ for each sequence (e.g., W1-G1-W2 or W1-G1-S1-G2-W2), where the specification is on pages 91 / 170, 101 CN.121358861 A Separator sequence is shown in bold.

[0636] Example 8: Inhibition of mouse DMPK expression in Sol8 cells using modified multisegment antisense oligonucleotides

[0637] The effect of modified multisegment antisense oligonucleotides targeting DMPK nucleic acid on DMPK mRNA in vitro was tested. Mouse skeletal muscle Sol8 cells cultured in 96-well plates at a density of 18,000 cells / well were treated with serial dilutions of 60 nM modified multisegment antisense oligonucleotides.

[0638] After a treatment period of approximately 48 hours, RNA was isolated from the cells and DMPK mRNA levels were measured by quantitative real-time PCR as described herein. DMPK mRNA levels were measured using mouse DMPK primer probes and normalized relative to housekeeping gene GAPDH mRNA levels. Results are expressed as a percentage of DMPK inhibition relative to untreated control cells. ISIS 486178 (AUS-D1000) as described in WO 2015 / 021457A2 was used as a reference control. Several novel modified multi-segment antisense oligonucleotides were more effective than ISIS 486178 (AUS-D1000) (Table 8A, Figures 3A-3E and 4A-4F). Table 2.2 shows an illustration of the modifications at each residue shown in Table 8A.

[0639] The separator placed at position 10 of the modified multi-segment antisense oligonucleotide with a length of 20 residues resulted in greater maximum inhibition compared to the control notched polymer sequence without the separator. Furthermore, the LNA modification in the 3′ wing also increased the maximum inhibition compared to the control notched polymer sequence without modification at the 3′ wing. The combination of the separator at position 10 with the LNA modifications at positions 17 and 20 (SEQ ID NO: 687) resulted in the greatest maximum inhibition.

[0640] Table 8A. Antisense inhibition of DMPK in mouse cells

[0641]

[0642] *Motifs show the region from 5′ to 3′ for each sequence (e.g., W1-G1-W2 or W1-G1-S1-G2-W2), where the separator sequences are shown in bold.

[0643] Example 9: Inhibition of mouse TTR expression in AML12 cells using modified multisegment antisense oligonucleotides

[0644] The effects of modified multisegment antisense oligonucleotides targeting TTR nucleic acids on TTR mRNA in vitro were tested. Mouse hepatocytes AML12 cultured in 96-well plates at a density of 18,000 cells / well were treated with serial dilutions of 60 nM modified multisegment antisense oligonucleotides. The sequences of AUS-T1001, AUS-T1002, and AUS-T1003 are identical to the reference antisense nucleotides, but with longer nicks. (Pages 92 / 170, CN 121358861 A

[0645] )The cells exhibit unique structures in terms of degree of nucleotide chemical modification and the localization of modified nucleotides (Table 9A). AUS-T1004, AUS-T1005, AUS-T1006, and AUS-T1007 are newly designed with different target sites but share a common 5-10-5 nicked polymer structure (Table 9B). After a treatment period of approximately 48 hours, RNA was isolated from cells, and TTR mRNA levels were measured by quantitative real-time PCR as described herein. TTR mRNA levels were measured using mouse TTR primer probes and normalized relative to housekeeping gene GAPDH mRNA levels. Results are expressed as a percentage of TTR inhibition relative to untreated control cells. The test ISIS 401724 (AUS-T 1000) as previously described in US 8,541,388B2 served as a reference control. Several newly designed modified multisegment antisense oligonucleotides are more effective than ISIS 401724 (AUS-T1000) (Tables 9A and 9B, Figures 5A-5D and 6A-6D). Table 2.2 shows an illustration of the modifications at each residue shown in Table 9A.

[0646] The separator placed at position 10 of the modified multisegment antisense oligonucleotide with a length of 20 residues resulted in greater maximum inhibition compared to the control notched polymer sequence without the separator. Furthermore, the LNA modification in the 3′ wing also increased the maximum inhibition compared to the control notched polymer sequence without modification at the 3′ wing. The combination of the separator at position 10 with the LNA modifications at positions 17 and 20 (SEQ ID NO: 687) resulted in the greatest maximum inhibition.

[0647] Table 9A. Antisense inhibition of TTR in mice

[0648]

[0649]

[0650] *Motifs show the regions from 5′ to 3′ of each sequence (e.g., W1-G1-W2 or W1-G1-S1-G2-W2), where

[0651] the separator sequences are shown in bold.

[0652] Table 9B. Nucleotide sequences targeting TTR (mus_NM_013697.5)

[0653]

[0654] Example 10: Inhibition of mouse AAT expression in AML12 cells using modified multisegment antisense oligonucleotides

[0655] The effects of modified multisegment antisense oligonucleotides targeting AAT nucleic acids on AAT mRNA in vitro were tested. Mouse hepatocytes AML 12, cultured at a density of 18,000 cells / well in 96-well plates, were treated with serial dilutions of a modified multisegment antisense oligonucleotide from 60 nM (see page 93 / 170, CN 121358861 A). Reference antisense oligonucleotide (ACCCAATTCAGAAGGAAGGA; SEQ ID NO: )697) Highly conserved in mice. A reference control was administered subcutaneously to C57BL / 6 mice at a dose of 100 mg / kg.

[0656] After a treatment period of approximately 48 hours, RNA was isolated from the cells and AAT mRNA levels were measured by quantitative real-time PCR as described herein. AAT mRNA levels were measured using mouse AAT primer probes and normalized relative to housekeeping gene GAPDH mRNA levels. The results are expressed as a percentage of AAT inhibition relative to untreated control cells (Table 10A and Figures 7A-7D). Table 2.2 shows an illustration of the modifications at each residue shown in Table 10A.

[0657] Table 10A. Antisense inhibition of AAT in mouse cells

[0658]

[0659] *Motifs show the regions from 5′ to 3′ of each sequence (e.g., W1-G1-W2 or W1-G1-S1-G2-W2), where the separator sequences are shown in bold.

[0660] Example 11: Stability of duplexes formed from modified multisegment antisense oligonucleotides

[0661] Replacing a nucleoside with a sugar-modified nucleoside (e.g., 2′-O-MOE) in conventional notched polymers results in enhanced binding affinity to the target sequence. This type of enhancement has been explored in conventional notched polymer design to form more stable duplexes with the target sequence, thereby improving notched polymer activity. The stability of the duplex can be determined by quantitative melting temperature (Tm). Higher melting temperatures generally indicate enhanced binding to the target sequence and are expected to lead to increased recruitment and functional activity of nucleases (e.g., silencing of target expression). Experiments were performed to directly compare the melting temperatures of modified multisegment antisense oligonucleotides (with separators) with the same template sequence used as a notched polymer (without separators). The stability of the duplex can be determined by quantitative melting temperature (Tm).

[0662] Methods

[0663] Here, modified multisegment antisense oligonucleotides were designed by inserting a separator segment of a 2′-modified ribonucleotide into a continuous extension of a 2′-deoxyribonucleotide in a notch. The melting temperature of the modified multisegment antisense oligonucleotides was measured. A comparable oligonucleotide (i.e., a notch polymer designed for the same target sequence, without a separator sequence) was used as a control.

[0664] Results

[0665] The melting temperatures of oligonucleotides with or without separators, along with the sequences and motifs of the oligonucleotides tested, are provided in Table 11A below.

[0666] As mentioned above, the introduction of the 2′-modified ribonucleotide was expected to enhance the binding affinity to the target sequence, which in turn led to an increase in Tm. Unexpectedly, the measured Tm of the modified multisegment antisense oligonucleotide (with separator) was lower than the Tm value of the corresponding notch polymer (without separator). The Tm reduction was significant, with a maximum reduction of 4°C.

[0667] The melting temperatures of various modified multisegment antisense oligonucleotides targeting HBV were also measured. The results are presented in Table 11B below. Despite the reduced melting temperatures, the modified multisegment antisense oligonucleotides still resulted in higher functional inhibition than the conventional nicked polymers. For example, in genotype C 1.0 HBV transgenic mice, when each compound was administered once by SC at 40 mg / kg on day 0, the modified multisegment antisense oligonucleotides with the same structure as AUS1049 (Tm 69.5 °C) and AUS1056 (Tm 70 °C) resulted in maximum reductions of HBsAg of 2.18 and 1.87 log10, respectively, compared to 1.15 log10 for the nicked polymer AUS1233 (Tm 71.5 °C). Specification 94 / 170 pages 104 CN 121358861 A

[0668] Table 11B. Demothering temperature of modified multi-segment antisense oligonucleotides targeting HBV

[0669] Specification 95 / 170 pages 105 CN 121358861 A

[0670]

[0671] *Modal shows the region from 5′ to 3′ of each sequence (e.g., W1-G1-W2 or W1-G1-S1-G2-W2), where the separator sequence is shown in bold.

[0672] The decrease in Tm is a general phenomenon observed in the multiple sequences evaluated, with the vast majority of sequences showing a decrease in Tm value of more than 2°C. Without wishing to be bound by theory, the significant decrease in Tm indicates that the entire motif containing the separator and molecule has a significant effect on the overall conformation of the modified multi-segment oligonucleotide, which leads to improved interaction with target RNA and / or nucleases (e.g., RNase H) despite the lower Tm value. These data suggest that modified multisegment antisense oligonucleotides with the shown separators and motifs offer new opportunities to increase drug selectivity.

[0673] Example 12: Evaluation of the cytotoxicity of modified multisegment antisense oligonucleotides

[0674] Experiments were performed to evaluate the cytotoxicity of modified multisegment antisense oligonucleotides targeting various motifs. Specifically, modified multisegment antisense oligonucleotides with separator sequences were compared with corresponding nick polymer sequences lacking separator sequences.

[0675] HepG2.2.15 cells were treated with modified multisegment antisense oligonucleotides as described in Example 1. The identity and motifs of the modified multisegment antisense oligonucleotides are provided in Tables 12A-12E below, and the sequences of the modified multisegment antisense oligonucleotides are provided in Table 11B. Tm data from Table 11B are also reproduced in Tables 12A-12E for reference.

[0676] As described in Example 1, cell viability was determined by MTT assay.

[0677] Table 12A. Viability of cells treated with modified multisegment antisense oligonucleotides targeting HBV

[0678]

[0679] As shown in Table 12A, under the same experimental conditions, the modified multisegment antisense oligonucleotides with the 5-4-1-5-5 motif produced higher CC25 levels in the MTT assay compared to the control nicked polymer sequence (AUS1233) without a separator but with the same wing structure. This indicates that the modified multisegment antisense oligonucleotides with the 5-4-1-5-5 motif increased cell viability and therefore lower cytotoxicity. Notably, the three 5-4-1-5-5 modified multisegment antisense oligonucleotides had different chemical modifications in the separator sequence (specifically, the 2'MOE separator in AUS1049, the 2'-F separator in AUS1050, and the LNA separator in AUS1051).

[0680] Table 12B. Viability of cells treated with modified multisegment antisense oligonucleotides targeting HBV

[0681]

[0682] As shown in Table 12B, under the same experimental conditions, the modified multisegment antisense oligonucleotides with 5-4-1-5-5 or 5-5-1-4-5 motifs produced higher CC25 levels in the MTT assay compared to the control nicked polymer sequence (AUS1233) without a separator but with the same wing structure. Furthermore, the modified multisegment antisense oligonucleotides with a separator had lower Tm values ​​compared to the control nicked polymer sequence. Here, both the modified multisegment antisense oligonucleotides AUS1130 and AUS1131 have a 2'-O-methyl separator.

[0683] Table 12C. Viability of cells treated with modified multisegment antisense oligonucleotides targeting HBV. Specification 97 / 170 pages 107 CN 121358861 A

[0684]

[0685] As shown in Table 12C, AUS1233 (a nicked polymer with an additional modified nucleotide and a 6-9-5 motif) had a higher Tm value compared to the 5-10-5 nicked polymer AUS1061, indicating a higher affinity for its target and a lower CC25 in the MTT assay. This suggests that AUS1061 is more cytotoxic than AUS1233. Conversely, the modified multisegment antisense oligonucleotides with a separator sequence (AUS1061 to AUS1072) had a lower Tm value compared to the corresponding control nicked polymer sequence without a separator (AUS1233), indicating a lower target-binding affinity and a higher CC25 value in the MTT assay. This indicates that modified multi-segment antisense oligonucleotides with multiple motifs exhibit lower cytotoxicity compared to the nicked polymer control.

[0686] Table 12D. Viability of cells treated with modified multi-segment antisense oligonucleotides targeting HBV.

[0687]

[0688] As shown in Table 12D, compared with the corresponding control nick polymer sequence (AUS1480) without the separator but with the same W2 modification, the modified multisegment antisense oligonucleotide AUS1490 had a lower Tm (indicating lower target binding affinity) and a higher CC25 level in the MTT assay. This indicates that the modified multisegment antisense oligonucleotide with the separator is less cytotoxic than the nick polymer control.

[0689] Table 12E. Viability of cells treated with modified multisegment antisense oligonucleotides targeting HBV

[0690] Specification 98 / 170 pages 108 CN 121358861 A

[0691] Finally, as shown in Table 12E, compared with the corresponding control nick polymer sequence (AUS1481) without a separator but with the same W2 modification, the modified multisegment antisense oligonucleotides with the 5-4-1-4-6 (AUS1316-AUS1320) or 6-4-1-4-5 (AUS1312 and AUS1313) motifs had lower Tm values ​​(indicating lower target binding affinity) and higher CC25 levels in the MTT assay. This indicates that the modified multisegment antisense oligonucleotides with a separator are less cytotoxic than the nick polymer control.

[0692] Example 13: RNase H cleavage assay

[0693] RNase H1 cleavage of target RNA directed by antisense oligonucleotides was evaluated in vitro. Nodule polymers or modified multi-segment antisense oligonucleotides (1.25 pmol each) were mixed with 12.5 pmol of target RNA in saline to a total volume of 15 μL. RNase H enzyme was added, and the sample was incubated at 37°C for 1 hour. The mixture was rapidly heated to 95°C for 5 minutes, then cooled to 4°C. RNase H cleavage products were analyzed in a 20% pre-prepared UREA-TBE PAGE gel. The gel was stained with SYBR gold and photographed using a MolecularImager FX (Bio-Rad, USA).

[0694] The gel band at approximately 50 K in channels 1-9 represents the target RNA. The band above the target RNA band represents the oligonucleotide + target RNA complex. The band below the target RNA band represents the degradation products after incubation with RNase H.

[0695] The ...

Claims

1. A modified multi-segment antisense oligonucleotide complementary to a nucleotide sequence in a gene transcript, wherein the modified multi-segment antisense oligonucleotide comprises, from 5' to 3': 5' W1-G1-S1-G2-W2 3' (Formula I) wherein: W1 is a 5' wing segment; W2 is a 3' wing segment; G1 is a first gap segment; S1 is a first spacer segment; and G2 is a second gap segment, wherein each segment is connected by an internucleoside linkage, and wherein at least one nucleoside of each of W1, W2, and S1 is a modified nucleoside.

2. The modified multi-segment antisense oligonucleotide of claim 1, wherein the modified multi-segment antisense oligonucleotide comprises, from 5' to 3': 5' W1-G1-S1-G2-S2-G3-W2 3' (Formula II) wherein: S2 is a second spacer segment; and G3 is a third gap segment, wherein at least one nucleoside of S2 is a modified nucleoside.

3. The modified multi-segment antisense oligonucleotide of claim 1 or claim 2, wherein W1 comprises 2 to 25 linked nucleosides.

4. The modified multi-segment antisense oligonucleotide of claim 3, wherein the first 5' nucleoside of W1 is a modified nucleoside and / or wherein the last 3' nucleoside of W1 is a modified nucleoside.

5. The modified multi-segment antisense oligonucleotide of any one of claims 1 to 4, wherein W2 comprises 2 to 35 linked nucleosides.

6. The modified multi-segment antisense oligonucleotide of claim 5, wherein the first 5' nucleoside of W2 is a modified nucleoside and / or wherein the last 3' nucleoside of W2 is a modified nucleoside.

7. The modified multi-segment antisense oligonucleotide of any one of claims 1 to 6, wherein G1 comprises 1 to 10 linked deoxynucleosides.

8. The modified multi-segment antisense oligonucleotide of any one of claims 1 to 7, wherein G2 comprises 1 to 10 linked deoxynucleosides.

9. The modified multi-segment antisense oligonucleotide of any one of claims 1 to 8, wherein S1 comprises 1 to 3 linked nucleosides.

10. The modified multi-segment antisense oligonucleotide of any one of claims 2 to 9, wherein G3 comprises 1 to 10 linked deoxynucleosides.

11. The modified multi-segment antisense oligonucleotide of any one of claims 2 to 10, wherein S2 comprises 1 to 3 linked nucleosides.

12. The modified multi-segment antisense oligonucleotide of any one of claims 1 to 11, wherein the modified multi-segment antisense oligonucleotide is 11 to 50 nucleobases in length.

13. The modified multi-segment antisense oligonucleotide of any one of claims 1 to 11, wherein the modified multi-segment antisense oligonucleotide is 11 to 30 nucleobases in length.

14. The modified multi-segment antisense oligonucleotide of any of claims 1-11, wherein the modified multi-segment antisense oligonucleotide is at least 20 nucleobases in length.

15. The modified multi-segment antisense oligonucleotide of any of claims 1-11, wherein the modified multi-segment antisense oligonucleotide is 20 nucleobases in length.

16. The modified multi-segment antisense oligonucleotide of claim 15, wherein W1 comprises 2 to 8 linked nucleosides.

17. The modified multi-segment antisense oligonucleotide of claim 15, wherein W1 comprises 2 to 6 linked nucleosides.

18. The modified multi-segment antisense oligonucleotide of claim 15, wherein W1 comprises 4, 5, or 6 linked nucleosides.

19. The modified multi-segment antisense oligonucleotide of claim 15, wherein W1 comprises 5 linked nucleosides.

20. The modified multi-segment antisense oligonucleotide of any of claims 15-19, wherein G1 comprises 2 to 7 linked deoxynucleosides.

21. The modified multi-segment antisense oligonucleotide of any of claims 15-19, wherein G1 comprises 4 linked deoxynucleosides.

22. The modified multi-segment antisense oligonucleotide of any of claims 15-19, wherein G1 comprises 5 linked deoxynucleosides.

23. The modified multi-segment antisense oligonucleotide of any of claims 15-19, wherein G1 comprises 6 linked deoxynucleosides.

24. The modified multi-segment antisense oligonucleotide of any of claims 15-23, wherein G2 comprises 1 to 7 linked deoxynucleosides.

25. The modified multi-segment antisense oligonucleotide of any of claims 15-23, wherein G2 comprises 2 to 7 linked deoxynucleosides.

26. The modified multi-segment antisense oligonucleotide of any of claims 15-23, wherein G2 comprises 1 to 2 linked deoxynucleosides.

27. The modified multi-segment antisense oligonucleotide of any of claims 15-23, wherein G2 comprises 4 linked deoxynucleosides.

28. The modified multi-segment antisense oligonucleotide of any of claims 15-23, wherein G2 comprises 5 linked deoxynucleosides.

29. The modified multi-segment antisense oligonucleotide of any of claims 15-23, wherein G2 comprises 6 linked deoxynucleosides.

30. The modified multi-segment antisense oligonucleotide of any of claims 15-23, wherein G2 comprises 7 linked deoxynucleosides.

31. The modified multi-segment antisense oligonucleotide of any of claims 15-30, wherein G3 comprises 2 to 7 linked deoxynucleosides.

32. The modified multi-segment antisense oligonucleotide of any of claims 15-30, wherein G3 comprises 4 linked deoxynucleosides.

33. The modified multi -segmented antisense oligonucleotide of any of claims 15-30, wherein G3 comprises 5 linked deoxynucleosides.

34. The modified multi -segmented antisense oligonucleotide of any of claims 15-30, wherein G3 comprises 6 linked deoxynucleosides.

35. The modified multi -segmented antisense oligonucleotide of any of claims 15-30, wherein G3 comprises 7 linked deoxynucleosides.

36. The modified multi -segmented antisense oligonucleotide of any of claims 15-35, wherein SI comprises at least one linked nucleoside.

37. The modified multi -segmented antisense oligonucleotide of any of claims 15-35, wherein SI comprises one linked nucleoside.

38. The modified multi -segmented antisense oligonucleotide of any of claims 15-35, wherein SI comprises 2 linked nucleosides.

39. The modified multi -segmented antisense oligonucleotide of any of claims 15-38, wherein S2 comprises at least one linked nucleoside.

40. The modified multi -segmented antisense oligonucleotide of any of claims 15-38, wherein S2 comprises one linked nucleoside.

41. The modified multi -segmented antisense oligonucleotide of any of claims 15-38, wherein S2 comprises 2 linked nucleosides.

42. The modified multi -segmented antisense oligonucleotide of any of claims 15-41, wherein W2 comprises 2 to 8 linked nucleosides.

43. The modified multi -segmented antisense oligonucleotide of any of claims 15-41, wherein W2 comprises 2 to 6 linked nucleosides.

44. The modified multi -segmented antisense oligonucleotide of any of claims 15-41, wherein W2 comprises 3 linked nucleosides.

45. The modified multi -segmented antisense oligonucleotide of any of claims 15-41, wherein W2 comprises 4 linked nucleosides.

46. The modified multi -segmented antisense oligonucleotide of any of claims 15-41, wherein W2 comprises 5 linked nucleosides.

47. The modified multi -segmented antisense oligonucleotide of any of claims 15-41, wherein W2 comprises 6 linked nucleosides.

48. The modified multi -segmented antisense oligonucleotide of any of claims 15-47, wherein the SI is at position 10 of the modified multi -segmented antisense oligonucleotide.

49. The modified multi -segmented antisense oligonucleotide of any of claims 15-47, wherein the SI is at position 11 of the modified multi -segmented antisense oligonucleotide.

50. The modified multi -segmented antisense oligonucleotide of claim 48, wherein: W1 comprises 4 linked nucleosides, G1 comprises 5 linked deoxynucleosides, SI comprises 1 linked nucleoside, G2 comprises 5 linked deoxynucleosides, and W2 comprises 5 linked nucleosides. ​ ​ ​ ​ ​ 51. The modified multi -segmented antisense oligonucleotide of claim 48, wherein W1 comprises 5 linked nucleosides, G1 comprises 4 linked deoxynucleosides, S1 comprises 1 linked nucleoside, G2 comprises 5 linked deoxynucleosides, and W2 comprises 5 linked nucleosides.

52. The modified multi -segmented antisense oligonucleotide of claim 1, wherein: W1 comprises 2 to 8 linked nucleosides, G1 comprises 2 to 7 linked deoxynucleosides, S1 comprises 1 to 2 linked nucleosides, G2 comprises 2 to 7 linked deoxynucleosides, and W2 comprises 2 to 8 linked nucleosides.

53. The modified multi -segmented antisense oligonucleotide of claim 52, wherein: W1 comprises 2 to 6 linked nucleosides, G1 comprises 2 to 7 linked deoxynucleosides, S1 comprises 1 linked nucleoside, G2 comprises 2 to 7 linked deoxynucleosides, and W2 comprises 2 to 6 linked nucleosides.

54. The modified multi -segmented antisense oligonucleotide of claim 2, wherein: W1 comprises 2 to 8 linked nucleosides, G1 comprises 2 to 7 linked deoxynucleosides, S1 comprises 1 linked nucleoside, G2 comprises 1 to 2 linked deoxynucleosides, S2 comprises 1 linked nucleoside, G3 comprises 2 to 7 linked deoxynucleosides, and W2 comprises 2 to 8 linked nucleosides.

55. The modified multi -segmented antisense oligonucleotide of claim 54, wherein: W1 comprises 2 to 6 linked nucleosides, G1 comprises 2 to 7 linked deoxynucleosides, S1 comprises 1 linked nucleoside, G2 comprises 1 to 2 linked deoxynucleosides, S2 comprises 1 linked nucleoside, G3 comprises 2 to 7 linked deoxynucleosides, and W2 comprises 2 to 6 linked nucleosides.

56. The modified multi -segmented antisense oligonucleotide of any one of claims 52-53, wherein the G1-S1-G2 segment is between 8 and 12 nucleobase lengths in length.

57. The modified multi -segmented antisense oligonucleotide of any one of claims 54-54, wherein G1-S1-G2-S2-G3 is between 8 and 12 nucleobase lengths in length.

58. The modified multi -segmented antisense oligonucleotide of any one of claims 1-57, wherein G1, G2, and / or G3 comprises a nucleoside comprising a modification to a 2’-deoxynucleoside.

59. The modified multi -segmented antisense oligonucleotide of claim 58, wherein G1, G2, and / or G3 comprises a nucleoside comprising a 2’-deoxy 5-methylcytidine sugar modification.

60. The modified multi -segmented antisense oligonucleotide of any one of claims 1-59, wherein S1 and / or S2 comprises a nucleoside comprising a 2’-0-methoxyethyl sugar modification.

61. The modified multi -segmented antisense oligonucleotide of any one of claims 1-59, wherein S1 and / or S2 comprises a nucleoside comprising a 5-methylcytidine.

62. The modified multi -segmented antisense oligonucleotide of any of claims 1-59, wherein S1 and / S2 comprise nucleosides comprising 2'-0-methyl sugar modifications.

63. The modified multi -segmented antisense oligonucleotide of any of claims 1-59, wherein S1 and / S2 comprise nucleosides comprising 2'-0-ethyl sugar modifications.

64. The modified multi -segmented antisense oligonucleotide of any of claims 1-63, wherein S1 and / S2 comprise nucleosides comprising 2'-OH sugar modifications.

65. The modified multi -segmented antisense oligonucleotide of any of claims 1-64, wherein S1 and / S2 comprise nucleosides comprising 2'-fluoro sugar modifications.

66. The modified multi -segmented antisense oligonucleotide of any of claims 1-65, wherein S1 and / S2 comprise nucleosides comprising 2'-fluoro-arabino nucleic acid (2'-fluoro- ANA) sugar modifications.

67. The modified multi -segmented antisense oligonucleotide of any of claims 1-66, wherein S1 and / S2 comprise glycol nucleic acid (GNA).

68. The modified multi -segmented antisense oligonucleotide of any of claims 1-67, wherein S1 and / S2 comprise locked nucleic acid (LNA).

69. The modified multi -segmented antisense oligonucleotide of any of claims 1-68, wherein W1 comprises nucleosides comprising 2'-deoxy sugar modifications.

70. The modified multi -segmented antisense oligonucleotide of any of claims 1-69, wherein W1 comprises nucleosides comprising 2'-0-methoxyethyl sugar modifications.

71. The modified multi -segmented antisense oligonucleotide of any of claims 1-70, wherein W1 comprises nucleosides comprising 2'-0-methyl sugar modifications.

72. The modified multi -segmented antisense oligonucleotide of claim 71, wherein W1 comprises 2'-0-methyl 5-methylcytosine.

73. The modified multi -segmented antisense oligonucleotide of any of claims 1-71, wherein W1 comprises nucleosides comprising 2'-fluoro sugar modifications.

74. The modified multi -segmented antisense oligonucleotide of any of claims 1-73, wherein W1 comprises nucleosides comprising 2'-fluoro-arabino nucleic acid (2'-fluoro- ANA) modifications.

75. The modified multi -segmented antisense oligonucleotide of any of claims 1-74, wherein W1 comprises glycol nucleic acid (GNA).

76. The modified multi -segmented antisense oligonucleotide of any of claims 1-75, wherein W1 comprises locked nucleic acid (LNA).

77. The modified multi -segmented antisense oligonucleotide of any of claims 1-76, wherein W1 comprises nucleosides comprising 2'-0-ethyl sugar modifications.

78. The modified multi -segmented antisense oligonucleotide of any of claims 1-77, wherein W2 comprises nucleosides comprising 2'-deoxy sugar modifications.

79. The modified multi- segment antisense oligonucleotide of any of claims 1-78, wherein W2 comprises a nucleoside comprising a 2’-O-methoxyethyl sugar modification.

80. The modified multi- segment antisense oligonucleotide of claim 79, wherein W2 comprises a 2'-O methoxyethyl 5-methylcytosine.

81. The modified multi- segment antisense oligonucleotide of any of claims 1-78, wherein W2 comprises a nucleoside comprising a 2’-fluoro sugar modification.

82. The modified multi- segment antisense oligonucleotide of claim 81, wherein W2 comprises a nucleoside comprising a 2’-fluoro-arabinonucleic acid (2’-fluoro-ANA) modification.

83. The modified multi- segment antisense oligonucleotide of any of claims 1-82, wherein W2 comprises a glycol nucleic acid (GNA).

84. The modified multi- segment antisense oligonucleotide of any of claims 1-83, wherein W2 comprises a locked nucleic acid (LNA).

85. The modified multi- segment antisense oligonucleotide of any of claims 1-84, wherein W2 comprises a nucleoside comprising a 2'-O-ethyl sugar modification.

86. The modified multi- segment antisense oligonucleotide of any of claims 1-85, wherein at least one internucleoside linkage is a phosphodiester linkage.

87. The modified multi- segment antisense oligonucleotide of any of claims 1-86, wherein at least one internucleoside linkage is a modified internucleoside linkage.

88. The modified multi- segment antisense oligonucleotide of claim 87, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.

89. The modified multi- segment antisense oligonucleotide of claim 87, wherein the modified internucleoside linkage comprises a phosphorodiamidate morpholino modification.

90. The modified multi- segment antisense oligonucleotide of any of claims 1-89, wherein: a. EC of cells treated with modified multi-segmented antisense oligonucleotides 50 / EC of cells treated with modified antisense oligonucleotides having the same template nucleobase sequence but not comprising a spacer segment 50 is about 0.05 to about 250; b. the MTT CC25 value of a cell treated with the modified multi- segment antisense oligonucleotide is from about 10 nM to about 250 nM; c. the CCK8 CC30 value of a cell treated with the modified multi- segment antisense oligonucleotide is from about 10 nM to about 250 nM; d. the ratio of CC30 fold / EC50 fold of a cell treated with the modified multi- segment antisense oligonucleotide compared to a modified antisense oligonucleotide having the same template nucleobase sequence but not comprising a spacer segment is from about 0.01 to about 50; e. exhibits a decrease in melting temperature of at least 1.1 fold compared to a modified antisense oligonucleotide having the same template nucleobase sequence but not comprising a spacer segment; and / or f. exhibits an increase in recruitment of endonuclease of at least 1.1 fold compared to a modified antisense oligonucleotide having the same template nucleobase sequence but not comprising a spacer segment.

91. The modified multi-segmented antisense oligonucleotide of any one of claims 1-90, wherein the modified multi-segmented antisense oligonucleotide is complementary to a nucleotide sequence in a viral gene transcript, optionally wherein the viral gene is selected from the group consisting of HPV, HBV, EBV, HSV, HIV, and RSV genes.

92. The modified multi-segmented antisense oligonucleotide of any one of claims 1-90, wherein the modified multi-segmented antisense oligonucleotide is complementary to a human gene transcript.

93. The modified multi-segmented antisense oligonucleotide of claim 92, wherein the modified multi-segmented antisense oligonucleotide is complementary to a human gene transcript selected from the group consisting of: DM1 protein kinase (DMPK), alpha-1 antitrypsin (AAT), transthyretin (TTR), proprotein convertase subtilisin / kexin type 9 (PCSK9), apolipoprotein B (ApoB), apolipoprotein C-III (ApoCIII), TNF-alpha, SERPINA8 (AGT), Complement Factor B (CFB), diacylglycerol O-acyltransferase 2 (DGAT2), Patatin-like phospholipase domain-containing protein 3 (PNPLA3), 5'-aminolevulinic acid synthase 1 (ALAS1), and hydroxyacid oxidase 1 gene transcripts.

94. The modified multi-segment antisense oligonucleotide of any of claims 1-90, wherein the modified multi-segment antisense oligonucleotide is complementary to a gene transcript selected from the group consisting of: DM1 protein kinase (DMPK), alpha-1 antitrypsin (AAT), transthyretin (TTR), proprotein convertase subtilisin / kexin type 9 (PCSK9), apolipoprotein B (ApoB), apolipoprotein C-III (ApoCIII), TNF-alpha, SERPINA8 (AGT), complement factor B (CFB), diacylglycerol O-acyltransferase 2 (DGAT2), Patatin-like phospholipase domain-containing protein 3 (PNPLA3), 5'-aminolevulinic acid synthase 1 (ALAS1) or hydroxy oxidase 1, Mat1 alpha, (pro)renin receptor / (P)RR, COVID-195'UTR, Acc1, Acc2, ACE2, androgen receptor, ApoB, ASGR1, ASO, ATXN2, B1AR, B2AR, C9ORF72, caspase 2, CD19, CD4, Chikungunya virus, CLPro, complement component 5, COVID19, COX2, CTGF, DGAT2, DMD, DMPK, DNM2, DUX4, E2 gene, EGFR, envelope, EphA2, epithelial sodium channel alpha subunit, exon 100 dystrophin, exon 101 dystrophin, exon 102 dystrophin, exon 103 dystrophin, exon 104 dystrophin, exon 105 dystrophin, exon 106 dystrophin, exon 107 dystrophin, exon 108 dystrophin, exon 109 dystrophin, exon 110 dystrophin, exon 111 dystrophin, exon 112 dystrophin, exon 113 dystrophin, exon 114 dystrophin, exon 115 dystrophin, exon 116 dystrophin, exon 117 dystrophin, exon 118 dystrophin, exon 119 dystrophin, exon 120 dystrophin, exon 121 dystrophin, exon 122 dystrophin, exon 123 dystrophin, exon 124 dystrophin, exon 125 dystrophin, exon 126 dystrophin, exon 127 dystrophin, exon 128 dystrophin, exon 129 dystrophin, exon 130 dystrophin, exon 131 dystrophin, exon 132 dystrophin, exon 133 dystrophin, exon 134 dystrophin, exon 135 dystrophin, exon 136 dystrophin,dystrophin exon 137, dystrophin exon 138, dystrophin exon 139, dystrophin exon 140, dystrophin exon 141, dystrophin exon 142, dystrophin exon 143, dystrophin exon 144, dystrophin exon 145, dystrophin exon 146, dystrophin exon 147, dystrophin exon 148, dystrophin exon 149, dystrophin exon 150, dystrophin exon 151, dystrophin exon 152, dystrophin exon 44, dystrophin exon 53, dystrophin exon 54, dystrophin exon 55, dystrophin exon 56, dystrophin exon 57, dystrophin exon 58, dystrophin exon 59, dystrophin exon 60, dystrophin exon 61, dystrophin exon 62, dystrophin exon 63, dystrophin exon 64, dystrophin exon 65, dystrophin exon 66, dystrophin exon 67, dystrophin exon 68, dystrophin exon 69, dystrophin exon 70, dystrophin exon 71, dystrophin exon 72, dystrophin exon 73, dystrophin exon 74, dystrophin exon 75, dystrophin exon 76, dystrophin exon 77, dystrophin exon 78, dystrophin exon 79, dystrophin exon 80, dystrophin exon 81, dystrophin exon 82, dystrophin exon 83, dystrophin exon 84, dystrophin exon 85, dystrophin exon 86, dystrophin exon 87, dystrophin exon 88, dystrophin exon 89, dystrophin exon 90, dystrophin exon 91, dystrophin exon 92, dystrophin exon 93, dystrophin exon 94, dystrophin exon 95, dystrophin exon 96, dystrophin exon 97, dystrophin exon 98, dystrophin exon 99, Fabp3, Factor VII, Factor XI, FAK, FGFR4, FOXP3, FUS, FXII, GFAP, GFP, glycogen synthase, H1N1, HBV, heat shock protein 47, heat shock protein 48, heat shock protein 49, heat shock protein 50, heat shock protein 51, heat shock protein 52, heat shock protein 53, heat shock protein 54, heat shock protein 55, heat shock protein 56,Heat shock protein 57, heat shock protein 58, heat shock protein 59, helicase, HIV, HOXB13, HPRT, HPV, Hsd11 beta 1, HTT, hydroxy acid oxidase 1, hydroxysteroid 17 beta-dehydrogenase 13, hypoxia-inducible factor 2 alpha, kinesin spindle protein and vascular endothelial growth factor, KRAS, leader sequence, leucine-rich repeat kinase 2 (LRRK2), MERS-CoV, MGMT, miR-16, miR-21, MMP-2, MMP-9, MTL-CEBPA, MuRF1, Mycobacterium tuberculosis, COVID-19 N, Rabies N 123, Rabies N 749, Rabies N 903, Rabies N1082, Rabies N53, Rabies N8, Chikungunya virus ns1 gene, Chikungunya virus ns2 gene, Chikungunya virus ns3 gene, Chikungunya virus ns4 gene, ORF1 b, ORF1 a, HIV P24, Rabies P330, P53, Rabies, P721, Rabies P91, PCSK9, PDGF, PDL1, COVID-19 PLP, PNPLA3, Polo-like kinase 1, Protein kinase N3, RAF1, RAF-1, RDRP, RSV, SMN2, SNCA, Covid-19 Spike protein, STAT3, TAU, TGFB 1, TGFB 1 and Cox2, TMPRSS2, TMPRSS6, TNF alpha, Transthyretin, VEGF, VEGFR2, VER2, Xanthine dehydrogenase, and YAP 1.

95. The modified multi-segmented antisense oligonucleotide of any one of claims 1-90, wherein the modified multi-segmented antisense oligonucleotide is complementary to a gene transcript selected from the group consisting of: oncogene transcripts, inflammatory gene transcripts, metabolic disease gene transcripts, cardiovascular gene transcripts, liver disease gene transcripts, infectious disease gene transcripts, nervous system disease gene transcripts, neuromuscular disease gene transcripts, eye disease gene transcripts, kidney disease gene transcripts, respiratory disease gene transcripts, blood disease gene transcripts, wound healing gene transcripts, transplantation gene transcripts, autoimmune disease gene transcripts, and neuropsychiatric gene transcripts.

96. A modified multi-segmented antisense oligonucleotide comprising the structure of the modified multi-segmented antisense oligonucleotide of any one of SEQ ID NOS: 11-1453 or 5000-30983.

97. A modified multi -segmented antisense oligonucleotide comprising the structure of a modified multi -segmented antisense oligonucleotide of any one of SEQ ID NOs: 11-1453 or 5000-30983, or an oligonucleotide having at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% sequence identity thereto.

98. A modified multi -segmented antisense oligonucleotide comprising the structure of a modified multi -segmented antisense oligonucleotide of any one of SEQ ID NOs: 11-1453 or 5000-30983, or an oligonucleotide comprising at least 1, 2, 3, 4, or 5 additional modifications thereto.

99. A pharmaceutical composition comprising a modified multi -segmented antisense oligonucleotide according to any one of claims 1-98, or a salt thereof, and at least one pharmaceutically acceptable carrier or diluent.

100. A method of treating a disease, disorder, or condition, comprising administering to a subject a modified multi -segmented antisense oligonucleotide according to any one of claims 1-98 or a pharmaceutical composition according to claim 99.

101. The method of claim 100, wherein the administering to a subject is parenteral.

102. The method of claim 100, wherein the administering to a subject is subcutaneous.

103. The method of claim 100, wherein the administering to a subject is transdermal.

104. The method of claim 100, wherein the administering to a subject is intraocular.

105. The method of claim 100, wherein the administering to a subject is intramuscular.

106. The method of claim 100, wherein the administering to a subject is intravenous.

107. The method of any one of claims 100-106, wherein the subject is a human.

108. The method of any one of claims 100-106, wherein the subject is a non-human primate.